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ABSTRACT OF THE DISSERTATION 
Mutations in the Chaperone Hsp104 Differentially Propagate Yeast Prions 
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Molecular chaperones are critical elements of the protein quality control network and are 
responsible for protecting cells from protein misfolding and aggregation.  In yeast, molecular 
chaperones also participate in the propagation of self-replicating, protein-only elements called 
prions.  The AAA+ ATPase Hsp104 is a disaggregase essential for yeast prion maintenance 
and is responsible for fragmentation of prions to generate the transmissible prion propagons.  
This work focuses on further understanding the role of Hsp104 in prion propagation and protein 
aggregate resolubilization.  To do this, I first identified novel mutations in Hsp104 which altered 
[PSI+] propagation and characterized their effects on Hsp104 function, protein disaggregation, 
and prion variant propagation.  One mutant propagated a phenotypically undetectable [PSI+] 
phenotype that resulted from soluble oligomers of Sup35.  I discovered that soluble, more SDS-
sensitive oligomers of Sup35 were sufficient to transmit the prion state but were not capable of 
producing the nonsense suppression phenotype associated with Sup35 aggregation in the 
[PSI+] state.  I found that these oligomers are also present in wild type [PSI+] cells and can be 
distinguished from the large Sup35 aggregates and still transmit the prion conformation. 
Next, I characterized another set of mutations that are located in a less well-understood 
domain of Hsp104.  I used these mutations to elucidate the function of the middle domain in 
prion maintenance and its affect on the biochemical activities of Hsp104.  I found that this 
ix 
 
domain mediates the disaggregation and ATPase activities of Hsp104 and has differential 
effects on the propagation of specific prion variants.  I hypothesize that the regulation of Hsp104 
function by the middle domain plays a significant role in the selective amplification of specific 
conformational variants. 
Finally, I investigated the affect that changes in Hsp104 activity have on prion variant 
propagation and protein disaggregation.  I utilized two novel mutations which significantly 
decreased the activity of Hsp104 to examine the requirements of two individual yeast prions, 
[PSI+] and [RNQ+], for Hsp104.  I found that propagation of both prions was altered when the 
activity of Hsp104 was significantly decreased, although specific conformational variants of each 
could be maintained.  I hypothesize that structural variants of yeast prions require varying 
amounts of Hsp104 activity for optimal propagation. 
These experiments elucidate how alterations in the activity of the molecular chaperone 
Hsp104 affect remodeling of prions and specific prion conformational variants as well as 
amorphous aggregates.  As an essential chaperone in yeast prion propagation, characterizing 
the disaggregation mechanism of Hsp104 is important for understanding the mechanism of 
amyloid aggregation and thus, has broad implications for both functional and disease-related 
amyloid models. 
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Chapter 1: Background and Significance  
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1.1 Overview: Protein Aggregation 
Efficient and accurate protein folding is essential for cell function and viability.  All proteins possess 
the inherent ability to aggregate often resulting in loss-of-function, which in many cases can lead to 
disease by disrupting normal cellular homeostasis.
1-3
  One broad class of protein conformational disorders 
involves the deposition of protein into insoluble and highly-structured fibrillar protein aggregates, called 
amyloid.
4, 5
  Amyloid deposition is associated with multiple, severe physically and mentally debilitating 
neurodegenerative diseases.  The mechanisms underlying the amyloid deposition associated with these 
diseases are still mostly unclear despite intense investigation. 
There are three characterized pathways by which protein conformational disorders develop.  
Inherited, familial genetic mutations often enhance the likelihood of protein aggregation and thus disease 
progression.
6-9
  Alternatively, the majority of protein conformational disorders arise sporadically with age 
as the greatest risk factor.  One possibility for the strong correlation of protein conformational disorders 
with age is decreased function of the protein quality control networks, specifically molecular chaperones, 
which regulate and protect the cells from protein misfolding and aggregation.  However, the mechanisms 
behind sporadic amyloid aggregation as well as the effect of age on the proteostatic cellular pathways are 
not well understood.  The third known pathway is by infection.  Prion diseases are a specific class of 
amyloid-associated protein conformational disorders, which are capable of being transmitted between 
species, as evidenced by the transmission of bovine spongiform encephalopathy (or Mad Cow disease) 
to humans in the late 1990’s.  This mode of amyloidosis development is extremely rare, but study of prion 
infection across species has led to significant advances in understanding the underlying mechanism of 
transmission. 
Interestingly, recent data have demonstrated that several non-disease related proteins are capable of 
converting into amyloid-like fibrils.
2, 10-18
  These data led to the hypothesis that amyloid fiber formation is a 
generic property of polypeptides.
19
  Furthermore, several examples of functional amyloid that play a role 
in normal protein and cellular function have been identified in a variety of organisms, including bacteria, 
fungi, insects, and even humans.
20
  The identification of functional amyloid suggests that this protein fold 
is evolutionarily conserved, and as such, investigation of the regulation of amyloid species by molecular 
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chaperones in lower organisms may provide insight into the role of the protein quality control network in 
the mechanism of aggregation of both functional and disease-related amyloid in higher eukaryotes. 
In this chapter, I will focus on protein aggregation and its regulation by the protein quality control 
network, specifically molecular chaperones.  First, I will examine the characteristic features of amyloid 
aggregates and discuss the role of amyloid as both a disease-associated and a functional protein 
conformation.  I will describe what is known about the mechanisms behind amyloid formation, including 
the formation of oligomeric intermediates and their proposed role in disease pathology.  I will also discuss 
conformational variation in amyloid structures and how this impacts both the function and toxicity 
associated with these amyloid structures.  Next, I will examine the structure and propagation of yeast 
prions, specifically the [PSI+] and [RNQ+] prions, and their proposed functional roles in the cell.  I will 
characterize how conformational variation of these prions affects both their function and their interaction 
with molecular chaperones, of which Hsp104 will be the focus.  Subsequently, I will discuss the function 
of the molecular chaperone Hsp104 by first analyzing each distinct domain of Hsp104 and remarking on 
how they cooperate as a functional unit.  I will then discuss the role of Hsp104 in yeast prion propagation 
and how its interaction with yeast prions differs from its other substrates.  Additionally, I will discuss how 
other molecular chaperones cooperate with Hsp104 to both promote prion propagation as well as efficient 
resolution of stress-related protein aggregation.  Finally, I will examine how Hsp104 has been utilized in 
studying mammalian protein conformational disorders. 
 
1.2 Amyloid Structure, Mechanism, and Significance 
Amyloid is generally defined as a fibrous quaternary protein structure composed of 
intermolecularly hydrogen-bonded β-sheets.
21
  These β-sheets laterally associate to form fibers that 
range from 5 to 15 nm in diameter.  Investigation of these amyloid fibers by X-ray diffraction revealed a 
characteristic pattern of the backbone and side chains called a “cross-β” structure.
22, 23
 This pattern is 
reflective of β-sheets oriented parallel to the fibril axis while their extended peptide strands are aligned 
perpendicularly to the fibril axis.  This “cross-β” structure soon came to be recognized as a hallmark of 
amyloid structure.  Additionally, amyloid fibers are typically long, unbranched structures formed from the 
entwinement of several smaller fibers, which results in a twisted or helical ultrastructural appearance.  
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Amyloid fibers also bind the dye congo red and display fluorescence when bound to the dye thioflavin T.
24
  
These properties are common to all amyloid structures despite significant variation in the primary 
sequence of the amyloidogenic proteins themselves.
25
  These properties, unfortunately, also make 
investigation of amyloid structures challenging.  Amyloid fibers are generally too large to be studied 
efficiently using X-ray crystallography or nuclear magnetic resonance (NMR).  However, short peptides 
from amyloidogenic proteins can fold into the “cross-β” structure allowing characterization by 
crystallography and NMR.
26
  Both electron microscopy (EM) and atomic force microscopy have been 
useful in revealing the higher-order assembly properties of amyloid fibers.  In addition, several methods 
have been used to elucidate the amyloid-forming regions of the protein including hydrogen-deuterium 
exchange (H-D exchange), solid-state NMR (ssNMR), and mutagenesis and conjugation of probes to 
specific residues.
27, 28
 
Within the amyloid fold itself, variation exists in the orientation of β-strands, which comprise what 
is called the amyloid core.  The core β-strands orient in two common forms within the β-sheet, parallel 
and antiparallel, with the former being the most prevalent.  Parallel β-sheets can be further described by 
the alignment of the amino acids between the strands.  For example, parallel, in-register β-sheets are 
composed of identical residues on different strands aligned in-register - each residue is adjacent to the 
identical residue on the neighboring strand – to promote hydrogen bonding between these residues.
29
  
Moreover, the columns of hydrogen bonds in a β-sheet are characterized as a polar zipper, hydrogen 
bonds between the side chain and main chain amides, and increase stability of the sheets, adding to the 
overall strength and stability of the fiber.  Parallel β-sheets can also be out-of-register or pseudo-register, 
though these structures are much less common than the parallel in-register.
30
 
Another type of amyloid fold that is different from the parallel or anti-parallel orientations is the β-
solenoid structure.
31
  In these fibers, a single polypeptide strand forms the first layer then loops back 
around to form the second layer as well.  Since the same polypeptide strand forms two or more layers, 
these strands cannot be in-register as the residues on the first strand will not contact the same residues 
on the neighboring strand.
31
  These β-solenoid structures can be pseudo-in-register though, provided the 
neighboring β-strands share a high degree of sequence similarity. 
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Additionally, the tight packing between β-sheets plays an integral role in the strength and stability 
of the amyloid fold.  The orientation of these sheets promotes interdigitation of the side chains, such that 
even water is excluded from these interfaces.
26
  The close packing and interdigitation of the neighboring 
β-sheets is called a “steric zipper” for its ultrastructural appearance as well as its exclusion of water 
molecules.
26
  These “pair-of-sheets” units, as they are termed, are then able to wind around each other to 
form the fibrous structure.  One hypothesis suggests that these “pair-of-sheets” units are the minimal 
structures needed for further propagation and conversion of monomer to the amyloid conformation. 
Thus, amyloid fibers are highly structured and stable aggregates; they are significantly different 
than unstructured and amorphous aggregates that result from general protein misfolding.  Fibers from 
amyloidogenic proteins are resistant to proteolysis and denaturation by detergents.  Additionally, amyloid 
fibers act as a template for the conversion of monomer from a folded or disordered form to a β-sheet rich 
structure capable of extending the amyloid fiber. 
 
Disease-Associated Amyloid 
Several age-related neurodegenerative disorders are associated with the progressive 
accumulation of amyloid fibers.  Alzheimer’s disease, the best known and the most prevalent, is 
characterized by the extracellular deposition of a proteolytic fragment of the Amyloid Precursor Protein 
(APP).
32
  This fragment, called Aβ, is secreted by the cell to the extracellular space via the endocytic 
pathway where it then forms amyloid plaques.  The amyloid formation of Aβ results in widespread 
neuronal dysfunction and cell death.  Another protein shown to play a role in the pathology of Alzheimer’s 
disease is the microtubule-associated protein tau.  Aggregated tau is the main constituent of the 
neurofibrillary tangles present in the cytoplasm of neurons and in diseased tissues.  Aggregated tau is 
commonly present in several other neurodegenerative disorders.
33
   
Nine different neurodegenerative disorders are associated with proteins containing expanded 
polyglutamine (polyQ) tracts (homopolymeric amino acid sequences) including Huntington’s disease and 
several spinocerebellar ataxias.
34
  PolyQ proteins aggregate when the length of the polyQ tract crosses a 
critical threshold, resulting in destabilization of the folded protein and amyloid formation.
35
  Aggregates of 
polyQ proteins occur both in the nucleus and the cytoplasm.  Interestingly, glutamine-rich polypeptide 
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domains (25% or more glutamine residues) and polyQ tracts are often identified in transcription factors 
and proteins that play roles in DNA and RNA processing. 
Another well-studied amyloidogenic protein is the membrane-bound prion protein (PrP).  The 
mammalian prion diseases such as Creutzfeldt-Jacob disease in humans, scrapie in sheep, and chronic 
wasting disease (CWD) in deer and elk, are characterized by the accumulation and aggregation of PrP on 
the cell surface.  More detail will be provided for mammalian prions in a later chapter. 
Several lines of evidence suggest that amyloid aggregates, or amyloid precursors, have a 
clinically significant role in disease pathogenesis.
5
  Multiple hypotheses exist as to how amyloid deposits 
may contribute to disease pathology.  Initially, the amyloid aggregates themselves were proposed to be 
the cause of disease through a toxic gain-of-function.
36
  However, this hypothesis is challenged by the 
observation of amyloid fibers in the brains of healthy individuals as well as the lack of correlative evidence 
between the presence of amyloid aggregates and disease severity.
36
  Another more recent hypothesis 
suggests that the toxic species are actually intermediates formed during the aggregation process.  As a 
result, this hypothesis proposes that the amyloid aggregates may be benign or even, perhaps, protective 
as a strategy to sequester the toxic species.  Toxic oligomers of several amyloidogenic proteins can be 
formed in vitro and shown to cause cellular toxicity and disease pathology when introduced into cell and 
animal models.  Whether these two hypotheses are mutually exclusive or both contribute to disease 
progression remains to be seen.   
  
Functional Amyloids 
In addition to amyloids associated with degenerative diseases, several functional amyloids have 
been characterized in bacteria, fungi, insects, and now in humans.
20
  Several of these functional amyloids 
have been studied by EM, Congo red and thioflavin T binding, and X-ray diffraction and show similar 
structural patterns to the disease-related amyloids described above.
37-39
  Bacteria employ several 
structural amyloids, such as curli and the chaplins, to establish a bio-matrix that enables surface adhesion 
and colony formation, respectively.
40, 41
  Fungi also express structural amyloid called hydrophobins that 
assemble at the air-water interface and provide stabilization for aerial growth of hyphae for spore 
formation.
42
  In addition, hydrophobins also provide adherence to the surface of host organisms, thereby 
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facilitating pathogenesis.  One final example of a structural amyloid is the chorion proteins, which are 
present in fish and insect eggshells and protect the developing larvae from harm by stabilizing the 
eggshell structure.
20
  Thus, proteins from several different organisms that function in structural roles often 
adopt amyloid folds to provide rigid and stable structures for efficient functioning.  
 Not all functional amyloids are involved in structural roles; the amyloid prions in fungi are known 
to facilitate phenotypic variation through the method of protein-only inheritance in a non-Mendelian 
manner.  The yeast prions formed from the aggregation of the proteins Sup35 and Rnq1 in 
Saccharomyces cerevisiae are especially directed towards this role and are discussed in depth in the 
next section.
43
  The HET-s prion in the fungus Podospora anserina regulates heterokaryon (multi-
nucleated cell) formation important for mating and vegetative growth.
44
  Additionally, the structure of the 
HET-s prion has been identified as the β-solenoid structure.
31
  Non-disease related amyloids have also 
been proposed to exist in higher eukaryotes.  In sea slugs, the cytoplasmic polyadenylation element 
binding protein (CPEB) may also utilize an amyloid fold to regulate synaptic changes important for 
learning and memory.
45
  Additionally, in humans, the structural protein Pmel17 forms amyloid fibers that 
act as a scaffold for melanin deposition in the melanosome.
46
  Thus, amyloids have been shown to play 
roles in several biological processes, which only underscore the importance of understanding the 
mechanisms of amyloid formation and function. 
 
Mechanism of Amyloid Formation 
 In order for amyloid to form, proteins must first go through the thermodyhamically unfavorable 
process of unfolding to increase exposure of amyloid-forming segments.
47
  Also, because of the highly 
structured and bonded nature of the amyloid cores, several molecules need to come together to form a 
stable nucleating structure capable of further propagation, in a process called nucleation.
27, 48-51
  For these 
reasons, nucleation is a rare event.  However, conditions that promote exposure of these regions such as 
denaturing conditions, high temperatures, or high protein concentrations often enhance amyloid 
formation.
52
  In addition, interaction with polyanions, lipids, or proteoglycans can also promote amyloid 
fiber formation.
53-58
  These amyloid conformers then nucleate the amyloid aggregate by converting 
unfolded molecules to the amyloid form, thereby polymerizing into amyloid aggregates.  The strongest 
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evidence in favor of the nucleated conformational conversion model is that addition of pre-formed amyloid 
fibers to amyloid protein monomer accelerates fiber formation, essentially by eliminating the nucleation 
step.  This has been demonstrated both in vitro with recombinant protein and in vivo when recombinant 
fibers can be introduced into cell and mouse models to induce disease pathology and progression.
57, 59
 
Following nucleation, addition of new protein molecules occurs rapidly.
60
  Several hypotheses 
exist for how the growing fiber polymerizes and what the identity of the added unit is.  The pre-eminent 
hypothesis suggests that fiber polymerization occurs by monomer addition to the ends of fibers.
61
  In this 
model, the fiber, which has adopted the stable β-sheet rich fold, binds to monomer that has exposed 
amyloid-forming segments and templates these destabilized regions to β-sheets.  Another hypothesis 
suggests that monomer do not template from amyloid aggregates directly, but form oligomeric 
intermediates which then polymerize to amyloid fibers.  Oligomeric intermediates in the process of 
amyloid formation have been described for several amyloidogenic proteins.  On the other hand, these 
oligomers may not be true intermediates of amyloid formation but may instead assemble as a result of off-
pathway protein-protein interactions.
62
  Although these hypotheses may seem mutually exclusive, recent 
data have shown that the same amyloidogenic protein may assemble fibers via multiple pathways.
63
  For 
example, the human amyloid protein, β2-microglobulin can form two distinct amyloid structures, worm-like 
and rod-like, under different conditions at low pH, and that the pathways used to generate these two 
fibers are distinct and in direct competition.
64-66
  Further examples are observed when the mammalian 
prion protein PrP forms amyloid under different conditions.  At acidic pH, recombinant PrP assembles into 
amyloid oligomers while at neutral pH, recombinant PrP converts into amyloid fibers.
67-70
 
Interestingly, in the absence of amyloid fibers, the amyloid oligomers of such proteins as Aβ
71, 72
, 
α-synuclein
73, 74
, polyQ
75, 76
, and PrP
77
 can cause toxicity when introduced into cell and animal models of 
disease.  Amyloid oligomers can encompass a range of sizes and structures
78
, bind the amyloid-binding 
dyes
79
, and exhibit robust β-sheet structures, similar to the larger amyloid fibers.
80-82
  Similar to the 
ubiquitous nature of the amyloid fold, amyloid oligomers of several distinct proteins share a common 
structure and as such may share a common method of pathogenesis.
83-85
  These oligomers, formed in 
vitro, can nucleate amyloid aggregation and cause disease pathology in disease models.
86
  These 
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findings led to the hypothesis that oligomeric intermediates are the primary toxic species.  Consequently, 
amyloid fibers may be benign or even protective by sequestering the toxic oligomers.
36, 87-89
 
 
1.3 Prions in Mammals and Yeast 
Among the amyloid-forming proteins, prions are unique.  Prions, or proteinaceous infectious 
particles, are infectious amyloid as these aggregated proteins can be transmitted between organisms, 
and in some cases, between species.  Prions are found in both mammals and yeast, though the protein 
determinants of mammalian and yeast prions are not the same.  However, mammalian and yeast prions 
do share several features, including their amyloid fold structure, the mechanism of formation, and their 
ability to exist in several distinct conformations.  Unlike mammalian prions, yeast prions are not toxic to 
the cell and instead may play a functional role.  Given their mechanistic similarities, investigating yeast 
prions has proven beneficial to the understanding of mammalian prion propagation, infectivity, and strain 
formation. 
 
Mammalian Prions 
 The mammalian prion protein, PrP
C
, is a glycosylphosphatidyl-inositol-linked cell surface protein 
expressed mainly in the central nervous system.
90
  PrP can exist in two states, the soluble PrP
C
 state and 
the insoluble, protease-resistant aggregate PrP-res.
91
  The primary structure of the constitutive PrP
C
 is 
mostly α-helical with the N-terminal domain highly unstructured and containing an octapeptide-repeat 
region that contributes to aggregate formation.
92
  The aggregated PrP-res is similar to other amyloids, 
being highly β-sheet rich and able to bind congo red and thioflavin T.
93
  Recombinant PrP can form 
amyloid fibers under acidic conditions, perhaps alluding to conditions in the lysosome which might 
catalyze PrP aggregation as it travels through the secretory pathway.  Interestingly, aggregated 
recombinant PrP or PrP-res isolated from the brains of infected animals can be used to nucleate PrP
C
 
aggregation in an uninfected animal. 
 Prion populations that differ in their phenotypic or physiochemical properties are known as prion 
strains.  Prion strains were first characterized by differences their incubation time and neuropathology.
94
  
Prion strains have been identified in scrapie-infected sheep and goats, cattle, and humans.  Differences 
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in prion strains can be characterized by differences in proteinase K sensitivity and cleavage pattern, 
stability toward denaturing agents, and glycosylation pattern.
94
  Indeed, prion strains resistant to one drug 
but not another could “evolve” to be resistant to the second drug suggesting that a heterogeneous 
population of prion conformations simultaneously exists or prion conformations are not necessarily 
irreversible and can continue to change.
95
 
 
1.32 Yeast Prions 
 Similar to the mammalian prion protein, some proteins in yeast can exist both in their soluble form 
and in a self-propagating aggregate called a yeast prion.
96, 97
  The characterized prions in yeast are not 
toxic, but, instead, are epigenetically inherited, self-replicating, protein-only modes of information transfer 
(Figure 1.1).
96
  Prions exist in several species of yeast and are 
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Figure 1.1 Yeast prions are inherited epigenetically.  Mating a [PRION+] haploid to a [prion-] haploid 
results in [PRION+] diploids.  The aggregated prion proteins in the [PRION+] haploid template the 
monomeric prion proteins in the [prion-] haploid, resulting in aggregated prion proteins in the diploid.  
These aggregates are then cytoplasmically inherited by all four haploid progeny following meiosis.  Thus, 
prion inheritance is an epigenetic, non-Mendelian mechanism.  
12 
 
 thought to be evolutionarily conserved.
98, 99
  Although each prion is formed from a distinct determinant 
protein, heterologous interactions between the prions have been demonstrated.
100-103
 
 Yeast prions share several characteristics that are used as criteria when identifying a new yeast 
prion.  One is that yeast prions are reversibly curable.
104
  Reversible curability means that colonies can 
switch back and forth between the [prion-] and [PRION+] states in the absence of an associated genetic 
change.  Secondly, yeast prions can be induced by overexpressing the protein determinant of that 
prion.
104
  Finally, prion formation of a protein mimics a null mutation of that protein.
104
  In that regard, 
aggregation of yeast prion proteins acts as a molecular switch to turn off and on the function of that 
protein.  Additionally, prion proteins are composed of modular domains, one of which is the prion-forming 
domain.  This domain is required for prion formation and propagation and is separable from the domain 
required for protein function.
105, 106
 
 Yeast prions also share structural and mechanistic characteristics with disease-related amyloids 
despite vast difference in protein primary sequence.  For instance, structural studies of several yeast 
prions suggest that the aggregated form is β-sheet rich and forms amyloid fibers in vitro, similar to PrP, 
Aβ, polyQ, and other amyloidogenic proteins.
5
  Thus, yeast prions have proven valuable as a model 
system to understand the effects of cellular and genetic factors on amyloid formation.  One key difference 
between yeast prions and other amyloids is that yeast prions are maintained and actively propagated.  
The mechanism of prion aggregation must generate propagatable species that can be transmitted to 
progeny during mitosis.  These propagatable species are called propagons and are proposed to be 
soluble, amyloid oligomers that maintain the prion conformation.
107, 108
  To generate these propagons, the 
large amyloid fibers need to be fragmented.  The disaggregase chaperone Hsp104 is proposed to 
fragment the large prion aggregates and, as such, most of the known yeast prions require Hsp104 for 
propagation.
109
  In concert with Hsp104, yeast prions are also regulated by various Hsp70 and Hsp40 
chaperones.  An interesting hypothesis, then, is that environmental factors indirectly regulate prion 
propagation via molecular chaperones. 
 Another interesting phenomenon associated with yeast prions is the ability of the same primary 
sequence to adopt multiple prion conformations, known as prion variants.
110, 111
  Prion variants are similar 
in theory to mammalian prion strains.  Prion variants have been described for at least three separate 
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yeast prions and have been shown to be structurally and functionally distinct.  Prion variants also respond 
to chaperone levels differentially and may be preferentially selected for given a certain set of 
environmental or cellular conditions. 
  
[PSI+] 
 The [PSI+] prion results from the aggregation of the translation termination factor, Sup35.
112-114
  
Sup35 (eRF3) is a GTPase that interacts with Sup45 (eRF1) to form a translation termination complex to 
recognize termination codons during translation.
115, 116
  Sup35 is composed of three modular domains 
termed the N domain, the M domain and the C-terminal domain.
112, 117
  The C-terminal domain contains 
the GTPase domain, is mostly α-helical, and alone, is sufficient to provide the essential function of 
Sup35.
112, 116
  The N domain of Sup35 constitutes the prion-forming domain of Sup35.
112, 118
  The N 
domain contains a glutamine and asparagine (Q/N) rich region encompassing residues 1-40, which is 
crucial for nucleation of Sup35 aggregates, though some studies suggest that the sequence is less 
important than the amino acid composition of the domain.
119-121
  This suggests that proteins with Q/N rich 
regions, regardless of sequence similarity, might also form amyloid.
121-123
  Residues 41-97 of the N 
domain are composed of 5 and a half repeating units of the peptide (P/QQGGYQQ/SYN) which resemble 
the five “octarepeat” sequences (PHGGGWGQ) present in the amino terminus of PrP.
124
  Truncation or 
replacement of these repeats destabilizes or eliminates [PSI+].
125, 126
  The M domain is highly charged, 
and confers stability and structure to the N domain.
127
  Structural studies suggest that while the C-
terminus of Sup35 is folded, the N-terminus is unstructured allowing it to better adopt the prion 
conformation.
128
 
 Recombinant Sup35, like other amyloid proteins, can form amyloid fibers in vitro.
129
  Both the 
PFD of Sup35, Sup35NM, and full-length Sup35 form fibers that are resistant to SDS, bind thioflavin T, 
and can be seeded by the addition of preformed fibers supporting a nucleated conformational conversion 
model.
129, 130
  Analysis of Sup35 peptides suggests that these amyloid fibers are composed of parallel β-
sheets.  Additionally, amyloid fibers of recombinant Sup35 can be introduced into [psi-] cells to generate 
[PSI+] cells.
131
  Hence, amyloid fibers formed from recombinant Sup35 are infectious and can provide 
insight into the characteristics of infectious amyloid species. 
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 The [PSI+] prion is important to study not only for its structural implications, but also because of 
the unique function and phenotype it confers in cells.  Since the [PSI+] prion is composed of Sup35, the 
function of the translation termination complex is intimately connected to the presence of [PSI+].
132
  When 
cells are [psi-], Sup35 is monomeric and functional in efficient translation termination.  On the other hand, 
when cells are phenotypically [PSI+], Sup35 is aggregated and unable to fully interact with Sup45 causing 
an increase in nonsense suppression.  Increased nonsense suppression occurring in the presence of 
[PSI+] can result in translation of normally silent regions of the genome.
133
  [PSI+] cells have been shown 
to have an advantage over [psi-] cells while growing in certain conditions, presumably because the [PSI+] 
state offers variation through increased nonsense suppression.
134
  This advantage is a fine balance 
though, as overexpression of Sup35 in [PSI+] cells leads to toxicity because the increase in Sup35 
aggregation sequesters Sup45 resulting in significant defects in translation termination.
135
  Thus, the 
[PSI+] prion may be beneficial for cell adaptability and survival, but regulation of the prion phenotype is 
integral to preventing toxic gain-of-function. 
Both intragenic and extragenic factors regulate Sup35 aggregation in vivo.  Mutations in the PFD 
can destabilize or inhibit [PSI+] while some mutations or truncations have no effect.  Additionally, the 
propagation of [PSI+] is regulated by chaperones, specifically, Hsp104.
109
  As with all yeast prions, [PSI+] 
is cured when Hsp104 is deleted.
109
  Uniquely, [PSI+] is the only prion that is also cured by the 
overexpression of Hsp104 suggesting that [PSI+] is extremely sensitive to changes in Hsp104 activity or 
expression.   
 Variants of [PSI+] were initially identified based on their functional and phenotypic differences.  
Two variants of [PSI+] have previously been described that display distinct levels of nonsense 
suppression.  Strong variants of [PSI+] are so named because they display high levels of nonsense 
suppression which correlates with a very low amount of soluble Sup35.
110
  On the other hand, weak 
variants of [PSI+] exhibit less nonsense suppression correlative with an increased pool of soluble Sup35 
(Figure 1.2).
136
  When cells carrying strong and weak variants of [PSI+] are mated, the progeny are strong 
[PSI+] suggesting that strong variants of [PSI+] out-compete weak variants for the available monomer 
pool and thus propagate more efficiently.
137
  Additionally, amyloid fibers formed in vitro have provided 
valuable insight about the structural characteristics of prion variants.  Several studies have shown that 
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varying the temperature at which amyloid is assembled affects the conformation of the fiber formed as 
well as the resulting [PSI+] phenotype when introduced into [psi-] cells.
138
  Structural variants of Sup35 
that contain a short amyloid core (~40amino acids) display faster kinetics of aggregation, are less 
thermostable, and generate mostly strong [PSI+] variants when transformed into [psi-] cells.
138
  Sup35 
structural variants that contain a long amyloid core (~70 amino acids) display slower aggregation kinetics, 
are highly thermostable, and generate mostly weak variants of [PSI+] when introduced to [psi-] cells.
138
  
Thus, a hypothesis developed whereby less stable strong variants of [PSI+] are more easily fragmented 
and able to template monomer such that strong [PSI+] variants can out-propagate weak [PSI+] variants.  
This recent hypothesis is still being investigated, but does suggest that Hsp104 and other chaperones 
may play an important role in [PSI+] variant selection and propagation. 
 
[RNQ+] 
 The [RNQ+] prion is formed from the aggregation of the protein Rnq1 whose monomeric function 
in the cell is still unknown.
139
  Rnq1, like Sup35, can be divided into modular domains.  The N-terminal 
domain is folded with function unknown.  The C-terminal domain is Q/N rich and is necessary and 
sufficient for [RNQ+] formation.
139
  Rnq1 was initially identified as a prion candidate by a BLAST search 
for Q/N rich proteins that were also able to aggregate in vivo.
139
  Like [PSI+], [RNQ+] is also dependent 
on Hsp104 as deletion of Hsp104 cures [RNQ+].
139
  [RNQ+] is also dependent on the Hsp40 chaperone 
Sis1.
140-142
  Although the monomeric Rnq1 has no known function, the [RNQ+] prion has a function as 
[PIN+] or a “[PSI+] inducible” element.
101
  The [PIN+] hypothesis suggests that prions facilitate the 
appearance of other prions via heterologous templating.
101, 103
  Thus, as [PIN+], the [RNQ+] prion can 
template monomeric  
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Figure 1.2 [PSI+] exists in conformationally distinct states.  Strong and weak [PSI+] variants are 
conformationally distinct and can be distinguished by differing amounts of soluble Sup35.  The amount of 
nonsense suppression is directly related to the amount of soluble Sup35, resulting in decreased 
nonsense suppression associated with weak [PSI+] variants. 
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Sup35 aggregation and induce the [PSI+] phenotype.  Interestingly, the [PSI+] prion can also induce the 
formation of [RNQ+] as can the [URE3+] prion.
101
  Therefore, the [RNQ+] prion is a component of a 
complicated and interconnected prion network that is its own regulatory mechanism. 
 Definitive proof for Rnq1 as a prion protein was demonstrated when recombinant Rnq1 was 
shown to form amyloid fibers in vitro and those fibers were capable of inducing [RNQ+] formation when 
transformed into [rnq-] cells.
139, 143, 144
  In fact, pre-formed fibers of Rnq1 amyloid can seed Rnq1 
monomer demonstrating that alter Rnq1 amyloid formation follows the nucleated conformational 
conversion model.
139
  Similar to Sup35, mutations or truncations of both the PFD and the N-terminal non-
prion domain affect Rnq1 aggregation and regulate [RNQ+] formation.
145, 146
  Changes in the amino acid 
sequence not only regulate [RNQ+] formation, but also the ability of [RNQ+] to template Sup35.
147, 148
 
 Not only do mutations affect the function of [RNQ+], but changes to the conformation in the 
absence of mutations also differentially affect [PSI+] induction.  Several variants of [RNQ+] were identified 
and characterized by their level of [PSI+] induction.  These variants termed low, medium, high, and very 
high [RNQ+] for their ability to induce [PSI+] have also been differentiated by their ability to form 
fluorescent foci.
101, 137, 149
  Two fluorescent patterns were exhibited, multi-dot and single-dot fluorescence.  
The low, medium, high, and very high variants of [RNQ+] demonstrated single-dot fluorescence while 
multi-dot fluorescence was characteristic of only the high [RNQ+] variant.  These variants also display 
differences in stability and the amount of soluble Rnq1.
137, 150
 
 
1.4 Hsp104, an AAA+ ATPase Chaperone 
Hsp104 is a AAA+ ATPase molecular chaperone in Saccharomyces cerevisiae.  Hsp104 is a 
member of the ClpA/ClpB family of proteins, chaperones that function in protein disaggregation and 
degradation and is homologous to the bacterial chaperone ClpB.
151
  The heat shock protein Hsp104 is 
upregulated in response to stress and mediates protein disaggregation following heat shock.
151, 152
  
However, the disaggregase Hsp104 does not prevent protein aggregation, nor does it promote proteolysis 
of protein aggregates like ClpA.
152
  Instead, Hsp104 acts more like Hsp70 in that it modulates 
resolubilization of proteins from insoluble aggregates.
152
  Additionally, as already mentioned, Hsp104 
plays an essential role in prion propagation.
109
  All known yeast prions require Hsp104 for propagation.
109
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The pre-eminent hypothesis for the mechanism of Hsp104 action is that Hsp104 disaggregates the prion 
aggregates to generate the propagons for further propagation.
153
   
In order to perform the disaggregation function, Hsp104 forms a hexamer in response to ATP 
binding.
154, 155
  The hexameric state of Hsp104 can also be induced by high concentration of Hsp104
155
 
and high salt concentrations.
154, 155
 The structure of Hsp104 was originally modeled off the structure of 
ClpB determined by X-ray crystallography and cryo-EM (Figure 1.3).
156
  Hsp104 is composed of five 
functionally distinct domains including two nucleotide-binding domains (NBD1 and NBD2) connected by a 
coiled-coil linker domain and flanked by N-terminal and C-terminal domains.  The crystal structure of ClpB 
suggested that the hexamer was a three-tiered structure (the N-terminal domain, NBD1, and NBD2) with 
the middle domain projecting from the body of the hexamer.
156
  Despite debate over the position of the 
middle domain
157
, a recent cryo-electron microscopy structure of Hsp104 strongly suggested its 
placement on the outside of the hexamer.
158
  As an AAA+ ATPase, Hsp104 binds and hydrolyzes ATP to 
generate energy for disaggregation but must form a hexamer to do so.
154, 159
  Only ATP is capable of 
being hydrolyzed by Hsp104 and ADP inhibits ATP hydrolysis.
159
  Despite independent functions for each 
domain, all of the domains cooperate to ensure synchronization of the hexamer subunits for efficient 
disaggregation. 
 
The N-terminal Domain (NTD) 
 The NTD of ClpB (residues 1-150) is mostly α-helical and highly mobile.
156
  Deletion of the NTD 
of ClpB was reported to maintain the same level of ATP hydrolysis and disaggregation activity as the full-
length ClpB and was suggested to be unnecessary for ClpB function.
160
  However, additional studies 
demonstrated that deletion of the ClpB NTD prevented maximum disaggregation activity, specifically 
when co-chaperones were limiting suggesting that the NTD of 
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Figure 1.3 Modeling of hexameric Hsp104 from the cryo-EM structure.  The cryo-EM model of 
Hsp104 (EMDatabank accession number 1630) was used to model the domains of Hsp104.  Three tiers 
can be observed in this model corresponding to the NTD (green residue), NBD1 (blue residue), and 
NBD2 (red residue).  The coiled coil linker domain is marked by a purple amino acid, and extends away 
from the body of the hexamer.  The CTD is marked by a residue colored yellow and sits on the C-terminal 
face of Hsp104.  This model was kindly provided by Dr. Francis Tsai for elucidation of Hsp104 mutants 
characterized in this thesis. 
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ClpB may provide a site of interaction for co-chaperones and may enhance disaggregation activity.
161
  
Furthermore, mutants in the NTD of ClpB that cross-linked the NTD to the body of the hexamer to restrict 
mobility of the NTD reduced the disaggregation activity, substrate threading, and substrate-stimulated 
ATPase activity.
162  Several studies have demonstrated interactions between the ClpB NTD and 
substrates,
163
 especially strongly aggregated proteins.
164
  Thus, the NTD of ClpB is important for 
interacting with both substrates and co-chaperones for efficient protein disaggregation. 
 In contrast, the role of the NTD in the disaggregation mechanism of Hsp104 is much less clear.  
Deletion of the NTD of Hsp104 does not affect prion propagation or thermotolerance.
165, 166
  Additionally, 
mutations in the NTD or deletion of the NTD can enhance [PSI+] propagation and can compensate for 
[PSI+] propagation defects in the presence of a mutant Hsp70.
165
  Thus, the NTD of Hsp104 may be 
similar to that of ClpB in that it enhances disaggregation activity to ensure prion propagation and is a site 
of interaction for Hsp70s.  Interestingly, deletion of the NTD does not support elimination of [PSI+] by 
excess Hsp104.
165
  Moreover, structural studies of Hsp104 suggest that deletion of the NTD results in 
expansion of the central channel possibly suggesting that the NTD plays a role in preventing non-specific 
polypeptide binding in the channel of Hsp104.
157
  Therefore, despite being unnecessary for Hsp104 
function, the NTD clearly still plays a role in prion and non-prion substrate disaggregation and may 
instead serve as a “backup” to mediate efficient disaggregation. 
 
Nucleotide-binding Domains (NBD1 & NBD2) 
 As a member of the Hsp100/Clp subfamily of AAA+ ATPases, the energy for the protein 
disaggregation mechanism for Hsp104/ClpB is provided by ATP hydrolysis.
167
  Hsp104/ClpB has two 
NBDs, that in the ring-shaped hexamer, are stacked on top of each other.  The ATP hydrolysis 
mechanism can be generally described in a few over-simplified steps resulting from numerous studies 
examining kinetics of several Hsp104 mutants.  Within a single subunit in the Hsp104 hexamer (1) ATP 
binds to NBD2 and stabilizes the hexamer (2) generating a conformational change that is propagated 
through the middle domain to NBD1 where (3) ATP now binds while (4) ATP is hydrolyzed at NBD2 
releasing ADP to (5) reverse the conformational change promoting (6) ATP hydrolysis at NBD1 to 
complete the cycle.
168
  This cycle is synchronous in the hexameric Hsp104 so that at any one time, 
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multiple individual subunits in the hexamer are hydrolyzing ATP.
169, 170
  From this general model of the 
ATP hydrolysis mechanism, independent functions for each NBD can be recognized.  For example, ATP 
binding and hydrolysis at NBD2 was thought primarily to promote hexamerization and provide the energy 
needed for the conformational change rather than significantly adding to the catalytic energy.
171
  Thus, the 
binding affinity of NBD2 for ATP is much higher than that of NBD1.
171
  Conversely, ATP hydrolysis at 
NBD1 provides the majority of the catalytic energy required for disaggregation. 
NBDs are very highly conserved and have several distinct domains important for ATP 
hydrolysis.
167, 172
  The Walker A and Walker B motifs contain residues that directly interact with ATP.  The 
Walker A motif consists of the consensus sequence GXXXXGK[T/S] (where X is any amino acid) and the 
lysine (K) residue in this motif is essential for ATP binding and hydrolysis.
159
  In Hsp104, mutation of 
these lysines, K218T and K620T, results in loss of ATP binding and hydrolysis at that domain.
159
  The 
double mutant, K218T/K620T, mimics a deletion of Hsp104.  The K218T mutation results in loss of 
function at NBD1 without altering the ability to oligomerize while the K620T mutation displays a 
corresponding oligomerization defect.
154
  Both of these mutations inhibit thermotolerance and [PSI+] 
propagation.
109, 151
  The Walker B motif also plays a role in ATP binding.  The glutamate residue in the 
Walker B consensus sequence, hhhhDE where h is a hydrophobic residue, is important for ATP 
hydrolysis.
167, 173
  Mutation of these residues in Hsp104 (E285Q/A and E687Q/A) does not prevent ATP 
binding but inhibits ATP hydrolysis resulting in the commonly called “substrate trap” because substrates 
are bound but unable to be released.
173, 174
  The E285Q/A mutation is especially interesting because it 
displays 300% ATPase activity of wild type supporting the hypothesis that NBD2 is a major contributor to 
the catalytic energy.
174
 
Another conserved set of domains in the NBDs are the sensor 1 and sensor 2 domains.  These 
domains participate in ATP hydrolysis by interacting with the γ-phosphate of ATP.  The sensor 1 domain 
contains a highly important polar residue that when mutated, impairs ATP hydrolysis.
167, 171
  In Hsp104, 
mutation of these polar residues, T317A in NBD1 and N728A in NBD2, both impair ATP hydrolysis and 
have been used to study the kinetics of the individual NBDs.
171
  Both mutations inhibit [PSI+] propagation 
and thermotolerance though N728A displays a more severe effect.
171
  Thus, these mutations can impair 
ATP hydrolysis without impairing ATP binding.  The sensor 2 motif contains a conserved arginine residue 
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that is also important for ATP binding and hydrolysis.
167
  Mutation of the arginine residue in Hsp104 
NBD2, R826M, impairs ATP binding as well as prevent [PSI+] propagation and thermotolerance.
175
  
Mutations in these two domains highlight the importance of ATP hydrolysis for the function of Hsp104.  In 
addition to the conserved arginine residue in the sensor 2 domain, another set of conserved arginine 
residues are also extremely important for ATP hydrolysis and hexamer formation in response to ATP 
binding.  These arginine residues known as “arginine fingers” extend from one subunit into the ATP 
binding domain of the neighboring subunit and coordinate ATP binding.
167, 176
  Mutation of these arginine 
residues impairs ATP hydrolysis and hexamer formation.
176
  In fact, accurate positioning of the arginine 
fingers has been used to validate structural models of Hsp104 as it has been shown that arginine finger 
residues are essential for ATPase and chaperone activities.
158, 177
 
The purpose of ATP hydrolysis is to drive the disaggregation mechanism of Hsp104, and 
therefore, both the ATPase activity and disaggregation should be coupled for maximum efficiency.  
Several studies have shown that substrate binding is dependent on ATP binding at NBD1 and NBD2 
though more strictly regulated by NBD1.
174, 178-180
  As expected, then, the release of substrate is triggered 
by ATP hydrolysis, coupling the two cycles.
174, 178, 180, 181
  This coupling is optimized within the hexamer 
such that asymmetry of ATP binding and hydrolysis among the NBDs in the six subunits promotes 
continuous substrate binding and processing to prevent substrate release and incomplete 
disaggregation.
170, 182
  Additionally, substrate binding or interaction stimulates ATP hydrolysis of 
Hsp104/ClpB, perhaps to ensure efficient processing of the substrate.
168, 183
  To further complicate the 
disaggregation mechanism, ATP hydrolysis and substrate binding and release are also coupled to co-
chaperone interactions which enhance Hsp104/ClpB functions.
166, 184
  Thus, regulating substrate binding 
and ATP hydrolysis provides optimal disaggregation activity and provides the foundation for threading of 
substrates as the primary method of disaggregation. 
 
Substrate Threading: A Mechanism of Disaggregation 
 The model of the hexameric structure of Hsp104/ClpB displays a narrow channel running through 
the center of the hexamer that is open at both the N- and C-terminal faces of the hexamer.
156-158
  This 
channel is a conserved structural feature among the Clp proteins and Hsp100s.
172, 185
    The use of this 
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channel in protein disaggregation is most apparent in the disaggregation mechanisms of ClpA and ClpX 
which bind to the protease ClpP at the C-terminus to degrade substrate proteins.
185
  Translocation of 
substrates through the central channel positions the substrate in the protease for degradation.
186, 187
  The 
application of the threading model to non-degrading chaperones like Hsp104/ClpB was made possible by 
the identification of conserved pore loops that did not affect hexamerization or ATP hydrolysis, but 
prevented aggregate refolding.
188-190
  These channel loops contain the conserved domain sequence 
GYVG where the tyrosine residue is specifically important.
190-193
  Mutation of the conserved tyrosine 
residue in these loops prevents thermotolerance by Hsp104.
192, 193
  These loops are deep in the axial 
channel and function to bind the substrate and translocate the substrate through the channel through a 
series of conformational changes coupled to ATP binding and hydrolysis.
192, 193
  The loops in the channel 
act like levers, flipping up and down in the channel to move the aggregate down to the next set of lever-
like loops.
192, 193
  Asymmetrical loop function among the hexamer subunits ensures that the substrate is 
constantly engaged in the channel to prevent loss of interaction between the chaperone and substrate.
194
  
The disaggregation mechanism of threading was further verified for Hsp104 and ClpB when a tripeptide 
sequence encoding an interaction domain for ClpP was introduced into the C-terminal domain of Hsp104 
and ClpB such that any substrates threaded through the central channel would be degraded by ClpP.
173, 
195
  These chimeras, termed HAP for Hsp104 and BAP for ClpB, have also been coupled with the 
“substrate trap” mutation to identify aggregates that get trapped in ClpP, suggesting that these 
aggregates are disaggregated by the threading mechanism.
173, 195
  Use of the HAP chimera identified 
Sup35 from [PSI+], but not [psi-], cells as a threading substrate of Hsp104.  Indeed, mutation of the pore 
loops either reduces or inhibits [PSI+] propagation.  These data suggest that Hsp104 propagates the 
prion by extraction of Sup35 molecules from the aggregate.   
 
The Middle Domain (M-domain) 
 The M-domain of Hsp104, composed of residues 412-532, is a coiled-coil domain inserted 
between NBD1 and NBD2 and is not well conserved among Hsp100/Clp chaperones.  In fact, the 
presence of this domain loosely correlates with a function in protein disaggregation.
196
  Insertion of the 
coiled-coil domain into the C-terminal region of NBD1 is often limited to members of the Hsp100 family 
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that function in protein disaggregation.  The position of this domain in relation to hexameric Hsp104 is still 
unclear as multiple structural models have been proposed which show vastly different placement for this 
domain.
156, 157
  From the cryo-EM reconstruction of hexameric ClpB, the M-domain was suggested to 
project from the body of the hexamer similar to blades in a propeller.
156
  Subsequent studies positioned 
the M-domain inside the hexamer, intercalated between the NBDs of neighboring subunits and potentially 
contacting substrates as they were threaded through the central channel.
157
  However, this model also 
resulted in the repositioning of the canonical arginine fingers.  More recent data examining the role of the 
arginine fingers demonstrated that the structure that correlates best with Hsp104 function is one in which 
the M-domain is highly mobile and solvent-exposed.
197
  Furthermore, examination of M-domain residues 
by H/D exchange and cross-linking suggest that the M-domain interacts with NBD1 of the neighboring 
subunit by nestling into the body of the hexamer.
198
  
 The model of Hsp104 function, as discussed above, suggests that the M-domain is responsible 
for driving hydrolysis at NBD1 through an intrasubunit signal transduction pathway.
168
  When peptide 
binds to the C-terminal domain, ATP binding and hydrolysis at NBD2 induces a conformational change in 
the M-domain resulting in an increase in ATP binding at NBD1.
168
  The peptide used for these studies 
was lysine-rich, a region proposed to be important for normal Hsp104 substrate recognition.  As such, 
these data suggest that the M-domain is responsible for coupling substrate binding and ATP hydrolysis.  
This mechanism has important implications for disaggregation activity as deletion of the M-domain or 
specific mutations can abrogate protein disaggregation.
172, 177, 192, 193
 
 Recent evidence suggested that M-domain cycles between distinct conformational states which 
regulate the function of Hsp104/ClpB.
198-200
  In the repressed state, the M-domain interacts with the 
neighboring NBD1 through electrostatic interactions.
198, 199
  Disruption of these interactions is proposed to 
cause the M-domain to move away from the body of the hexamer and become accessible to co-
chaperones, though how the conformation switch is governed is still unknown.
198, 199, 201
  Mutations which 
prevent this interaction result in Hsp104 hyperactivity and are toxic to cells, especially under stressful 
conditions.
198, 199
  In contrast, mutations that stabilize the interaction of the M-domain with the neighboring 
NBD1 repress the function of Hsp104.
198, 199
  Though the mechanism of how the M-domain regulates 
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distinct activities of Hsp104 is still relatively unclear, data have shown that regulating this interaction is 
essential not only for Hsp104 function, but also for cell viability.
198, 199, 201
  
 
The C-terminal Domain (CTD) 
 The CTD of Hsp104 is by far the least understood domain of Hsp104.  For the Clp chaperones 
that couple disaggregation activity with the protease activity of ClpP (ClpA and ClpX), the CTD is the 
interface and interaction site for ClpP.  The residues that encompass the ClpP binding site (IGF) have 
been added to the CTD of Hsp104/ClpB to couple the protease to these chaperones indicating that the 
CTD is the “exit” site for disaggregated polypeptides.
173, 195
  However, the CTD has been proposed to be a 
substrate binding site.
168
  Additionally, the Hsp104 CTD contains an acidic motif (IDDDLD) at the extreme 
C-terminus, which resembles the C-terminal cofactor binding motifs characteristic of eukaryotic Hsp70 
and Hsp90 (VEEVD and MEEVD).
202
  Through these domains, Hsp70 and Hsp90 interact with proteins 
that contain TPR domains suggesting that the same may be true for Hsp104.
203, 204
  To this end, Hsp70- 
and Hsp90-interacting proteins, Sti1 and Cpr7, bind to the CTD of Hsp104.
205-207
  In addition, deletion of 
the CTD abrogates Hsp104/ClpB hexamerization and some mutations can cause defects in 
thermotolerance.
160, 202, 208
 
 
The Effect of GdHCl 
 One of the agents that causes conversion of [PSI+] cells to [psi-] is the chaotropic agent, 
guanidine hydrochloride (GdHCl).
209
  While this effect was first demonstrated with the [PSI+] prion, it was 
later shown to be a common property of all yeast prions.
104, 123, 139, 209
  As GdHCl cures at only millimolar 
concentrations and after only 12-16 generations of cell growth, GdHCl is a potent inhibitor of prion 
propagation.
209, 210
  Growing [PSI+] cells in media containing GdHCl does not affect existing Sup35 
aggregates and does not prevent new Sup35 from joining Sup35 aggregates.
211, 212
  However, GdHCl 
does prevent the formation of new [PSI+] propagons suggesting that this prion-curing agent may inhibit 
fragmentation of Sup35 aggregates.  Indeed, GdHCl was shown to specifically inhibit the ATPase activity 
of Hsp104.
213-215
  A mutation of the NBD1 residue D184 can prevent GdHCl curing of [PSI+] cells 
suggesting that GdHCl may act by directly binding and inhibiting Hsp104 activity.
214
  This mechanism has 
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recently been further clarified by demonstrating that GdHCl exerts dual effects on Hsp104.  First, GdHCl 
inhibits Hsp104 by stabilizing the M-domain interaction with the hexamer and preventing efficient Hsp70 
interaction.
200
  Secondly, GdHCl binding to Hsp104 prevents continuous ATP turnover by local 
conformational changes in the GdHCl binding site.
200
  On the other hand, there is data that GdHCl affects 
[PSI+] independent of Hsp104 suggesting that curing of [PSI+] by GdHCl may occur by several 
independent methods and clearly still needs some investigation.
216
 
 
Hsp104 is essential for yeast prion propagation 
 As mentioned previously, most of the known yeast prions are dependent on the function of 
Hsp104 as deletion or inhibition of Hsp104 prevents propagation of these yeast prions.
103, 109, 217
  As the 
essential regulator of yeast prions, much investigation has focused on the mechanism of Hsp104 
interaction with prions.  Furthermore, numerous mutations in all domains of Hsp104 have been 
characterized which affect prion propagation by modifying various Hsp104 activities.
172, 218
  Two different 
models have been proposed to explain the role of Hsp104 in prion propagation that are rooted in the 
ability of Hsp104 to remodel protein aggregates. 
 The first model hypothesizes that Hsp104 is involved in remodeling prion protein monomers to 
catalyze formation of the amyloid conformation.  The molecular basis of this mechanism is unclear, but 
Hsp104 could promote the amyloid conformation by unfolding the monomer via the threading mechanism.  
The unfolded monomer would then be primed for refolding into the altered, amyloid conformation.  
Kinetically, Hsp104 would reduce the transition energy required to form the amyloid nucleus or enhance 
joining to pre-existing aggregates.  This model is supported by mainly in vitro data that showed 
recombinant Hsp104 catalyzed the formation of amyloid fibers of recombinant Sup35NM.
219-221
  This 
conclusion was made based on the observation that addition of Hsp104 shortened the lag phase of 
Sup35NM fiber formation.
219-221
  An alternative conclusion from this observation is that Hsp104 remodels 
off-pathway aggregates, which allows more efficient amyloid fiber formation.  In fact, Hsp104 interacts 
with Sup35 but only in the [PSI+] state
195
; an interaction between Hsp104 and monomeric Sup35 in vivo 
has yet to be detected.  Moreover, recombinant prion protein can form amyloid fibers in the absence of 
Hsp104 in vitro.
130
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 The prion fragmenting hypothesis suggests that Hsp104 fragments large SDS-resistant 
aggregates to generate oligomeric propagons.  In order to efficiently propagate, prions need to be 
dissociated to maintain a pool of propagons that are able to be transmitted to budding cells.
222
  If 
fragmentation does not occur, prion aggregates would both increase in size and reduce in number 
impairing their ability to be inherited by daughter cells.
222
  The disaggregation activity of Hsp104 is the 
ideal feature to generate propagons to ensure prion propagation.  Several studies report data that 
supports this model as the primary role for Hsp104 in prion propagation.
136, 153, 210, 213, 223
  First, inhibition of 
Hsp104 results in an increase in aggregate size of Sup35.
108, 136
  As discussed, addition of GdHCl to 
[PSI+] cells inhibits Hsp104 and cures [PSI+].
210, 213
  [PSI+] cells treated with GdHCl exhibit larger Sup35 
aggregates, suggesting that GdHCl inhibition of Hsp104 prevents fragmentation of Sup35 aggregates.
136, 
153
  Additionally, [PSI+] cells grown in media containing GdHCl also decrease in propagon number as 
cells divide, further supporting a role for Hsp104 in prion fragmentation.
136, 222
  Furthermore, studies 
examining how inhibition of Hsp104 affects Sup35-GFP aggregation suggest that Hsp104 does not affect 
addition of the monomer to the aggregate, but rather, remodels existing Sup35-GFP [PSI+] complexes to 
promote transmission.
153
  Finally, addition of recombinant Hsp104 to Sup35 amyloid fibers in vitro has 
demonstrated that Hsp104 is capable of disaggregating these fibers.
219-221, 224, 225
  Though there is some 
debate about how disaggregation of in vitro-made amyloid fiber occurs, these studies further support the 
prion fragmentation mechanism and offer new insight into the structural components of this 
mechanism.
219-221, 224, 225
 
 Mutational analysis of Hsp104 suggests that optimal activity of all of the distinct properties of 
Hsp104, hexamer formation, ATP hydrolysis, and substrate translocation, is required for efficient prion 
propagation
172, 218
.  In general, inhibition of any one of these activities often results in prion loss.  For 
example, the NBD mutations K218T/K620T, which abrogate ATP hydrolysis and hexamer formation, also 
inhibit prion maintenance and do so in the presence of wild type.
109, 152
  The N728A mutation, which 
prevents ATP hydrolysis but not hexamerization, cures [PSI+].
175, 226
  Additionally, mutation of the pore 
loop tyrosine residues, Y257A and Y662A show a differential effect where Hsp104-Y257A only mildly 
destabilizes [PSI+], while Hsp104-Y662A cures [PSI+] cells.
165, 195
  Whole domain replacement with the 
corresponding domains from ClpB showed that NBD1, NBD2, and the M-domain are required for prion 
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propagation while the NTD and CTD could be deleted or replaced with no effect on [PSI+] propagation.
165, 
166
   
Strikingly, characterized mutations that inhibit thermotolerance also inhibit prion propagation, with 
a few exceptional mutations in the CTD.
172, 218
  On the other hand, mutations that inhibit prion propagation 
do not always inhibit thermotolerance, suggesting that the disaggregation mechanism for prion substrates 
and non-prion substrates is distinct.
172, 218
  Additionally, these data suggest that the amount of 
disaggregation activity required for thermotolerance is not as strict as for prion propagation.  Slight 
perturbations in Hsp104 function can have extreme effects on prion maintenance while having little to no 
effect on thermotolerance.  Indeed, recent data has shown that disordered aggregates like the type that 
result from heat shock require less cooperative activity to be resolved than do ordered, prion 
aggregates.
170
  This study also shows that ClpB requires more cooperative activity among the hexamer to 
disaggregate disordered substrates than does Hsp104, perhaps demonstrating a reason why ClpB 
cannot substitute for Hsp104 in prion propagation.
170
  Thus, substrate stability and structure are 
contributing factors in the ability of Hsp104 to efficiently disaggregate a particular substrate.   
Due to the conformational variation characteristic of individual yeast prions, one might predict that 
not all yeast prions are similarly regulated by Hsp104.  One very interesting example is that while deletion 
of Hsp104 cures most of the known prions, only [PSI+] is cured by overexpression.
109, 139, 217
  The 
mechanism of [PSI+] curing by Hsp104 overexpression is still unclear as is the reason why only [PSI+] is 
affected.  One hypothesis for the mechanism of [PSI+] curing by overexpression of Hsp104 is that an 
excess of Hsp104 dissolves prion aggregates to monomers.
227
  One observation challenging this 
hypothesis is that in the presence of excess Hsp104, aggregates of Sup35 increase in size.
136, 228
  This 
result contradicts the expected results if Hsp104 were to cause hyper-disaggregation of Sup35 
aggregates.  Another hypothesis, then, is that overexpression of Hsp104 leads to larger, non-
transmissible aggregates that are “dead-end” products, though much is still unclear about this 
mechanism. 
 To further investigate the underlying cause of the increased sensitivity of the [PSI+] prion to 
Hsp104 expression levels, recent data investigates the regions in Sup35 that interact with Hsp104.
229
  
These data show that a specific 20 amino acid stretch in the highly charged M domain of Sup35 (129-
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148) is a site for Hsp104 interaction.  The authors speculate that a region specific for Hsp104 binding, like 
this stretch found in Sup35, is absent in other prions, though no binding studies of Hsp104 with other 
prion proteins have been reported.  This hypothesis suggests that prions that expose regions of high 
affinity for Hsp104 are more susceptible to dissociation by Hsp104.  Thus, conformational variation 
among different yeast prions may govern the interactions with Hsp104, and as a result, the ability of 
Hsp104 to disaggregate individual yeast prions.  Indeed, several Hsp104 mutants have been 
characterized which cure [PSI+] but do not cure [RNQ+], though curiously, they all localize to a similar 
region of Hsp104.
150, 230
 
 In addition to the differences of separate yeast prions in their requirements for interaction with 
Hsp104, individual conformational variants of the same prion also display distinct interactions with 
Hsp104.  For example, a weak variant of [PSI+] with a longer structural core and increased soluble pool 
compared to a strong [PSI+] variant, is more susceptible to curing by overexpression of Hsp104.
108
  
Additionally, a mutation in NBD1 of Hsp104, E190K, which affects ATPase activity, can differentially affect 
propagation of the [RNQ+] variants.
150
  Moreover, a variant of [PSI+] has been characterized, which 
depends on excess Hsp104 for efficient propagation.
231
  This variant was identified as an induced [PSI+] 
variant when Hsp104 and Sup35 were overexpressed simultaneously.
231
  More recent data compare the 
effect of Hsp104 on conformational variants of Sup35 aggregates formed at different temperatures in 
vitro.  Amyloid fibers of Sup35 formed at 4°C (NM4) that resulted in mostly strong [PSI+] when 
transformed into [psi-] cells were more readily remodeled by recombinant Hsp104 than Sup35 aggregates 
assembled at 37°C (NM37) that result in mostly weak [PSI+] variants after transformation into [psi-] 
cells.
224
  Remodeling of NM4 fibers by Hsp104 lead to prion-competent oligomers while the same amount 
of Hsp104 remodeled NM37 fibers into non-templating structures.
224
  Additionally, treatment of NM4 fibers 
with Hsp104 before transformation into [psi-] cells resulted in an increased proportion of resulting strong 
[PSI+] cells while treatment of NM37 fibers lead to a decrease in cells containing weak [PSI+] variants.
224
  
These data suggest that Hsp104 selectively amplifies certain [PSI+] variants based on its ability to 
interact with those variants.  Thus, not only does activity and expression of Hsp104 affect prion variant 
propagation, but can also affect induction and selection of specific prion variants. 
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The role of Hsp104 in asymmetric inheritance 
 During progressive cycles of cell division, yeast cells accumulate age-related damages that affect 
protein function, regulation of mitosis, and general cellular function.
232
  To prevent these age-related 
damages accumulating in the budding cell, including carbonylated or oxidatively damaged proteins, from 
being inherited by the newly generated buds, damaged proteins and other factors are confined to the 
mother cell in a process called asymmetric inheritance.
233
   One factor central to the mechanism of 
asymmetric inheritance is the sirtuin, Sir2, as deletion of Sir2, sir2Δ cells, results in an increase in the 
amount of carbonylated protein aggregates in the new buds and a decrease in replicative lifespan.
234
  
Interestingly, overexpression of HSP104 in sir2Δ cells restores normal replicative lifespan.
235
  In fact, 
hsp104Δ cells also display a decrease in replicative lifespan compared to wild type cells suggesting a role 
for Hsp104 in promoting damage asymmetry.
235
  This process is dependent on the actin cytoskeleton and 
Hsp104 appears to be part of the network linking the cytoskeleton to the process of asymmetric 
inheritance.
235, 236
  Co-expression of the HAP construct with ClpP displays defects in cell morphology and 
the actin cytoskeleton, suggesting that cytoskeletal proteins are normal substrates of Hsp104.
236
  Indeed, 
some evidence suggests that Hsp104 interacts with the polarisome complex and the cytokinesis 
machinery, and that deletion of certain components of both as well as deletion of Hsp104 can result in the 
symmetric distribution of damaged proteins between the aging mother cell and the new bud.
236
  The exact 
role of Hsp104 in promoting asymmetric inheritance is not yet fully understood but offers a new way to 
investigate the function of Hsp104 and perhaps add insight to its role in prion maintenance. 
 
1.5 The Chaperone Network: Hsp104, Hsp70, Hsp40 
In order to cover the variety of protein misfolding and aggregation issues, cells have evolved an 
elaborate and highly cooperative network of molecular chaperones.  In yeast and bacteria, a bichaperone 
network composed of Hsp104/ClpB and the Hsp70 system are responsible for processing disordered and 
stress-induced aggregates as well as highly structured and stable prion aggregates.  The Hsp70 system 
is composed of Hsp70s and Hsp40s in yeast and DnaK and DnaJ in bacteria, each with distinct functions 
in protein folding and aggregate resolubilization.   
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Effects of Hsp40s on yeast prions 
 The primary functions of the Hsp40 chaperones are to direct the interaction of Hsp70s with 
aggregate and misfolded substrates by binding directly to these substrates as well as stimulate ATP 
hydrolysis in their Hsp70 partners.  In yeast, there are 13 Hsp40 proteins and 41 in humans.
237
  Hsp40s 
share a highly conserved J-domain critical for Hsp70 ATPase stimulation.
238
  In addition to the J-domains, 
Hsp40s possess variable extra domains which allow targeting of Hsp70 chaperones to diverse cellular 
targets.
239
  The two most well-characterized Hsp40s in yeast are Ydj1 and Sis1, which each display 
distinct substrate preferences as well as very different activities on prion propagation.
239
  Ydj1 and Sis1 
both physically associate with Sup35 aggregates
240
, but only Sis1 is essential for [PSI+] propagation.
166, 
241
  Additionally, Sis1 is required for [RNQ+] and [URE3] propagation.
140, 142, 241
  However, Ydj1 
overexpression cures [URE3]
217
 and some variants of [RNQ+].
137
  These data suggest opposing models 
in prion propagation for the two Hsp40s, highlighting the distinct roles each plays in the cell.  Additionally, 
Ydj1 and Sis1 bind Rnq1 when it is in the [RNQ+] state though each has a separate binding site.
140, 242, 243
  
Thus, one hypothesis is that binding of each Hsp40 to [RNQ+] targets different Hsp70s to the prion 
resulting in either propagation or curing.  Interestingly, Sis1 was recently shown to enhance [PSI+] curing 
in the presence of overproduced Hsp104.
244
  How individual prions are regulated by differential Hsp40 
binding and how the Hsp40s have differential effects is still relatively unclear. 
 
 Effects of Hsp70s on yeast prions 
 Hsp70s are conserved and essential chaperones that directly facilitate protein refolding by 
binding to exposed hydrophobic regions of incompletely folded proteins.
245, 246
  Binding to these 
hydrophobic regions typically prevents aggregation and promotes efficient folding.  Hsp70 functions by 
cycling between ATP- and ADP-bound states to bind and release substrates.
247
  In the ATP-bound state, 
Hsp70 has low substrate affinity and rapid exchange while in the ADP-bound state, affinity for substrate is 
high.  Hsp70 has a slow intrinsic rate of ATP hydrolysis which can be stimulated by binding Hsp40s.  At 
one time, Hsp40s present bound substrate to Hsp70 and stimulate Hsp70 ATP hydrolysis to initiate 
Hsp70 binding.
248
  Yeast express six cytosolic Hsp70s, four are the essential Ssa subfamily (Ssa1-4) and 
two are the ribosome-associated Ssb subfamily (Ssb1 & 2).
249
  Efficient Hsp70 function also requires 
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nucleotide exchange factors (NEFs) to accelerate ADP release and subsequent rebinding of ATP.  The 
major NEFs in yeast are Fes1 and Sse1 (Hsp110).
250
 
 The Ssa and Ssb Hsp70s have both been demonstrated to associate with Sup35 in the [PSI+] 
state where Ssa1 is a major component (1 Ssa1:2 Sup35)
240
, however, the two chaperones demonstrate 
opposite effects on the [PSI+] prion.  For example, increased levels of Ssa1 prevent [PSI+] curing by 
excess Hsp104 and with some variants of [PSI+], increase phenotypic expression.
251
  Conversely, excess 
Ssb1 increases [PSI+] curing by excess Hsp104 and inhibits phenotypic expression of some [PSI+] 
variants.
252
  Excess Ssa1 is proposed to result in an increase in the size of Sup35 aggregate, which then 
counteracts the disaggregating effect of Hsp104.
253
  Moreover, excess Ssa1 on its own can cure [PSI+] 
and lead to an increase in aggregate size of specific [RNQ+] variants.
254
  On the other hand, a mutation in 
Ssa1 (Ssa1-21; L483W) decreases the number of [PSI+] propagons, thus destabilizing the [PSI+] prion.  
Interestingly, several mutations in the NTD of Hsp104 can overcome the defect imposed by Ssa1-21 and 
restore normal [PSI+] propagation.  Clearly, the functions of Hsp70 and Hsp104 in prion propagation are 
interdependent as mutations or changes in one can be compensated for by mutations changes in the 
other.  However, it is unclear if this mechanism holds true for prions in general as these mutations have 
only been tested with [PSI+]. 
 Not only do Hsp70s play a role in prion propagation, but the NEFs associated with Hsp70 also 
show interesting prion phenotypes.  For example, increased expression of the Hsp110 Sse1 strongly 
increased de novo [PSI+] formation whereas deletion of SSE1 severely inhibited it.
255
  Additionally, 
overproduction of Sse1 led to very strong variants of [PSI+] while depletion of Sse1 resulted in only weak 
[PSI+] variants.
255
  Furthermore, the Hsp90 co-chaperone, which can also interact with Hsp70 and has 
been shown to bind Hsp104, destabilized [PSI+] when overexpressed and stabilized [PSI+] when 
depleted.
256
  Undoubtedly, the mechanism of prion regulation by chaperone is complicated, resulting in 
highly varied phenotypes among different Hsp70:Hsp40:NEF interactions and more work is needed to 
understand these mechanisms. 
 
The Bichaperone network: Hsp104, Hsp70, and Hsp40 
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 Many studies have shown that the cooperation of the Hsp70 system and Hsp104/ClpB is required 
for efficient solubilization of protein aggregates.  Disaggregation of heat-aggregated proteins by the yeast 
chaperone Hsp104 required the presence of Ssa1 and Ydj1 and similar data was shown for ClpB, DnaK, 
and DnaJ in bacteria.
257, 258
  In both organisms, Hsp70/DnaK is proposed to act upstream of 
Hsp104/ClpB, promoting disaggregation by binding to aggregated substrates.
166, 259
  The engineered 
constructs, HAP and BAP, were able to degrade aggregated substrates in the presence of ClpP, but 
strictly in an Hsp70/DnaK-dependent manner.
191, 195
  These data suggested that Hsp70/DnaK were 
required for the initial substrate binding and translocation by Hsp104/ClpB.  Consistent with this 
hypothesis, binding of substrates to the N-terminal pore loop of ClpB required DnaK
190
 and DnaK binding 
to the substrate required DnaJ.
260
 
 Increasing evidence supports the binding of Hsp70/DnaK to the M-domain of Hsp104/ClpB during 
the disaggregation process.
261
  Indeed, a recent structural study using NMR has also shown specific 
contacts between DnaK and the M-domain of ClpB.
262
  Mixing domains of Hsp104 and ClpB 
demonstrated that the M-domain from Hsp104 is required for interaction with Ssa1 and Ydj1, but 
replacement with the M-domain from ClpB was able to couple Hsp104 to DnaK and DnaJ.
166, 177, 263
  
Surprisingly, Hsp104 and Ssa1 can also function with DnaJ, suggesting that the interface between 
Hsp104 and Hsp70 is the species-specific factor.
257
  Thus, the current proposed mechanism for the 
bichaperone network is that Hsp40/DnaJ recruits Hsp70/DnaK to the aggregated substrate whereby 
Hsp70/Hsp40/substrate then binds to the M-domain of Hsp104 and stimulates disaggregation of the 
substrate by Hsp104/ClpB.  Additionally, Hsp70 stimulation of the M-domain to depends on the 
conformation of the M-domain such that the M-domain must be accessible and in the de-repressed 
conformation for binding and stimulation to occur.
201, 264
  Although the mechanism of protein 
disaggregation by the bichaperone network is not entirely clear, recent structural studies have provided a 
deeper understanding of this interaction and its effects on aggregated substrates. 
 If this bichaperone mechanism is true for protein aggregates, then, can it also be applied to the 
mechanism of prion propagation?  Initial studies suggest that, indeed, prion disaggregation may occur in 
a similar fashion.  One study showed that incorporation of Hsp70 and Hsp40 into amyloid fibers in vitro 
made the fibers a better substrate for Hsp104 disaggregation.
265
  Additionally, amyloid fibers that were 
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disaggregated by Hsp104 in the presence of Ssa1 retained more infectivity than fibers disaggregated by 
Hsp104 alone.
265
  Furthermore, disaggregation of fibers in the presence of Ssb1 decreased the infectivity 
of the fibers.
265
  This in vitro data mimics the [PSI+]-promoting (Ssa1) and [PSI+]-antagonizing (Ssb1) 
phenotypes observed in vivo.  More recently, Ssa1 was shown to be required for Hsp104 fragmentation of 
Rnq1 fibrils in vivo.
266
  In the absence of Ssa1, Hsp104 was able to bind Rnq1 fibrils, but was incapable of 
remodeling them.
266
  Additionally, excess Hsp104 outcompeted Ssa1 for binding to Rnq1 fibrils in vivo 
suggesting a mechanism for the observed antagonism of excess Hsp104 curing of [PSI+] by excess 
Ssa1.
266
 
 
1.6 Hsp104 in Models of Protein Aggregation Disorders 
To date, no clear metazoan homolog or analog of Hsp104 has been identified.  Initial attempts to 
isolate a disaggregase by cellular fractionation have proven mostly unsuccessful.  One study shows that 
crude whole lysates of Caenorhabditis elegans are able to disaggregate and degrade Aβ fibers, but the 
factor(s) responsible have yet to be identified.
267
  It appears as if metazoan proteostasis focuses on 
clearing aggregates by proteolysis and autophagy instead of disaggregation and renaturation.  Given the 
common structure of amyloid fibers and oligomers and the ability of Hsp104 to rapidly and efficiently 
remodel yeast prions, the use of Hsp104 to remodel the mammalian disease-associated amyloid 
structures is an attractive thereapeutic model to reverse amyloid aggregation.
30, 83, 172
  Hsp104 has 
previously been expressed in mammalian cell lines and has been shown to collaborate with human 
Hsp70 and Hsp40 chaperones to refold thermally denatured firefly luciferase.
268
  Several different disease 
models have been generated to examine the ability of Hsp104 to interact with and disaggregate disease-
associated amyloid substrates. 
Expression of expanded polyQ tracts in yeast results in polyQ aggregation that is dependent on 
the [RNQ+] prion.
269, 270
  When cells are [RNQ+], expanded polyQ can aggregate and cause toxicity.  
Overexpression of Hsp104 in these cells resulted in significantly reduced toxicity potentiated by small 
heat shock proteins Hsp26.
269-271
  As such, Hsp104 may be able to cooperate with small heat shock 
proteins to disaggregate amyloid in other systems.  Interestingly, small heat shock proteins have also 
been shown to suppress Aβ toxicity suggesting that an interaction between Hsp104 and the small heat 
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shock proteins may be applicable to more than just polyQ disorders.
272
  The co-expression of expanded 
polyQ and Hps104 in C. elegans resulted in reduced inclusion formation and alleviation of developmental 
defects.
273
  Most remarkably, expression of Hsp104 in mouse models of Huntington’s disease prolonged 
life span of these mice by 20% though the physical symptoms were not improved.
274
  Additionally, 
Hsp104 caused a significant decrease in the number of inclusions.
275
 
As another model for a disease-associated protein, overexpression of human α-synuclein in yeast 
leads to toxicity and formation of cytoplasmic foci.
276
  Unlike the effects on expanded polyQ, 
overexpression of Hsp104 has no effect on α-synuclein toxicity.
271
  However, the cytoplasmic foci that 
form from aggregation of α-synuclein may not be amyloid-like aggregates.  Similarly, in a C. elegans 
model of Parkinson’s disease, Hsp104 also had no effect on toxicity.
277
  In a rat model, however, when 
Hsp104 and α-synuclein A30P were simultaneously expressed, Hsp104 reduced inclusion formation and 
prevented neurodegeneration.
278
  Nevertheless, several challenges remain to fully validate Hsp104 as a 
potential therapy for Parkinson’s disease. 
Finally, Hsp104 can interact with Aβ42 and can prevent formation of Aβ42 fibers in an ATP-
independent manner.
279
  However, Hsp104 is unable to disaggregate Aβ42 fibers in vitro.  Although these 
data show promising results for a therapeutic interaction between Hsp104 and Aβ42, no complementary 
in vivo approaches have been reported.  More recently, aggregates of mutant SOD1 were shown to be 
disaggregted by Hsp104, and these observations may provide insight into the mechanism of amyotrophic 
lateral sclerosis amyloid formation and disease progression.
280
 
 
1.7 Summary and Significance 
Protein aggregation and amyloid deposition are common features of several protein 
conformational disorders and investigating the mechanisms of amyloid aggregation has contributed 
significantly to our understanding of these diseases.  As non-toxic, epigenetic amyloid conformers, the 
use of yeast prions has allowed investigation of the genetic and environmental factors which contribute to 
amyloid formation.  One class of amyloid regulating factors is the molecular chaperones, whose normal 
function in preventing protein aggregation and misfolding make them ideal partners to ensure prion 
propagation.  Indeed, amyloid-associated protein conformational disorders are age-related and suggest 
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that changes in the chaperone network over time may contribute to cellular dysfunction and disease 
pathology.  Unfortunately, the very nature of the disease does not allow efficient investigation or treatment 
of the factors promoting amyloid formation.  In humans, detection of disease symptoms is often too late to 
treat the disease and studying normal mouse models without artificially speeding up the aggregation 
process would take years.  Therefore, yeast prions and their regulation by the bichaperone network 
provide an easily manipulated system in which to investigate amyloid aggregation and chaperone 
function. 
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Abstract 
Amyloidogenic proteins aggregate through a self-templating mechanism that likely occurs via 
oligomeric or prefibrillar intermediates.  For disease-associated amyloidogenic proteins, such 
intermediates have been suggested to be the primary cause of cellular toxicity.  However, 
isolation and characterization of these oligomeric intermediates has proven difficult, sparking 
controversy over their biological relevance in disease pathology.  Here, we describe an oligomeric 
species of a yeast prion protein in cells that is sufficient for prion transmission and infectivity.  
These oligomers differ from the classic prion aggregates as they are soluble and less resistant to 
SDS.  We found that the large SDS-resistant aggregates are required for the prion phenotype but 
soluble, more SDS-sensitive oligomers contain all the information necessary to transmit the prion 
conformation.  Thus, we identified distinct functional requirements of two types of prion species 
for this endogenous epigenetic element.  Furthermore, the non-toxic, self-replicating amyloid 
conformers of yeast prion proteins have again provided valuable insight into the mechanisms of 
amyloid formation and propagation in cells. 
 
Introduction 
The amyloid hypothesis proposes that large, protease-resistant amyloid fibers underlie the toxicity 
associated with several neurodegenerative diseases(Caughey and Lansbury, 2003; Chiti and Dobson, 
2006). A definitive link between the amyloid aggregate and toxicity and neurodegeneration has not been 
established(Haass and Selkoe, 2007). A recent alternative proposal posits that an intermediate in the 
amyloid pathway is the primary toxic agent, while the large, insoluble aggregates may sequester 
oligomers and perhaps aid in cell survival(Kirkitadze et al., 2002). Soluble oligomers of several 
amyloidogenic proteins including amyloid-β, huntingtin, α-synuclein, and PrP have been detected both 
from analysis of amyloid-forming recombinant proteins and in cell and mouse models(Conway et al., 
1998; Lasmezas et al., 1997; Lesne et al., 2006; Sajnani et al., 2012; Sanchez et al., 2003; Silveira et al., 
2005; Tzaban et al., 2002). These oligomers, characterized as putative intermediates in amyloid 
formation, encompass a variety of sizes and structures that cause toxicity when introduced into disease 
models(Klyubin et al., 2005; Sajnani et al., 2012; Silveira et al., 2005). Isolation of these dynamic, soluble 
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oligomers has remained largely elusive and, as such, investigation of their role in amyloid formation has 
proven challenging. 
 
The yeast prion protein Sup35 forms self-perpetuating amyloid conformers that are transmissible and 
infectious(Patino et al., 1996; Paushkin et al., 1996; Serio et al., 2000). To propagate the [PSI+] prion, 
Sup35 aggregates must undergo remodeling by the chaperone Hsp104, which facilitates monomer 
addition by severing amyloid structures to generate transmissible species, or propagons(Chernoff et al., 
1995; Kryndushkin et al., 2003; Satpute-Krishnan et al., 2007; Shorter and Lindquist, 2006). Until now, in 
vivo studies have primarily reported on the role of Hsp104 in aggregate fragmentation(Ness et al., 2002; 
Satpute-Krishnan et al., 2007). Interestingly, Hsp104 has also been shown to catalyze amyloid formation 
in vitro, specifically impacting the formation of amyloid oligomers(Shorter and Lindquist, 2004). Moreover, 
recent in vitro evidence identified Sup35 oligomers as intermediates during amyloid formation under some 
conditions(Ohhashi et al., 2010). Here, we identify soluble, more SDS-sensitive oligomers of Sup35 as 
prion propagons and show that Hsp104 plays a role in their maintenance. 
 
Results and Discussion
 
We performed a screen to identify cellular changes that rescued cells from toxic overexpression of SUP35 
in [PSI+] cells(Vishveshwara et al., 2009). As this toxicity is dependent on [PSI+], we expected to uncover 
factors that affected Sup35 aggregation. One mutation identified, hsp104-R830S, caused [PSI+] cells to 
appear phenotypically [psi-] by a readout of translation termination efficiency of a reporter that is 
indicative of the functional, soluble state of Sup35 (Fig. 2.1A). Fluorescent imaging showed that Sup35 in 
hsp104-R830S cells appeared diffuse (Fig. 2.1B), and by semi-denaturing detergent-agarose gel 
electrophoresis (SDD-AGE), only monomeric Sup35 was detected in hsp104-R830S cells (Fig. 2.1C). 
Strikingly, mating hsp104-R830S cells that appeared [psi-] to wild type HSP104 [psi-] cells produced 
many diploids that were phenotypically [PSI+], as seen by increased nonsense suppression (Fig. 2.2). 
Furthermore, sporulation of these diploids produced two [PSI+] and two [psi-] haploid progeny (Fig. 2.1D), 
thereby indicating that prion-competent propagons had been maintained in hsp104-R830S cells that 
resulted in cryptic [PSI+] (phenotypically undetectable). Indeed, transformation of hsp104-R830S cell 
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lysates into wild type [psi-] cells demonstrated that these propagons were infectious and produced [PSI+] 
cells. Out of 1,154 cells transformed, 45 were [PSI+] (3.9% infectivity). Control transformations of [psi-] 
lysates into [psi-] cells resulted in only red colonies.  Of the thousands of red colonies resulting from these 
control transformations, over 400 were further analyzed and confirmed to be [psi-]. Thus, the infectious 
propagon in hsp104-R830S cells is unable to cause observable nonsense suppression, but re-establishes 
and maintains the [PSI+] phenotype in the presence of wild type HSP104. 
 
Hsp104 normally functions to disaggregate non-prion aggregrates and promote cellular recovery from 
stress(Glover and Lindquist, 1998). Therefore, we tested the activity of the Hsp104-R830S mutant with 
other known substrates. Interestingly, the thermotolerance of hsp104-R830S cells resembled that of wild 
type cells (Fig. 2.3A). Moreover, hsp104-R830S cells efficiently resolubilized heat-aggregated luciferase 
(Fig. 2.3B). Hsp104 threads substrates through a central channel as a mechanism of 
disaggregation(Tessarz et al., 2008). The Hsp104 variant, HAP, has been used to investigate threading 
activity by coupling Hsp104 to the ClpP protease so that threaded substrates are degraded, resulting in 
decreased viability(Tessarz et al., 2008). We created the HAP-R830S variant and found that the mutant 
maintained threading activity (Fig. 2.3C). Hsp104 is an AAA+ ATPase. Mutations that inhibit ATP 
hydrolysis or hexamerization typically prevent [PSI+] propagation(Glover and Lum, 2009). We purified 
Hsp104-R830S and measured a reduced initial rate of ATP hydrolysis of 0.1659±0.0308 nmol Pi·µg
-1
·min
-
1
, as compared to the initial rate of wild type Hsp104 of 0.2975±0.412 nmol Pi·µg
-1
·min
-1
, which is 
comparable to previously published data(Tkach and Glover, 2004).  We next analyzed the distribution of 
Hsp104-R830S, relative to wild type Hsp104, using glycerol gradients and size-exclusion 
chromatography. These analyses revealed that Hsp104-R830S forms unstable hexamers (Fig. 2.3D & 
2.4). Together, these data reveal that the reduced activity of Hsp104-R830S impairs the maintenance of 
the [PSI+] phenotype. 
 
Next, we assessed the state of Sup35 in hsp104-R830S cryptic [PSI+] cells. We first performed 
sedimentation analysis with hsp104-R830S cryptic [PSI+] lysates and found that Sup35 was soluble (Fig. 
2.5A). Next, we subjected lysates of hsp104-R830S cryptic [PSI+] and HSP104 [psi-] cells to sucrose 
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gradient fractionation. Monomeric Sup35 in [psi-] cells remained in the top fractions, while Sup35 from 
hsp104-R830S lysates was detected further down the gradient, demonstrating the existence of some 
oligomeric species (Fig. 2.5B). To understand how these oligomers relate to the large SDS-resistant 
aggregates associated with the [PSI+] phenotype, we created a system to examine the effect of hsp104-
R830S on pre-existing Sup35 aggregates. We covered hsp104-R830S cryptic [PSI+] with wild type 
HSP104 expressed from a glucose-repressible promoter such that cells grown in non-repressing 
galactose allowed the propagation of [PSI+] and maintained SDS-resistant aggregates (Fig. 2.5C, Gal). 
We then shifted the cells to glucose to repress wild type HSP104 (Fig. 2.6A) and performed SDD-AGE to 
monitor the effect of hsp104-R830S on SDS-resistant Sup35 aggregates. Within twelve hours of wild type 
HSP104 repression, monomeric Sup35 was apparent in hsp104-R830S cells. Within twenty-four hours, 
SDS-resistant aggregates had disappeared (Fig. 2.5C). As expected, when hsp104-R830S pGAL-
HSP104 cells were switched from glucose back to galactose to derepress wild type HSP104, they 
became phenotypically [PSI+] (Fig. 2.6B). Therefore, despite the loss of SDS-resistant aggregates, the 
propagons remained. Thus, the large SDS-resistant Sup35 aggregates are not strictly required for 
transmission of the prion. 
 
We therefore reasoned that a less stable subpopulation of Sup35 might be capable of prion transmission. 
Indeed, that the addition of SDS to Sup35 prion aggregates results in smaller SDS-resistant polymers 
suggests that some less SDS-resistant species exists within the large prion aggregates(Kryndushkin et 
al., 2003). We investigated whether the soluble oligomers in hsp104-R830S cryptic [PSI+] cells were less 
resistant to SDS, as has been reported for another prion (Taneja et al., 2007). We again performed SDD-
AGE on hsp104-R830S cryptic [PSI+] lysates but decreased the SDS concentration, and only then did we 
observe the presence of oligomeric species (Fig. 2.5D). To determine how these species related to prion 
propagons and the cryptic [PSI+] phenotype, we repeated the wild type HSP104 repression time course 
with hsp104-R830S cells using a low SDS SDD-AGE. We observed the maintenance of less SDS-
resistant, oligomeric species throughout the time course (Fig. 2.5E), suggesting that the soluble, less 
SDS-resistant oligomers are the transmissible propagons in hsp104-R830S cryptic [PSI+] cells. 
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Although we observed the unstable, soluble oligomers in the absence of insoluble aggregates, it is likely 
that both species exist in wild type cells, and the more SDS-sensitive, soluble oligomers are more readily 
detectable in cells lacking insoluble aggregates. Therefore, we separated the Sup35 species in both 
hsp104-R830S cryptic [PSI+] and wild type [PSI+] cells by sucrose gradient and performed protein 
transformation to determine whether the soluble fractions contained infectious propagons. Both hsp104-
R830S and HSP104 cells contained soluble Sup35 oligomers that were infectious to [psi-] cells (Fig. 
2.7A). While much of the Sup35 species from wild type lysates migrated to the bottom of the gradient 
(35% of the total Sup35 which correspond to 54% of the infectivity), there were highly infectious oligomers 
in wild type [PSI+] cells that did not migrate with the heavy-sedimenting aggregates.  This soluble pool of 
Sup35 contains 46% of the infectivity in wild type [PSI+] lysates.  Curiously, the high-molecular weight 
aggregates observed in hsp104-R830S cells were not very infectious, suggesting that these aggregates 
are not the same high-molecular weight aggregates present in wild type [PSI+] cells and are not efficient 
[PSI+] propagons.  We then performed a simple solubility assay to separate wild type [PSI+] lysates into 
soluble and insoluble fractions (see Fig. 2.5A) and then performed infectivity assays and SDD-AGE 
analysis. Strikingly, we found much of the infectivity in the soluble fraction (32.8% of the total Sup35 
which corresponds to 30% of the infectivity) from sedimentation analysis (Fig. 2.7B).  Additionally, by 
SDD-AGE, we found that there were no Sup35 oligomers resistant to 2% SDS in the soluble fraction (Fig. 
2.7C).  As such, these data support our hypothesis that insoluble aggregates are not strictly required for 
prion transmission. 
 
Propagons contain the variant-specific properties required for inheritance and propagation of distinct prion 
phenotypes(Satpute-Krishnan and Serio, 2005; Tanaka et al., 2004). Therefore, the soluble oligomers in 
hsp104-R830S cryptic [PSI+] cells should retain the properties necessary to propagate the parental 
strong [PSI+] phenotype. If hsp104-R830S altered the prion structure, instead of cryptic [PSI+], weakened 
nonsense suppression and enhanced mitotic loss could be expected. After crossing hsp104-R830S 
cryptic [PSI+] cells to [psi-] cells, we compared the [PSI+] meiotic progeny to the parental strong [PSI+] 
variant used initially in the screen. We found that the [PSI+] progeny were indeed strong [PSI+] 
phenotypically (Fig. 2.7D). We then performed SDD-AGE analysis of the resulting [PSI+] haploids as 
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compared to the strong [PSI+] and a weak [PSI+] variant(Bagriantsev and Liebman, 2004; Derkatch et al., 
1996; Kryndushkin et al., 2003). The SDS-resistant Sup35 aggregates in the [PSI+] progeny appear the 
same as strong [PSI+] (Fig. 2.7E). We also noted that all the [PSI+] transformants from infection of 
hsp104-R830S lysates into [psi-] cells were strong [PSI+]. Thus, Hsp104-R830S did not alter the 
properties of the original variant phenotypically or biochemically, suggesting that there was no change in 
prion structure. 
 
We have shown, for the first time, the presence of soluble, prion-competent, less SDS-resistant oligomers 
of Sup35 in vivo. The less SDS-resistant, soluble oligomers are sufficient for transmission of the prion 
conformation, but are not sufficient to produce the nonsense suppression phenotype associated with 
[PSI+]. We have also shown that the insoluble aggregates that characterize [PSI+] cells are not required 
for prion transmission or infectivity. Furthermore, we have uncovered two novel features of yeast prion 
propagons. First, they can be more SDS-sensitive, where previously only SDS-resistant aggregates of 
Sup35 were shown to be infectious(Bagriantsev et al., 2008). This sensitivity parallels the previously 
described PK-sensitive PrP species which can also transmit the prion(Sajnani et al., 2012). Second, 
soluble oligomers were able to act as propagons in vivo. Oligomers of several amyloidogenic proteins 
have been described and can cause toxicity in the absence of large aggregates(Haass and Selkoe, 
2007). Indeed, our data correlate well with previous reports that visible Sup35 aggregates are lost in the 
mother cell and yet the prion is faithfully propagated(Taguchi and Kawai-Noma, 2010). Perhaps the SDS-
resistant, insoluble Sup35 aggregates function as a reservoir for the continued renewal of transmissible 
propagons. This role for SDS-resistant yeast prion aggregates mirrors the proposed role for amyloid 
aggregates as traps for oligomers(Kirkitadze et al., 2002). As such, we clearly show separate functions of 
two distinct aggregate species that are structurally-related components of the same prion propagation 
pathway. A mutant in Hsp104 enabled us to initially tease out these species. We favor a model whereby 
the decreased activity of hsp104-R830S results in reduced fragmentation of aggregates but our data do 
not exclude the possibility that Hsp104 normally plays a role in generating the large insoluble aggregates. 
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The soluble oligomers that exist in many conformational disorders are challenging to characterize due to 
their dynamic and metastable nature. In addition, conflicting reports on the properties and structure of 
oligomers complicate the elucidation of the important oligomeric species(Haass and Selkoe, 2007). The 
properties and mechanisms associated with yeast prion propagons may be similar to those associated 
with amyloidogenic proteins involved in self-propagating protein conformational disorders. Therefore, 
investigating these features may lead to a better understanding of the function and structure of soluble, 
self-templating oligomers, as well as the role of amyloid in disease. 
 
Materials and Methods 
Strains and Yeast cultivation 
The yeast strains used in this study are derivatives of Saccharomyces cerevisiae 74-D694 and 
were grown using standard culture techniques.  YPD is rich yeast medium whereas SD is synthetic 
medium lacking amino acids as needed to select for maintenance of plasmids or screen for a nonsense 
suppression phenotype (SD-Ade).  The strain used in the screen, 74-D694 [PSI+] can1Δ::MFA1pr-HIS3-
MFa1p r-LEU2 ade1-14 ura3-52 lys2Δ::KanMX4 pRS315CUP1-SUP35, was transformed with ten 
independent plasmid pools of the mini-transposon (3XHA/lacZ(mTn3)) mutagenized library (kindly 
provided by M. Snyder) and selected on media containing 350µM copper sulfate to induce expression of 
SUP35.  Candidates that rescued toxicity associated with increased expression of SUP35 were passaged 
a second time on copper sulfate media and were examined for the effect on [PSI+] phenotypically by 
color and genetically by mating to unmutagenized 74-D694 [PSI+] and [psi-] isogenic strains.  Several 
mutants, not linked to the transposon, were analyzed and determined to be in Hsp104 thru genetic 
analysis.  The mutant characterized here, hsp104-R830S, was recreated and these strains were used for 
further characterization.  Phenotypic assays are based on the amount of functional Sup35 to terminate 
the premature stop codon in ade1-14, which results in the accumulation of a red-pigmented intermediate 
in the adenine biosynthesis pathway(Liebman and Derkatch, 1999). 
SDD-AGE protein analysis 
  Cells were lysed by beadbeating in Buffer A (25mM Tris-HCl pH 7.5, 50mM KCl, 10mM MgCl2, 
1mM EDTA, 10% Glycerol plus mini EDTA-free protease inhibitors (Roche), Aprotinen (Sigma) and PMSF 
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(Sigma)).  Samples were treated at room temperature for 7 minutes in sample buffer containing 2% SDS 
then electrophoresed through a 0.1% SDS, 1.5% agarose gel.   The gels were subjected to western blot 
with anti-Sup35 antibody.  The experiments done with lower SDS concentrations contained 0.01% SDS in 
the gel and between 0.05 and 0.1% SDS in the sample buffer, as indicated.  Molecular weight markers 
were not used because non-denatured protein aggregates were being analyzed. 
Fluorescence Microscopy 
Cells were transformed with pRS426CUP1-SUP35NM-GFP and grown in media lacking uracil.  
50µM CuSO4 was added to logarithmically growing cells and grown for four hours to induce expression of 
SUP35NM-GFP.  Images of cells expressing Sup35NM-GFP, in water and at room temperature, were 
captured on an Olympus Bmax-60F microscope containing a 1.35NA 100X UPlanApo objective lens, 
spinning disc Confocal Scanner Unit (CSU10), and a Stanford Photonics XR-Mega10 ICCD camera.  
Images were acquired using QED software and analyzed by Image J. 
Protein Transformation 
 Recipient [psi-] cells from logarithmically growing cultures were spheroplasted with lyticase.  
Samples from cell lysis, sedimentation analysis, and sucrose gradient fractionation were added to the 
spheroplasts in 1M sorbitol along with a vector containing the URA3 gene for selection on media lacking 
uracil.  The cells were incubated at room temperature then recovered at 30°C.  Media containing glucose, 
sorbitol, and agar was added to the cells before plating the cells on sorbitol plates lacking uracil.  
Transformants were replica plated to YPD plates, and individual colonies were picked from those YPD 
plates and spotted onto YPD and both media lacking adenine and containing GdHCl for quantification of 
infectivity. 
Purification of Hsp104 
Hsp104 was purified as previously described(Lum et al., 2004).  Recombinant Hsp104 tagged 
with a 6x- Histidine tag was expressed in E. coli cells and affinity purified using a Ni
2+
-sepharose column.  
Next, the 6x-Histidine tag was removed by cleavage with the TEV protease and the untagged Hsp104 
was separated from the uncleaved, tagged Hsp104 by affinity purification.  The untagged Hsp104 was 
further purified using anion exchange via a Q-sepharose column.  The pure Hsp104 collected from the Q-
sepharose column was then separated on an S-300 gel filtration column to isolate monomeric Hsp104.  
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Purified, monomeric Hsp104 was pooled, concentrated, and frozen at -80°C.  Multiple purification 
preparations were used for all assays in repeat experiments. 
ATP Hydrolysis Assays 
ATP hydrolysis was monitored by the Malachite Green assay.  2µg purified Hsp104 was 
equilibrated in buffer (40mM TrisHCl pH7.5, 175mM NaCl, 5mM MgCl2, 0.02% Triton X-100) at 37°C 
before adding 5mM ATP (Sigma).  During incubation of Hsp104 with ATP at 37°C, samples were taken 
and free phosphate was measured by addition of Malachite green dye (Sigma).  Color development 
occurred over one minute and was terminated by the addition of 34% citric acid (Sigma).  Absorbance 
was measured at 650nm.   
Glycerol Gradients 
Purified protein at 75ug was incubated in buffer (20mM Tris pH 8, 100mM NaCl, 10mM MgCl2, 
2mM EDTA, 10% glycerol) +/- ATP for 5 minutes on ice before loading onto linear glycerol gradients (15-
35%).  The gradients were spun at 34,000 rpm for 18 hours in an SW55 rotor.  Gradients were 
fractionated and the fractions analyzed by SDS-PAGE and western blot with anti-Hsp104 antibody. 
Size Exclusion Chromatography 
Purified protein at 1mg/mL was incubated in buffer (50mM Tris pH7.5, 200mM KCl, 10mM MgCl2, 
2mM DTT, 2mM EDTA) +/- ATP for five minutes.  The sample was applied to an S-300HR column and 
fractions were collected.  The concentration of Hsp104 was measured by Bradford analysis (Bio-Rad). 
Thermotolerance Assays 
Cells were grown to mid-log phase at 30°C.  An equal number of cells from each sample were 
aliquoted and pre-treated at 37°C for thirty minutes.  Samples were heat shocked at 50°C for the 
indicated amounts of time and then diluted five-fold before plating onto solid rich medium. 
In Vivo Luciferase Refolding Assay 
In vivo luciferase refolding assays were performed as previously described(Tipton et al., 2008).  
Briefly, cells carrying pRS316GPD-Lux (kindly provided by B. Bukau) were pretreated at 37°C for one 
hour to induce expression of HSP104, then heat shocked at 44°C for an hour.  After fifty minutes of heat 
shock, cycloheximide was added to prevent new protein synthesis.  After heat shock, the cells recovering 
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at 30°C were aliquoted at fifteen minute intervals and D-luciferin (Sigma) was added.  Luminescence was 
measured and plotted as a percentage of total luciferase activity before heat shock.   
Hsp104 Shutoff Experiments 
The diploid strains, HSP104/hsp104Δ::leu2 and HSP104/hsp104-R830S were transformed with 
pRS416GAL-HSP104, sporulated, and dissected on CSM-Ura + 0.25% Galactose + 2% raffinose.  Low 
levels of galactose were used to avoid curing [PSI+] by overexpression of HSP104.  Progeny were 
selected that contained the plasmid and were pink in color as evidence that [PSI+] was maintained.  Cells 
were grown in CSM-Ura + 0.25% galactose + 2% raffinose for 48 hours before switching the cells to 
glucose media lacking uracil to repress expression of the HSP104 plasmid.  At six hour intervals, aliquots 
of the sample were taken and both pelleted for SDD-AGE and plated on CSM-Ura + 0.25% galactose + 
2% raffinose plates. SDD-AGE was performed as described above.  Gels were transferred to PVDF 
membrane and probed with anti-Sup35 antibody. 
Sup35 Solubility Assays 
Cells were lysed by beadbeating in buffer (10mM NaPO4 pH 7.5, 250mM NaCl, 2% SDS, 1% 
Triton X-100 plus mini EDTA-free protease inhibitors (Roche), and PMSF (Sigma)).  Lysates were 
subjected to ultracentrifugation at 100,000rpm in a Beckman TLA-100 rotor for one hour.  The 
supernatant was collected and the pellet resuspended in lysis buffer.  Total, supernatant, and pellet 
fractions were subjected to SDS-PAGE and western blot with anti-Sup35 antibody as well as protein 
transformation. 
Sucrose Gradients 
Cells were lysed by beadbeating in Buffer A.  Total protein was normalized to 1mg/mL and loaded 
onto a 4mL linear sucrose gradient (15-60%) and centrifuged at 32,000rpm for either three or 22 hours.  
In order to compare infectivity of soluble and insoluble Sup35 from HSP104 [PSI+] by sucrose gradient, 
we increased the time of centrifugation to a time that reproducibly showed a large fraction of pelletable 
Sup35.  Thus, after a 22 hour spin, we are able to distinguish the soluble Sup35 and the insoluble Sup35 
which migrates to the bottom of the gradient.  Gradients were fractionated and the fractions were 
analyzed by SDS-PAGE, western blot, and protein transformation. 
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Figure 2.1 hsp104-R830S propagates cryptic [PSI+]. 
   
A, [PSI+], [psi-], and hsp104-R830S cells were spotted on media containing CuSO4 to induce toxic 
overexpression of Sup35, media lacking adenine (SD-Ade) to assess nonsense suppression of the 
premature stop codon in ade1-14, and rich media (YPD).  B, HSP104 [PSI+] and hsp104-R830S cells 
containing pSup35NM-GFP were imaged by fluorescence microscopy. Scale bar represents 10µm. C, 
Western blot of an SDS-containing agarose gel (SDD-AGE) shows Sup35 aggregate status in lysates of 
indicated strains. This blot is one representative of three individual experiments.  D, An example of two 
tetrads where mating hsp104-R830S to [psi-] cells, both containing the ade1-14 mutation, resulted in 
tetrads with two red (efficient translation termination, hsp104-R830S) and two light pink (increased 
nonsense suppression, [PSI+] HSP104) haploids. 
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Figure 2.2 hsp104-R830S haploids crossed to [psi-] haploids results in [PSI+] diploids.  
 
The presence of phenotypically undetectable [PSI+] prion propagons was apparent when red hsp104-
R830S haploids were mated to wild type red [psi-] haploids.  Though the hsp104-R830S haploids appear 
[psi-] (red in color due to efficient translation termination of ade1-14), prion propagons are still present 
that can efficiently template soluble Sup35 in the presence of wild type HSP104 to produce mostly pink 
[PSI+] HSP104:hsp104-R830S heterogeneous diploids.  Diploids from the cross were spotted onto YPD 
plates and [PSI+] and [psi-] controls are labeled in the upper left corner of the plate. 
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Figure 2.3 Analysis of Hsp104-R830S activity reveals the mechanism of altered activity.  
 
A, Growth on YPD plates of the strains heat shocked at 50°C for times indicated. Untreated cells were 
spotted before heat shock. B, HSP104 (black), hsp104-R830S (red), and hsp104Δ (orange) cells 
expressing heat-aggregatable luciferase were heat shocked at 44°C while blocking new protein synthesis.  
Luminescence during recovery at 30°C was plotted as a fraction of luminescence before heat shock. 
Error bars represent the standard deviation. C, hsp104Δ cells carrying pRS315CUP1-ClpP, covered by 
the indicated plasmids, were spotted on media containing CuSO4 to induce expression of ClpP. D, 
Hsp104 (upper) and Hsp104-R830S (lower) incubated +/- ATP (red/black) separated on a glycerol 
gradient by ultracentrifugation.  Top of the gradient is fraction number 1.  Fractions were analyzed by 
SDS-PAGE and western blot.  All experiments were repeated at least three times. 
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Figure 2.4 Hsp104-R830S does not form efficient hexamers.   
 
Recombinant Hsp104 (upper panel) and Hsp104-R830S (lower panel) were incubated either with ATP (♦) 
or without ATP (◊) and applied to an S-300 size exclusion column.  Fractions of the eluate were collected 
and Bradford analysis (absorbance at 595nm) was performed to quantify the amount of Hsp104 protein in 
each fraction.  Both recombinant Hsp104 and Hsp104-R830S without ATP migrate mainly as monomers 
or dimers.  Incubation of wild type Hsp104 with ATP causes hexamers to form, but Hsp104-R830S 
incubated with ATP is distributed across several fractions, suggesting an inability to efficiently hexamerize 
(or maintain stable hexamers) in response to ATP binding.  Proteins of known molecular weights, 
thyroglobulin (669kDa) and aldolase (158kDa), were also applied to the column and their elution peaks 
are labeled for reference. 
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Figure 2.5 hsp104-R830S propagates SDS-sensitive soluble oligomers of Sup35.  
 
A, Ultracentrifugation separated lysates into total (T), soluble (S) and pellet (P) fractions. B, Fractionation 
of [psi-] and hsp104-R830S cryptic [PSI+] lysates separated by a three hour centrifugation through a 
linear sucrose gradient. C, Hsp104 and hsp104-R830S cells carrying p416GAL-HSP104 grown in 
galactose were switched to glucose to repress p416GAL-HSP104 and p416GAL-HSP104 was efficiently 
repressed by 12 hours in glucose as shown by western blot in an hsp104Δ control (Fig. S3).  Aliquots 
were taken from galactose and between 12 and 72 hours in glucose and subjected to SDD-AGE. The 
shift in aggregate distribution occurs when changing carbon sources. D, Lysates of the indicated strains 
were analyzed by SDD-AGE.  The HSP104 [PSI+] and [psi-] and hsp104-R830S samples were incubated 
in sample buffer containing the indicated percentages of SDS. E, Same as (D) but samples were 
subjected to SDD-AGE containing 0.01% SDS.  All experiments were repeated at least three times and 
protein molecular weight markers (kD) are indicated. 
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Figure 2.6 Glucose represses expression of wild type HSP104 but [PSI+] propagons persist in the 
absence of SDS-resistant aggregates.   
(A) In order to establish a system whereby we could determine the effect of hsp104-R830S on pre-
existing [PSI+] aggregates, we transformed a plasmid expressing wild type HSP104 driven by the 
galactose promoter (pRS416-GAL-HSP104) into heterozygous diploids expressing either wild type 
HSP104 or hsp104-R830S and hsp104Δ on the chromosome.  In order to determine if switching the cells 
expressing pRS416-GAL-HSP104 to glucose efficiently repressed wild type HSP104, we performed a 
western blot to detect the amount of Hsp104 expressed while growing in galactose (plasmid-borne wild 
type HSP104 is expressed, Gal) and for various amounts of time after switching the cells to glucose 
(plasmid-borne wild type HSP104 is repressed, 6-48 for wild type and hsp104-R830S and 6-24 for 
hsp104Δ).  We compared wild type HSP104 and hsp104-R830S cells containing pRS416-GAL-HSP104 
to hsp104Δ cells containing pRS416-GAL-HSP104.  After only six hours in glucose, we could detect no 
Hsp104 in the hsp104Δ cells.  This suggests that over the time course of our assay (Fig. 3C), wild type 
HSP104 from the plasmid was efficiently repressed while growing in glucose. Total protein loading was 
assessed by membrane stain. (B) We investigated the effect of hsp104-R830S on pre-existing 
aggregates of Sup35 by both SDD-AGE (Fig. 3C & 3E) and by nonsense suppression phenotype (using 
ade1-14) after repression of wild type HSP104.  Briefly, cells (hsp104-R830S or hsp104Δ) carrying 
galactose-inducible wild type HSP104 on a plasmid were grown in low galactose (0.25%) to maintain 
[PSI+].  Cells were then switched to glucose media to repress wild type HSP104, grown for various times 
in liquid glucose media (hours post shift to glucose), and then plated on media plates lacking uracil and 
containing galactose (0.25%) to derepress wild type HSP104.  The restoration of wild type HSP104 
allowed for assessment of whether the cells contained any species capable of propagating [PSI+].  
Throughout the time course tested, the hsp104-R830S cells were phenotypically [PSI+] on galactose 
plates while the hsp104Δ cells had truly lost the prion phenotype (red in color indicating efficient 
translation termination). 
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Figure 2.7 Soluble oligomeric [PSI+] propagons are infectious and maintain the prion variant 
structure.  
 
A, Fractions of [PSI+] and hsp104-R830S cryptic [PSI+] lysates separated on a linear sucrose gradient by 
a 22 hour ultracentrifugation step were analyzed by western blot and the amount of Sup35 (presented as 
the percent of soluble Sup35) in each fraction was quantified by Image J and is indicated below each 
fraction in the western blot.  Equal volumes of each fraction were transformed into [psi-] cells.  The 
fraction of infected [PSI+] cells obtained from each gradient fraction is indicated for hsp104-R830S (black) 
and HSP104 (grey) cells. The fraction of infected [PSI+] cells was generated by compiling the infectivity 
data from four (HSP104) or five (hsp104-R830S) separate sucrose gradients and transformations.  Sup35 
in hsp104-R830S lysates appears to be more susceptible to proteolysis and frequently shows 
degradation products. Protein molecular weight markers (kD) are indicated. B, Total, soluble, and 
insoluble fractions of HSP104 [PSI+] lysates from sedimentation analysis were transformed into [psi-] 
cells.  The relative infectivity of the total, soluble, and insoluble fractions was calculated as above and is 
indicated. Inset: A western blot for Sup35 in Total (T), Soluble (S), and Insoluble (I) fractions from one 
sedimentation assay in this experiment with protein molecular weight marker (kD).  Of the thousands of 
red colonies resulting from transformation of the soluble and insoluble fractions from wild type [psi-] cells 
as a negative control, further analysis verified that 48 from each fraction were [psi-] in each of three 
independent experiments.  C, Total (T), Soluble (S), and Insoluble (I) fractions of HSP104 [PSI+] lysates 
from sedimentation analysis were analyzed by SDD-AGE.  The soluble fraction is from the top of the 
supernatant to prevent contamination from the pellet. This experiment was repeated three times.  D, Two 
representative tetrads from the mating of hsp104-R830S cryptic [PSI+] to [psi-] were spotted on YPD 
(upper) and SD-Ade plates (lower) to assess the level of nonsense suppression.  Strong [PSI+] (Control 
A), weak [PSI+] (Control B), and [psi-] (Control C) strains were spotted for reference. E, The lysates of the 
four white haploids from the tetrads in (C) were analyzed by SDD-AGE and compared to strong (St) and 
weak (Wk) [PSI+] controls. 
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Abstract 
 Molecular chaperones play a significant role in preventing protein misfolding and aggregation in 
order to prevent toxicity and protein loss-of-function.  Indeed, protein conformational disorders resulting 
from the misfolding and aggregation of proteins and have been linked to changes in the chaperone 
network.  In yeast, molecular chaperones also play a role in prion propagation.  Yeast prions are self-
replicating amyloid aggregates, which are proposed to play a functional role in yeast cell biology.  Yeast 
prion propagation requires the molecular chaperone Hsp104 to fragment prion aggregates to generate 
propagons which can transmit the prion conformation to soluble prion protein monomers.  Hsp104 is an 
AAA+ ATPase involved in disaggregating stress-induced protein aggregates that is essential for yeast 
prion propagation.  Here, we show that the coiled-coil middle domain of Hsp104 is an integral part of the 
prion propagation mechanism.  We have generated mutations in the M-domain of Hsp104 which are 
predicted to stabilize either the repressed or de-repressed conformation of the M-domain and have 
characterized the effect of these mutations on Hsp104 activity.  We show that mutations predicted to 
stabilize the repressed conformation of the M-domain inhibit general chaperone activity.  On the other 
hand, de-repressed mutations have differential effects on ATP hydrolysis and disaggregation suggesting 
that the M-domain is involved in coupling these two mechanisms.  Furthermore, we show that changes in 
the M-domain have more of an effect on weak [PSI+] variants whereas strong [PSI+] variants are less 
susceptible to de-regulation of the middle domain.  Additionally, changes in the M-domain differentially 
affect of [PSI+] and [RNQ+] propagation, further supporting the hypothesis that these two prions vary in 
their dependence and interaction with Hsp104.  Thus, we provide evidence that regulation of the M-
domain of Hsp104 is critical for efficient prion propagation and that elucidating the role of the M-domain in 
the mechanism of prion propagation is important for understanding propagation of individual prions as 
well as prion variants. 
 
Introduction 
Protein aggregates pose a considerable challenge to cellular homeostasis. As such, protein 
misfolding and aggregation are guarded against by molecular chaperones, which act as the cell’s first line 
of defense by promoting proteostasis.  In bacteria, fungi, and plants, the Hsp100 chaperones, together 
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with Hsp70 and Hsp40 chaperones, are responsible for disaggregating protein aggregates and promoting 
cell survival in response to cell stress[1,2].  The AAA+ ATPase Hsp104 is the primary disaggregase in the 
yeast Saccharomyces cerevisiae[3,4].  Hsp104 is essential for cell survival post-heat stress 
(thermotolerance) as well as recovery from various other stresses[4,5].  Like its bacterial homolog, ClpB, 
the hexameric Hsp104 threads aggregated protein substrates through a central channel to be refolded by 
Hsp70 chaperones[6,7]. 
 In addition to its role in protein disaggregation, Hsp104 is also essential for yeast prion 
propagation[8].  Prions in yeast are self-replicating, cytoplasmically inherited protein aggregates proposed 
to play a role in cellular adaptation and survival[9,10].  Prions are amyloidogenic in nature, and the self-
propagating templates are cross β-sheet structures that are highly stable and resistant to high 
temperature and detergents[11].  One of the best characterized yeast prions is formed from the reversible 
aggregation of the translation termination factor, Sup35[12,13,14].  This prion, called [PSI+], has been 
proposed to play a role in creating genetic diversity by promoting translation of normally silent regions of 
the genome[15].  Interestingly, the de novo formation of [PSI+] is regulated by another yeast prion, 
[RNQ+], resulting from the aggregation of the Rnq1 protein[16,17,18,19].  The proposed function for the 
prion [RNQ+] is to act as an amyloid template for the conversion of monomeric Sup35 to the prion 
conformation[16,18].  The formation of [PSI+] has been shown to increase cell viability under various 
stresses suggesting that the formation and propagation of [PSI+] is an important biological process and 
must be highly regulated[10,15,20].  As such, prion propagation and maintenance in yeast cells require 
efficient fragmentation to generate prion-competent oligomers, or propagons, that can be transmitted to 
daughter cells.  Hsp104 is proposed to remodel prion aggregates to produce propagons, which as a result 
generates more free fiber ends that appear to be required for additional monomer 
templating[21,22,23,24].  Furthermore, Hsp104 has been implicated in the selection and propagation of 
prion variants, or conformationally-distinct aggregates of the same protein sequence[25,26,27].  
Alterations in the stability of prions, in the different variant structures, are proposed to govern their 
interaction and fragmentation by Hsp104[25,28,29]. 
 Structurally, Hsp104 can be divided into five functionally-distinct, yet cooperative, domains.  The 
N-terminal domain is not required for either prion propagation or thermotolerance, but has been proposed 
79 
 
to be a site for substrate binding, as well as an interaction site for the Hsp70s and Hsp40s[30,31].  Two 
nucleotide-binding domains, NBD1 and NBD2, bind and hydrolyze ATP to catalyze the disaggregation 
mechanism and stabilize hexamer formation[32].  The role of the C-terminal domain is still not well 
understood as it is unnecessary for prion propagation and thermotolerance yet both activities are affected 
by mutations in this domain[30,33,34].  Finally, the linker region, or middle domain (M-domain), is 
proposed to regulate both ATP hydrolysis and substrate disaggregation by coordinating the individual 
actions of NBD1 and NBD2[30,35,36].   
 The M-domain is a coiled-coil insertion between NBD1 and NBD2 and is characteristic of Hsp100 
chaperones that function as disaggregases, including the bacterial homolog, ClpB[37,38].  Biochemical, 
genetic, and structural studies with both Hsp104 and ClpB suggest that the M-domain projects from the 
body of the hexamer and makes contact with the NBD1 of neighboring subunits[39,40,41].  In both 
Hsp104 and ClpB, the M-domain regulates ATP hydrolysis[40,42,43], is essential for substrate 
disaggregation[44,45,46], and mediates the interaction between Hsp104 and the Hsp70 
chaperones[44,47,48].  Recent data suggests that the M-domain of ClpB can occupy two distinct 
functional states, repressed and de-repressed[43].  In the repressed state, the M-domain is nestled 
against the body of the hexamer, maintaining contact with a neighboring NBD1.  Interaction with Hsp70 is 
proposed to promote a shift of the M-domain away from NBD1 to the de-repressed conformation, thereby 
increasing the ATPase activity and, in turn, promoting substrate disaggregation[36,43].  ClpB mutations 
that stabilize the M-domain in the repressed state prevent ATPase stimulation by substrate and decrease 
substrate disaggregation[43].  On the other hand, mutations in ClpB that prevent binding of the M-domain 
to NBD1 result in hyperactivity and cause toxicity in vivo[36,43].  Thus, the mobility of the M-domain plays 
a significant role in regulating the activity of ClpB, and is presumed to play a similar role in Hsp104.  As 
such, elucidating the function of the M-domain in each aspect of Hsp104 activity is critical to 
understanding how Hsp104 is able to disaggregate a broad range of substrates. 
 In the present study, we generated mutations in the M-domain of Hsp104 analogous to the 
repressed and de-repressed mutations in ClpB and investigated their effect on thermotolerance and yeast 
prion propagation.  We found that M-domain mutants predicted to repress the mobility of the M-domain 
prevent thermotolerance and prion propagation.  Strikingly, mutations we hypothesized would de-repress 
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Hsp104 M-domain function also result in prion elimination.  Our data show that the M-domain regulates 
Hsp104 disaggregase activity and suggest that changes in the mobility of the M-domain have significant 
consequences for prion propagation. 
 
Results 
Hsp104 M-domain mutant, hsp104-V426I, causes sectoring [PSI+] phenotype 
We performed a genetic screen to identify factors important for aggregation of the translation 
termination factor Sup35, and the resulting propagation of the [PSI+] prion.  To identify candidates, we 
used a color-based phenotypic assay established to follow [PSI+] propagation.  In this assay, a premature 
termination codon is present in the ADE1 gene, ade1-14, which prevents completion of the adenine 
biosynthesis pathway. Disruption of adenine biosynthesis causes the accumulation of a red-pigmented 
intermediate and prevents these cells from growing on media lacking adenine.  Suppression of the 
premature termination codon leads to completion of the adenine biosynthesis pathway resulting in cells 
that are phenotypically light pink or white when grown on rich media (YPD) and are able to grow on media 
lacking adenine.  When Sup35 is monomeric and functional (in non-prion containing [psi-] cells), 
translation termination is efficient, and the ade1-14 cells appear red in color and do not grow on media 
lacking adenine.  Conversely, when Sup35 is in a prion state, it is aggregated and less functional, and the 
[PSI+] colonies are ADE+ (light pink in color on YPD and able to grow on media lacking adenine).  From 
our screen, we identified a candidate that caused the [PSI+] cells to change from a light pink phenotype to 
a sectoring color phenotype (Fig. 3.1A).  When a fraction of the cells in a colony do not inherit [PSI+] 
propagons, those cells become [psi-] and phenotypically red.  All of the progeny resulting from those [psi-] 
cells will also be [psi-] and this pattern of inheritance can result in a sectoring color phenotype.  By 
genetic testing, we discovered that this phenotype resulted from a point mutation in Hsp104.  We 
sequenced HSP104 in this mutant strain and identified the mutation as hsp104-V426I.   
 To determine whether this Hsp104 mutant was affecting the aggregation of Sup35 in [PSI+] cells, 
we transformed the hsp104-V426I mutant strain with Sup35NM-GFP and analyzed the Sup35 
aggregation pattern by fluorescence imaging.  In hsp104-V426I cells, we observed cells that contained 
fluorescent foci indicative of Sup35 aggregates as well as cells that displayed diffuse fluorescence similar 
81 
 
to [psi-] cells (Fig. 3.1B).  Interestingly, the hsp104-V426I cells with fluorescent foci contained a single or 
a few large fluorescent foci, unlike the wild type [PSI+] cells, which contained multiple, small fluorescent 
foci (Fig. 3.1B).  Thus, we conclude that the mutant hsp104-V426I affects the aggregated state of the 
prion determinant Sup35 reflecting the changes in the [PSI+] phenotype. 
 
Hsp104-V426 is located in the coiled-coil M-domain 
 To determine how this mutation may be affecting Hsp104 function, we examined the structural 
models of Hsp104 to determine where this residue is located[39,49].  We discovered that V426 appears 
to be located in the first helix of motif 1 of the M-domain of Hsp104 and is analogous to the L424 residue 
in ClpB.  Recently, data on the structure and function of the M-domain of ClpB suggested that the L424 
residue plays a role in mediating the mobility and position of the coiled-coil M-domain by contributing to 
the interaction between the M-domain and NBD1 of the neighboring subunit.  Another residue in the M-
domain of ClpB, Y503, has also been shown to regulate M-domain mobility[43].  The Y503 residue 
interacts with NBD1, though it does so intramolecularly rather than interacting with the neighboring 
subunit like L424.  Mutation of this residue, Y503D, led to a pronounced decrease in KJE-dependent 
(DnaK-DnaJ-GrpE, KJE) ClpB disaggregation activity[42].  More recently, ClpB-Y503D was shown to 
increase the rate of substrate-stimulated ATP hydrolysis and cause toxicity when expressed in bacteria 
grown at high temperatures[43].  Thus, the Y503D mutation in ClpB was proposed to be hyperactive by 
stabilizing the de-repressed conformation of the M-domain.  As such, we wondered if the Hsp104-V426I 
mutation we identified in our screen might be disrupting the function of the Hsp104 M-domain in a similar 
fashion.  To further test this, we referred to two classes of ClpB M-domain mutants, repressed and de-
repressed, that had varying effects on the function of ClpB[43,50].  In a recent study, two repressed 
mutants, ClpB-E432A and ClpB-D480C, and two de-repressed mutants, ClpB-K476C and ClpB-Y503D, 
were analyzed for their affect on ClpB ATPase activity, disaggregation activity, and cell growth[43].  We 
created the analogous mutations in the M-domain of Hsp104 to determine if the effects of these mutants 
on disaggregase function are conserved between the chaperones.  The analogous repressed Hsp104 
mutations are predicted to be Hsp104-D434A and Hsp104-D484C.  Likewise, Hsp104-K480C and 
Hsp104-Y507D are analogous to the de-repressed mutations.  We also generated Hsp104-V426C 
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analogous to the ClpB-L424C mutation used to characterize the interaction of the M-domain with NBD1.  
We first analyzed the biochemical properties and disaggregation activities of these mutants to determine 
if they display similar functional effects as their counterparts in ClpB.  Then, we analyzed the effect of 
these mutants on the propagation of yeast two prions - [PSI+] and [RNQ+]. 
 
M-domain mutants display varying levels of ATPase activity and hexamer formation 
 One proposed function of the M-domain is to regulate ATPase activity by interacting with NBD1 of 
the neighboring subunit in the hexamer and coordinating ATP binding and hydrolysis between NBD1 and 
NBD2[40,42,51].  Both the repressed and de-repressed ClpB mutants showed basal levels of ATP 
hydrolysis similar to wild type ClpB[43].  However, the de-repressed ClpB mutants had significantly higher 
substrate-stimulated ATPase activity[43].  To determine if the analogous M-domain mutants in Hsp104 
had a similar impact on the ATPase activity, we purified recombinant wild type Hsp104 and the M-domain 
mutants and measured both the basal and substrate-stimulated ATP hydrolysis rates by the Malachite 
Green assay[32].  Interestingly, Hsp104-V426I, the mutant identified in our screen that altered [PSI+] 
propagation, maintained wild type rates of both basal and substrate-stimulated ATP hydrolysis (Fig. 3.2).  
Hsp104-D434A, Hsp104-D484C, and Hsp104-V426C exhibited decreased basal levels of ATPase activity 
as compared to wild type, while Hsp104-K480C and Hsp104-Y507D displayed higher rates of basal 
ATPase activity (Fig. 3.2).  Additionally, wild type Hsp104, Hsp104-V426I, Hsp104-V426C, Hsp104-
K480C, and Hsp104-Y507D all exhibited increased rates of ATP hydrolysis in the presence of substrate 
(Fig. 3.2).  Conversely, addition of substrate did not increase the ATP hydrolysis rate above the basal 
level for Hsp104-D434A or Hsp104-D484C. 
 The ATPase activity of Hsp104 depends on the oligomeric state of the chaperone.  Hsp104 
mutants that inhibit hexamer formation also inhibit ATP hydrolysis[32].  Indeed, the M-domain has also 
been implicated in hexamer formation[40].  We reasoned that the decreased rates of ATP hydrolysis for a 
subset of the M-domain mutants might correlate with inefficient hexamer formation or a change in stability 
of the hexameric state.  To test this, we incubated the purified Hsp104 M-domain mutants with ATP and 
then subjected the samples to ultracentrifugation on a linear glycerol gradient.  Both Hsp104-D434A and 
Hsp104-V426C, which displayed decreased rates of ATP hydrolysis, also displayed a decrease in stable 
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hexamer formation (Fig. 3.3A).  Hsp104-D484C appeared in two distinct populations: one that migrates 
like wild type Hsp104 that represents the hexameric pool, and one that migrates similar to the low-
molecular weight species observed for Hsp104-V426C and Hsp104-D434A (Fig. 3.3A).  Thus, the 
apparent lack of efficient hexamer formation of these three mutants, Hsp104-D434A, Hsp104-D484C, and 
Hsp104-V426C, likely contributes to the observed decrease in their ATPase activity.  Alternatively, 
Hsp104-V426I, Hsp104-K480C, and Hsp104-Y507D all form hexamers and sediment on the gradient like 
wild type Hsp104 (Fig. 3.3B).  Therefore, Hsp104-D434A, Hsp104-D484C, and Hsp104-V426C appear to 
decrease the ability of the M-domain to regulate ATPase activity and hexamer formation, while Hsp104-
K480C and Hsp104-Y507D appear to cause hyperactivity, resulting in increased basal ATPase activity 
and an apparent de-repressed state. 
 
Hsp104-K480C and Hsp104-Y507D cause cell toxicity in a temperature-dependent manner 
 Since the repressed and de-repressed ClpB mutants showed a difference in cell viability at high 
temperatures[43], we next tested if any of the Hsp104 M-domain mutants showed temperature-dependent 
growth defects.  We grew the mutant strains described above on media that selected for the plasmid at 
25, 30, and 37°C.  At 25 and 30°C, all the mutant strains grew as well as the wild type HSP104 cells (Fig. 
3.4).  At 37°C, however, both hsp104-K480C and hsp104-Y507D were unable to grow (Fig. 3.4).  This 
defect in growth at high temperature is similar to that of the analogous ClpB mutants, ClpB-K476C and 
ClpB-Y503D, which were hypothesized to be hyperactive mutants that result in cellular toxicity [43,50].  
For comparison, a vector-only control was also plated, and this strain shows normal cell growth.  
Therefore, the toxicity associated with these mutant strains is not due to a lack of Hsp104 or a simple 
loss-of-function, but suggests a toxic gain-of-function for these mutants that impairs cell growth.  As this 
toxicity is observed at 37°C which induces Hsp104 expression, we hypothesize that constitutive 
expression of these two mutants is detrimental to cellular homeostasis resulting in decreased viability. 
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M-domains mutants present varying levels of thermotolerance and non-prion aggregate 
disaggregation 
 Hsp104 is required for cell viability following heat shock (thermotolerance)[5].  To confer 
thermotolerance, Hsp104 must disaggregate non-prion substrates that aggregate as a consequence of 
the heat stress.  The M-domain of Hsp104 (and ClpB) is proposed to affect the disaggregation of 
substrates by providing a site for an interaction with co-chaperones (Hsp70 and Hsp40 in yeast, DnaK 
and DnaJ in bacteria)[42,47].  Thus, mutations in the M-domain which abrogate interaction with co-
chaperones may have a negative effect on the ability of the chaperone to disaggregate substrates.  
Furthermore, as the ATPase activity and disaggregation activity are interdependent, mutations in the M-
domain that affect the regulation of ATPase activity may also affect the disaggregation mechanism.  
Therefore, we investigated the disaggregation activity of the Hsp104 M-domain mutants in vivo by 
analyzing their ability to confer thermotolerance to yeast, as well as their ability to disaggregate heat-
aggregated luciferase.  We first transformed an hsp104Δ strain with a plasmid expressing each of the M-
domain mutant Hsp104 genes, wild type HSP104, or an empty vector control.  We then grew these 
strains to mid-logarithmic phase at 30°C, moved them to 37°C to induce expression of Hsp104, then heat 
shocked the strains at 50°C for various amounts of time before plating the cells to assess viability.  We 
found that, like the hsp104Δ strain, hsp104-D434A and hsp104-D484C cells were not thermotolerant (Fig. 
3.5A).  Alternatively, both hsp104-V426I and hsp104-V426C cells maintained wild type thermotolerance 
ability (Fig. 3.5A).  Interestingly, the two mutants with the highest ATPase activity, hsp104-K480C and 
hsp104-Y507D, presented an intermediate level of thermotolerance, where the amount of 
thermotolerance fell between that of wild type HSP104 and hsp104Δ strains (Fig. 3.5A).   
We next tested the ability of the M-domain mutants to disaggregate heat-aggregated luciferase, 
which has previously been shown to be a substrate of Hsp104[30].  The strains described above, 
containing a plasmid expressing either wild type or mutant Hsp104, were transformed with a plasmid 
expressing luciferase.  These strains were grown for an hour at 37°C to induce Hsp104 expression then 
heat shocked for an hour at 44°C to induce luciferase aggregation.  After heat shock, the cells were 
allowed to recover at 30°C and we took samples periodically to quantify the relative amount of 
luminescence as a measure of the amount of luciferase resolubilized by Hsp104.  As we saw in the 
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thermotolerance assays, hsp104-D434A and hsp104-D484C cells resembled the hsp104Δ strain in that 
there appeared to be no increase in the amount of resolubilized luciferase over time (Fig. 3.5B).  In 
contrast, hsp104-V426I, hsp104-V426C, hsp104-K480C, and hsp104-Y507D cells exhibited luciferase 
recovery at about half the rate as that observed in wild type HSP104 cells.  Thus, these data correlate 
with the thermotolerance data and suggest that Hsp104-D434A, Hsp104-D484C, Hsp104-K480C, and 
Hsp104-Y507D have defects in disaggregation.  Alternatively, Hsp104-V426I and Hsp104-V426C appear 
to affect the disaggregation of specific substrates. 
 
Hsp104 M-domain mutants vary in their ability to propagate variants of the [PSI+] prion 
 Given the varying effects of the M-domain mutants on ATPase activity and disaggregation ability, 
we next sought to ascertain the effect of the M-domain mutants on [PSI+] propagation.  We first 
demonstrated that Hsp104-V426I caused a defect in the propagation of one [PSI+] variant, strong [PSI+], 
and resulted in sectoring colonies (Fig. 3.1A).  To investigate the effect of the remaining M-domain 
mutants on strong [PSI+] propagation, we transformed a strong [PSI+] heterozygous diploid containing 
wild type HSP104 and hsp104Δ with a plasmid containing either wild type HSP104 or the M-domain 
mutants.  Instantly, we noticed that Hsp104-D434A was dominant and cured the [PSI+] diploids to 
generate red [psi-] diploids (Fig. 3.6A).  Next, the diploids were sporulated, and we selected haploids 
harboring hsp104Δ and each wild type or mutant Hsp104 plasmid and analyzed them phenotypically to 
assess [PSI+] propagation.  By nonsense suppression, hsp104-V426I cells appeared to sector while 
hsp104-V426C, hsp104-K480C, and hsp104-Y507D appeared darker pink, indicative of a weaker 
nonsense suppression phenotype (Fig. 3.6A).  In contrast, hsp104-D434A, and hsp104-D484C, appeared 
to resemble the vector control, suggesting that these mutations do not propagate strong [PSI+] (Fig. 
3.6A).  We next performed SDD-AGE analysis on the haploids to determine the effect of the mutants on 
Sup35 aggregate distribution and to confirm our analyses of the color phenotype.  By SDD-AGE analysis, 
hsp104-V426I, hsp104-V426C, and hsp104-K480C cells maintained aggregates of Sup35 while hsp104-
D434A, hsp104-D484C, and hsp104-Y507D cells did not (Fig. 3.6B).   
The distribution of Sup35 aggregates in hsp104-V426C and hsp104-K480C cells is shifted 
compared to wild type HSP104 strong [PSI+] cells, suggesting that cells expressing these mutants may 
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be propagating a weak variant of [PSI+] in correlation with the decreased nonsense suppression 
phenotype[24,52].  Therefore, we next tested if any of the mutants were capable of propagating a weak 
[PSI+] variant.  Using the same approach as for strong [PSI+], we transformed weak [PSI+] heterozygous 
diploids expressing wild type HSP104 and hsp104Δ with plasmids expressing either wild type HSP104 or 
the M-domain mutants.  Similar to our observations with the strong [PSI+] diploid, hsp104-D434A 
dominantly cured diploids carrying a weak [PSI+] variant (Fig. 3.6C).  Since hsp104-D434A dominantly 
cures two distinct variants of [PSI+], we propose that this mutation inhibits wild type Hsp104 function in 
mixed hexamers.  Interestingly, diploids expressing hsp104-K480C also appeared to decrease nonsense 
suppression suggesting that hsp104-K480C might have a dominant curing effect on weak [PSI+] (Fig. 
3.6C).  Next, we sporulated the diploids and isolated hsp104Δ haploids expressing the wild type or 
mutant HSP104 to assess the color phenotype.  We observed that none of the Hsp104 M-domain 
mutants were able to propagate the weak variant of [PSI+] (Fig. 3.6C).  To confirm this phenotypic 
observation, we performed SDD-AGE analysis and surprisingly found that hsp104-V426C cells contained 
Sup35 aggregates (Fig. 3.6D). 
Interestingly, despite several attempts to generate strong or weak [PSI+] haploids expressing 
hsp104-Y507D, we were only able to isolate a single haploid expressing hsp104-Y507D from the strong 
[PSI+] heterozygous diploid (Fig. 3.6B).  In fact, this single haploid was unable to further grow beyond the 
initial isolation (Fig. 3.6B).  In addition to sporulating diploids, we also attempted to replace the wild type 
HSP104 in a strong [PSI+] strain with hsp104-Y507D by co-expressing both wild type HSP104 and 
hsp104-Y507D and then eliminating the wild type HSP104 plasmid.  This method also proved 
unsuccessful at isolating [PSI+] cells expressing hsp104-Y507D.  From these data, we propose that 
hsp104-Y507D is highly toxic in the presence [PSI+].  Consequently, we would predict that [PSI+] cells 
that lost the prion and became [psi-] would still be viable in the presence of hsp104-Y507D.  Intriguingly, 
we were even unable to isolate any [psi-] cells expressing hsp104-Y507D after sporulation, suggesting 
that the combination of either strong or weak [PSI+] and hsp104-Y507D is so potent that toxicity occurs 
before cells have a chance to reverse the prion phenotype.  Furthermore, expression of hsp104-Y507D in 
hsp104Δ [psi-] [rnq-] cells showed no similar toxicity, suggesting that toxicity is dependent on Sup35 
aggregation.  Similar toxicity in the presence of [PSI+] has been observed for another M-domain mutant, 
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hsp104-A503V, suggesting that prion-dependent toxicity is not specific for this one residue, but may be 
caused by a deregulation of M-domain function[53]. 
 
M-domain mutants are able to propagate distinct variants of [RNQ+] 
 We next examined the ability of the M-domain mutants to propagate several variants of the 
[RNQ+] prion.  Similar to [PSI+], the [RNQ+] prion is also sensitive to changes in Hsp104 activity and 
variants of [RNQ+] are differentially affected by changes in Hsp104 activity[54,55].  Several variants of 
[RNQ+] exist that are characterized by their ability to induce the [PSI+] prion phenotype and the 
aggregate pattern observed in cells by fluorescence[16,56].  [RNQ+] variants display either a single-dot 
(s.d.) or multi-dot (m.d.) pattern of fluorescence describing the appearance of Rnq1-GFP aggregates in 
[RNQ+] cells[56].  [RNQ+] variants that display s.d. fluorescence can facilitate the induction of [PSI+] at 
low, medium, high, and very high rates upon Sup35 overexpression.  On the other hand, the only 
established m.d. variant of [RNQ+] exhibits a high rate of [PSI+] induction.  We utilized these five 
characterized [RNQ+] variants to ascertain the effect of M-domain mutants on conformational variants of 
[RNQ+]. 
 We utilized a plasmid shuffle technique to determine the effect of the M-domain mutants on the 
[RNQ+] variants.  Strains containing each [RNQ+] variant harbor a chromosomal hsp104Δ and are 
complemented by the expression of wild type HSP104 from a plasmid.  We transformed the plasmids 
containing the M-domain mutants into these strains, then, selected for cells that eliminated the wild type 
HSP104 by growing them on counter-selection media to determine the effect of the mutants on the pre-
existing [RNQ+] variants.  Interestingly, we observe a differential effect of these mutants on the 
propagation of the [RNQ+] variants.  Of the M-domain mutants, hsp104-V426I and hsp104-K480C cells 
were able to maintain all of the tested [RNQ+] variants (Fig.3.7).  On the other hand, cells expressing 
hsp104-D434A were [rnq-] in all of the tested variants of [RNQ+], suggesting that this mutant is a general 
prion inhibitor.  Interestingly, cells expressing hsp104-V426C and hsp104-Y507D were able to propagate 
all but the s.d. medium and s.d. very high [RNQ+] variants, while hsp104-D484C cells propagate only the 
s.d. low variant of [RNQ+].  Furthermore, all M-domain mutants, excepting hsp104-V426I, were 
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characterized by a shift in the aggregate distribution of Rnq1 aggregates in all of the tested [RNQ+] 
variants. 
 
Discussion 
 Here, we present analysis of six Hsp104 M-domain mutants, which have differential effects on 
chaperone function and cell viability.  Initially, we identified Hsp104-V426I from a screen for factors that 
affected [PSI+] propagation.  We observed that hsp104-V426I cells had defects in [PSI+] propagation that 
manifested as a sectoring [PSI+] phenotype.  We have observed this phenotype before from other 
Hsp104 mutants that have varying effects on Hsp104 structure and function (upublished data) but this 
was the only mutation we identified that is located in the M-domain.  The coiled-coil M-domain of Hsp104 
is proposed to regulate ATPase activity, substrate disaggregation, and co-chaperone interactions[38].  
We noted that the V426 residue in Hsp104 is analogous to the recently characterized L424 residue in 
ClpB, which was shown to play a role in regulating the position and mobility of the M-domain in ClpB[43].  
Previously, it was shown that the stability of the coiled-coil M-domain of ClpB depends on the leucine 
zipper-like interactions between leucine and isoleucine residues and that mutation of these residues to 
alanine caused significant changes in chaperone activity, ATP hydrolysis, and hexamer formation[57].  
Perhaps, then, mutation of the valine at residue 426 to an isoleucine disrupts the normal isoleucine-
leucine interactions, resulting in slight destabilization of the M-domain.  Although we do not have direct 
evidence that the V426I mutation in the M-domain of Hsp104 alters the interaction of the M-domain with 
the neighboring NBD1 domain, previous data from ClpB suggest that this residue may contribute to M-
domain positioning, and that mutation of this residue could disrupt interactions of the M-domain with 
neighboring subunits within the hexamer. 
In order to elucidate the effect of the V426I mutation on the function of the M-domain of Hsp104, 
we examined the rates of ATP hydrolysis, hexamer formation, and thermotolerance and disaggregation.  
We also examined these same properties among a set of mutations in the M-domain that in ClpB were 
proposed to stabilize the repressed or de-repressed conformation of the M-domain resulting in changes in 
the regulation of overall chaperone activity[43,50].  We generated the analogous mutations in Hsp104 
and characterized their ability to form hexamers, hydrolyze ATP, and disaggregate protein substrates.  
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We found that, in general, the M-domain mutants had similar effects on the activity of Hsp104 as they 
displayed in ClpB. 
Both Hsp104-D434A and Hsp104-D484C decreased overall ATPase activity and disaggregation 
activity suggesting that prolonged occupation of the repressed state inhibits Hsp104 activity[43].  The M-
domain mutants Hsp104-K480C and Hsp104-Y507D increased the overall rate of ATP hydrolysis and 
caused toxicity when cells were grown at higher temperatures indicative of the proposed effects of the de-
repressed conformation on M-domain function.  Interestingly, our data for the rates of ATP hydrolysis of 
Hsp104-K480C differed from a recent report in that we found an increase in the basal ATPase activity 
compared to wild type Hsp104[41].  Interestingly, from biochemical characterization, both Hsp104-V426I 
and Hsp104-V426C appear to stabilize neither the repressed nor the de-repressed conformation, as 
those effects are characterized by the other analyzed mutants.  Instead, we propose that the Hsp104-
V426I and Hsp104-V426C mutations result in a semi-repressed conformation that only moderately affects 
the regulatory function of the M-domain.  The difference in the ATP hydrolysis rates of Hsp104-V426I and 
Hsp104-V426C suggest that the biochemical properties associated with the side chain of this residue are 
important.  A range of phenotypes associated with the identity of the mutated residue is also observed for 
the Hsp104 M-domain residue D484.  In a previously published report, mutation of D484 to a lysine 
(D484K) was characterized by cellular growth defects and increased ATPase and chaperone activity, 
which is the opposite of our data for Hsp104-D484C[36].  Interestingly, this study suggests that disruption 
of the ionic interactions associated with Hsp104-D484 leads to hyperactivity while we show that disruption 
of these ionic interactions can also lead to reduced activity[36].  Thus, the M-domain is finely tuned to 
regulate various functions of Hsp104 and disruption of this balance can lead to severe consequences for 
Hsp104 function. 
Although several studies have examined the role of the M-domain in the regulation of protein 
disaggregation and ATPase activity, much less is known about the effect of the Hsp104 M-domain 
regulatory function on yeast prion propagation.  Here, we show that mutations that disrupt M-domain 
function also inhibit prion propagation.  The repressed mutants, Hsp104-D434A and Hsp104-D484C, 
inhibit propagation of both strong and weak [PSI+] variants.  The M-domain mutant Hsp104-D434A is 
even more pronounced as it inhibits wild type Hsp104 function to cause dominant curing of both variants 
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of [PSI+].  Additionally, the de-repressed mutants Hsp104-K480C and Hsp104-Y507 appear to have 
distinct effects on [PSI+] propagation despite similar biochemical properties.  Hsp104-K480C is able to 
propagate strong [PSI+] but has a semi-dominant curing effect on weak [PSI+].  These data correlate well 
with observations that overexpression of Hsp104 cures weak [PSI+] variants more efficiently than strong 
variants, though the mechanism of [PSI+] elimination by excess Hsp104 is not well understood[8,58,59].  
Another hypothesis to explain the differences observed between weak and strong [PSI+] is that weak 
[PSI+] variants are more dependent on Hsp70s and Hsp40s for efficient propagation, as varying levels of 
Hsp70 expression can have greater effects on weak [PSI+] variants than strong variants[60].  Indeed, 
Hsp104 acts in concert with Hsp70s and Hsp40s and the balance of this complex is important[1,61,62].  
As the de-repressed M-domain mutants of ClpB were shown to have reduced interaction with the KJE 
chaperones, and Hsp104-K480C is deficient in thermotolerance and luciferase refolding, perhaps a 
reduced interaction of Hsp104-K480C with co-chaperones is responsible for the curing of the weak [PSI+] 
variants. 
Our biochemical data for Hsp104-V426I as a semi-repressed mutant correlate well with the 
sectoring [PSI+] phenotype observed in hsp104-V426I cells.  Unlike the repressed mutants, Hsp104-
D434A and Hsp104-D484C, which cure [PSI+], the semi-repressed Hsp104-V426I and Hsp104-V426C 
maintain strong [PSI+], albeit inefficiently, and inhibit propagation of weak [PSI+].  Recently, a decreased 
interaction of Hsp104 with weak [PSI+], as compared to strong [PSI+], was demonstrated in vitro[25], and 
we have recently shown that decreased Hsp104 activity is sufficient to propagate strong but not weak 
variants of [PSI+] (Dulle and True, unpublished data).  Therefore, changes in the regulatory function of 
the M-domain alter the ability of Hsp104 to stably propagate distinct [PSI+] variants. 
In addition to changes in [PSI+] propagation, we also found differential effects of the M-domain 
mutants on the propagation of conformational variants of the [RNQ+] prion.  The repressed M-domain 
mutants, Hsp104-D434A and Hsp104-D484C cannot propagate any tested variant of [RNQ+].  Although 
we have previously characterized a mutant of Hsp104 that displays decreased activity but is still able to 
propagate specific variants of [RNQ+], clearly a threshold of activity exists that is required for [RNQ+] 
propagation[54].  Interestingly, the M-domain mutants Hsp104-Y507D and Hsp104-V426C are able to 
propagate the two variants of [RNQ+] (s.d. medium and very high) but not the others while Hsp104-
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D484C could propagate the s.d. low variant of [RNQ+].  We have previously characterized mutations in 
Hsp104, which showed differential propagation among the [RNQ+] variants[54].  One hypothesis for 
differential prion variant propagation suggests that the stability of the prion variant dictates the interaction 
with Hsp104[25].  However, the s.d. [RNQ+] variants have been shown to have similar stabilities, 
suggesting that stability is only one contributing factor toward Hsp104 interaction[63].  Another 
contributing factor may be the amount of soluble Rnq1 as the variants were shown to differ in the amount 
of soluble Rnq1 with s.d. very high and s.d. low [RNQ+] containing the most[63].  However, our data also 
suggest that medium [RNQ+], which contains less soluble Rnq1 than low and very high but more than 
high, is also propagated differentially among the M-domain mutants.  Curiously, the semi-repressed 
mutant, Hsp104-D484C, shows a similar pattern of [RNQ+] variant propagation as the de-repressed 
Hsp104-Y507D mutant.  How these two mutants with different biochemical properties show the same 
pattern of [RNQ+] propagation is as yet unclear.  Furthermore, our data clearly demonstrates the 
complexity of prion variant propagation and illustrates the need for further investigation to understand the 
mechanism of interaction between chaperones and conformationally distinct prion variants. 
The structure and function of the Hsp104/ClpB M-domain has been a subject of much 
investigation and controversy in recent years.  Various structural studies of ClpB and Hsp104 have 
proposed significantly different models for M-domain position in relation the hexameric 
structure[39,49,64].  More recent data suggest that the true placement of the M-domain may be a 
combination of previous models.  Specific residues in the M-domain are protected, suggesting that at 
least part of the M-domain is tightly packed into the body of the hexamer[43,47,49].  Additionally, cross-
linking and fluorescence quenching experiments suggest that the M-domain contacts residues in the 
NBD1 either in the neighboring subunit or in the same subunit[43].  Furthermore, the flexibility of the M-
domain to break and re-form these contacts is integral to regulation of the chaperone function by the M-
domain[36,43,50].  The data in our study do not lend direct support any one structural model, but do 
suggest that the M-domain of Hsp104 plays a key role in regulating the disaggregation of both prion and 
non-prion substrates. 
The M-domain has clearly been determined to play a significant role in regulating Hsp104/ClpB 
function.  Characterization of mutations in the M-domain demonstrates that this coiled-coil region affects 
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all of the distinct activities that Hsp104/ClpB possesses, suggesting that this domain may be the master 
regulator of Hsp104/ClpB function[35,36,42,43,44,47,50,53].  As such, elucidation of the M-domain 
regulatory mechanism is vital to our understanding of the disaggregation mechanism of Hsp104/ClpB. 
 
Materials and Methods 
Strain and Plasmid Construction 
 All S. cerevisiae strains were derivatives of 74-D694 and were grown using standard culture 
techniques.  Strains were grown in YPD (1% yeast extract, 2% peptone, 2% glucose) or synthetic media 
lacking amino acids with correlated with plasmid selection (0.67% yeast nitrogen base, 2% glucose). 
 Hsp104 mutants were cloned into the pRS313 vector for expression in vivo.  Point mutations in 
HSP104 were generated by bridge PCR (oligonucleotides listed in Supplementary Table One) using 
pRS313-phs-HSP104 (kindly provided by B. Bukau) as the template.  Bridge PCR and pRS313-phs-
HSP104 were digested with EcoRI and Bsu36I and ligated together.  Hsp104 mutants were also cloned 
into pProEx-HTb-HSP104 (kindly provided by J. Glover[34]) by the same digestion and ligation.  The 
pRS313-phs-hsp104-V426I plasmid was generated by PCR amplifying HSP104 from the EMS 
mutagenized strain, then digesting and ligating as described. 
 The Lindquist lab characterized and kindly provided the strong [PSI+] variant[8,65].  The Liebman 
lab characterized and kindly provided the weak [PSI+] variant[65].  The Sc4 and Sc37 [PSI+] variants, 
made by transforming Sup35 fibers assembled at 4°C and 37°C into [psi-] cells, were made and kindly 
provided by the Weissman lab[66].  To analyze the mutant pRS313-phs-HSP104 plasmids in the [PSI+] 
variants, each variant was mated to an hsp104Δ (hsp104::leu2) strain and diploids were selected.  The 
mutant pRS313-phs-HSP104 plasmids were transformed into the heterozygous diploids, the diploids 
were sporulated, and haploids were selected on media lacking histidine and leucine.  Colonies were 
verified as haploids by plating on A and α strains to determine mating type. 
The [RNQ+] variant strains were kindly provided by the Liebman lab.  To create strains carrying 
both the mutant Hsp104 plasmids and the [RNQ+] variants, we created an HSP104 plasmid shuffle strain.  
First, pRS316-phs-HSP104 (kindly provided by J. Weissman) was first transformed into each of the 
[RNQ+] variants.  HSP104 on the chromosome was deleted by transforming in the knock-out cassette 
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pAG32-HygromycinB that had been PCR amplified to contain flanking sequences to HSP104 
(oligonucleotide sequences in Supplementary Table One).  Deletion strains were confirmed first by 
selection on media lacking uracil and containing Hygromycin B (Invitrogen) then by colony PCR.  These 
strains were then transformed with each of the mutant pRS313-hsp104 plasmids, selected on media 
lacking histidine and uracil, grown overnight in liquid media lacking just histidine, and then plated on 
media lacking histidine and containing 5’Fluoroorotic acid (US Biologicals) to select for cells that had 
dropped the pRS316-phs-HSP104 plasmid.  Colonies that grew on media lacking histidine but not uracil 
were selected. 
 
EMS mutagenesis screen 
The strong [PSI+] yeast strain was subjected to EMS mutagenesis as previously described[54].  
Two cultures with viabilities of about 17% were plated to determine changes in color.  Candidates were 
selected based on color phenotype and were initially identified as mutations in HSP104 by back-crossing 
to an hsp104Δ strain and analyzing the progeny for segregation of the prion-dependent nonsense 
suppression phenotype.  Genomic DNA was PCR amplified and sequenced to identify the point mutations 
in HSP104. 
SDD-AGE 
Cells were lysed by disruption of the membranes with glass beads in Sup35 PEB buffer (25mM 
Tris-HCl pH 7.5, 50mM KCl, 10mM MgCl2, 1mM EDTA, 10% Glycerol plus mini EDTA-free protease 
inhibitors (Roche), Aprotinen (Sigma) and PMSF (Sigma)) or Rnq1 PEB buffer.  Samples were incubated 
in sample buffer at room temperature for seven minutes then separated on a 1.5% agarose gel.  The 
protein distribution was analyzed by western blot with anti-Sup35 antibody or antibody against Rnq1. 
Hsp104 Purification 
Recombinant Hsp104 was expressed and purified from E. coli cells as previously described[67].  
After purification, the pool of recombinant Hsp104 was separated on an S-300 gel filtration column to 
isolate Hsp104 monomers.  Purified, monomeric Hsp104 was concentrated and frozen at -80°C. 
ATP Hydrolysis Assays 
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The Malachite green assay was used to measure the rates of ATP hydrolysis[32].  Purified 
protein (2µg) was incubated with 5mM ATP in buffer (40mM TrisHCl pH7.5, 175mM NaCl, 5mM MgCl2, 
0.02% Triton X-100) at 37°C.  At each minute over a time course of 12 minutes, Malachite green dye was 
added to the sample and the reaction stopped by the addition of 34% citric acid.  The absorbance was 
measured at 650nm and the concentration of free phosphate calculated based on a standard of KH2PO4 
and normalized to the sample containing no Hsp104. 
Glycerol Gradients 
Purified Hsp104 was centrifuged at 34k rpm for 18 hours through a 4mL linear (10-35%) glycerol 
gradient.  The gradients were fractionated and equal volumes of each fraction were analyzed by SDS-
PAGE and western blot using anti-Hsp104 antibody.  Individual bands from each fraction were quantified 
using Image J and reported as a percent of total Hsp104.  
Thermotolerance 
An equal number of cells from cultures of HSP104, hsp104-V426I, hsp104-V426C, hsp104-
K480C, hsp104-Y507D, hsp104-D434A, hsp104-D484C, and hsp104Δ were treated at 37°C for 30 
minutes to induce HSP104 expression, then heat-shocked at 50°C.  At 10, 15, 20, 25, and 30 minutes 
during heat shock, samples were taken and spotted media lacking histidine in a five-fold dilution. 
Luciferase Refolding 
 An hsp104Δ strain containing plasmids expressing HSP104, hsp104-V426I, hsp104-V426C, 
hsp104-K480C, hsp104-Y507D, hsp104-D434A, hsp104-D484C, and an empty vector control were 
transformed with pRS316-GPD-luciferase, a plasmid expressing luciferase (kindly provided by 
B.Bukau)[6].  Cells were grown at 37°C for one hour, then heat-shocked at 44°C for one hour.  Fifty 
minutes into the heat shock, cycloheximide (Sigma) was added to the culture to block protein synthesis.  
At various times during recovery at 30°C, 100 µL samples were taken and 50µL of 1mM beetle luciferin 
(Promega) was added.  Luminescence was measured on a Sirius luminometer.  The resolubilization of 
luciferase was calculated by dividing the measured luminescence at each time point by the measured 
luminescence prior to heat shock and normalized to the luminescence measured immediately after heat 
shock. 
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Figure 3.1 A point mutation in Hsp104 destabilizes [PSI+].  A, Cells expressing hsp104-V426I or 
HSP104 were plated onto rich media to illustrate the destabilizing effect this mutation has on [PSI+].  In 
the presence of hsp104-V426I, [PSI+] is lost by a fraction of the buds, generating sectors of [psi-] 
(phenotypically red) cells in the [PSI+] colony.  B, The copper-inducible fluorescent protein, Sup35NM-
GFP, was transformed into hsp104-V426I and wild type [PSI+] and [psi-] cells.  Fluorescence imaging 
was done on an Olympus confocal microscope. 
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Figure 3.2 Hsp104 M-domain mutants affect ATPase activity.  The ATPase activity of recombinant 
Hsp104, Hsp104-V426I, Hsp104-V426C, Hsp104-D434A, Hsp104-D484C, Hsp104-K480C, and Hsp104-
Y507D was measured by the Malachite Green assay after incubation with 5mM ATP either in the 
absence (black) or presence (grey) of 0.25mg/mL β-casein.  The amount of free inorganic phosphate in 
each sample was calculated by comparison with a standard phosphate solution.  For each protein, the 
average initial rate of ATP hydrolysis is plotted.  Each protein was measured in quadruplicate from two 
separate purification preparations and error bars reflect standard deviation between the samples. 
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Figure 3.3 The M-domain plays a role in hexamer formation.  The oligomeric distribution of 
recombinant Hsp104 (dark blue, A & B) and Hsp104-V426I (red), Hsp104-K480C (yellow), and Hsp104-
Y507D (green) (A) and Hsp104-V426C (orange), Hsp104-D434A (purple), and Hsp104-D484C (grey) (B) 
was analyzed by ultracentrifugation through a linear glycerol gradient in the presence of 5mM ATP.  
Equal fractions from the gradients were collected and analyzed by western blotting with anti-Hsp104 
antibody.  The amount of Hsp104 in each fraction was quantified by Image J and graphed as a fraction of 
the total Hsp104.  The gradients were repeated twice with recombinant protein from two separate 
purification preparations. 
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Figure 3.4 Hsp104-K480C and Hsp104-Y507D are toxic at high temperatures.  Hsp104Δ strains 
expressing wild type HSP104, hsp104-V426I, hsp104-V426C, hsp104-K480C, hsp104-Y507D, hsp104-
D434A, and hsp104-D484C from a HIS3-expressing plasmid were plated on media lacking histidine and 
grown at 25, 30 or 37°C to assess temperature-dependent growth defects.  A vector-only control is also 
plated. 
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Figure 3.5 M-domain mutants have differing affects on the ability to disaggregate non-prion 
substrates.  A, hsp104Δ strains expressing wild type HSP104, hsp104-V426I, hsp104-V426C, hsp104-
K480C, hsp104-Y507D, hsp104-D434A, and hsp104-D484C from a HIS3-expressing plasmid were heat-
shocked to measure the mutants’ ability to function in thermotolerance.  The mutant and wild type cells as 
well as an empty vector control (Vector) were heat-shocked at 50°C for various amounts of time then 
plated on media lacking histidine to assess viability.  The spottings represent a five-fold serial dilution.  B, 
The same hsp104Δ strains containing a plasmid expressing luciferase and expressing wild type HSP104 
(red), hsp104-V426I (purple), hsp104-V426C (light blue), hsp104-K480C (yellow), hsp104-Y507D (green), 
hsp104-D434A (orange), hsp104-D484C (pink), or an empty vector control (dark blue) were grown at 
37°C to induce Hsp104 expression then heat-shocked at 44°C for an hour to induce luciferase 
aggregation.  At fifty minutes into heat shock, cycloheximide was added to the cells to block new protein 
synthesis.  At various times during recovery, samples were taken, luciferin was added, and the 
luminescence was measured.  The graph represents the amount of luciferase recovered as a fraction of 
the total luciferase before heat shock.  Three separate samples for each mutant were analyzed and error 
bars reflect standard deviation between the samples. 
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Figure 3.6 M-domain mutants differentially affect propagation of strong and weak variants of 
[PSI+].  A, Strong [PSI+] diploids or haploids were transformed with plasmids expressing HSP104, 
hsp104-V426I, hsp104-V426C, hsp104-D434A, hsp104-D484C, hsp104-K480C, hsp104-Y507D or an 
empty vector control (EV) and spotted on media selecting for the plasmid.  Each column is a five fold 
dilution.  B, Strong [PSI+] haploids expressing HSP104, hsp104-V426I, hsp104-V426C, hsp104-D434A, 
hsp104-D484C, hsp104-K480C, or hsp104-Y507D, as indicated, were subjected to SDD-AGE analysis 
and western blot with antibody against Sup35.  This is one representative of three separate experiments.  
C, Weak [PSI+] diploids or haploids were transformed with plasmids expressing HSP104, hsp104-V426I, 
hsp104-V426C, hsp104-D434A, hsp104-D484C, hsp104-K480C, hsp104-Y507D or an empty vector 
control (EV) and spotted on media selecting for the plasmids.  Each column is a five fold dilution.  D, 
Weak [PSI+] haploids expressing HSP104, hsp104-V426I, hsp104-V426C, hsp104-D434A, hsp104-
D484C, hsp104-K480C, hsp104-Y507D, or an empty vector control were subjected to SDD-AGE analysis 
and western blot with antibody against Sup35.  This is one representative of two separate experiments. 
109 
 
 
Figure 3.7 M-domain mutants differentially propagate [RNQ+] variants.  Strains containing the 
[RNQ+] variants, s.d. low, medium, high, and very high and m.d. high, expressing HSP104, hsp104-
V426I, hsp104-V426C, hsp104-D434A, hsp104-D484C, hsp104-K480C, hsp104-Y507D, or an empty 
vector control (EV) were subjected to SDD-AGE analysis and western blot with antibody against Rnq1.  
Each SDD-AGE is on representative of at least three separate experiments. 
110 
 
 
 
 
 
 
 
Chapter 4: Low Hsp104 Activity Sufficient for Propagation of Strong Variants of the [PSI+] Prion 
 
 
Jennifer Dulle and Heather True 
 
 
 
Manusript under review at the journal Prion 
  
111 
 
Abstract 
The molecular chaperone network plays a critical role in the formation and propagation of self-replicating 
yeast prions.  Not only do individual prions differ in their requirements for certain chaperones, but 
structural variants of the same prion can also display distinct dependences on the chaperone machinery, 
specifically Hsp104.  The AAA+ ATPase Hsp104 is a disaggregase required for the maintenance of most 
known yeast prions.  As a key component in the propagation of prions, understanding how Hsp104 differs 
in its interactions with specific variants is crucial to understanding how prion variants may be selected or 
evolve.  Here, we investigate two novel mutations in Hsp104, hsp104-G254D and hsp104-G730D, which 
allow us to elucidate some mechanistic features of Hsp104 disaggregation and its requirement for activity 
in propagating specific prion variants.  Both Hsp104 mutants propagate the [PSI+] prion to some extent, 
but show a high rate of prion loss.  Both Hsp104-G254D and Hsp104-G730D display reduced 
biochemical activity, yet differ in their ability to efficiently resolubilize disordered, heat-aggregated 
substrates.  Additionally, both mutants impair weak [PSI+] propagation, but are capable of propagating 
the more stable strong [PSI+] variant to some extent.  One of the Hsp104 mutants also has the ability to 
propagate one variant of the [RNQ+] prion.  Thus, our data suggest that changes in Hsp104 activity limit 
substrate disaggregation in a manner that depends more on the stability of the substrate than the nature 
of the aggregated species. 
  
Introduction 
Prions are self-templating, amyloidogenic protein aggregates.  In mammals, prions are 
associated with several neurodegenerative diseases, including scrapie in sheep, chronic wasting disease 
in deer and elk, and Creutzfeldt-Jacob disease in humans.
1, 2
  In the budding yeast Saccharomyces 
cerevisiae, prions are non-toxic, epigenetic elements of inheritance, but they do share many 
characteristics with mammalian prions and other disease-related amyloidogenic proteins.
3-5
  The yeast 
prion [PSI+] results from a self-propagating aggregated state of the translation termination factor Sup35.
6, 
7
  Aggregation of Sup35 results in partial loss-of-function that leads to an increase in global nonsense 
suppression.
8
  Consequently, the ability to generate [PSI+] cells, coupled with the reversible or 
metastable nature of this prion mechanism, and has been proposed to be advantageous due to the ability 
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to alter phenotypes through the [PSI+]-dependent translation of normally silent regions of the genome.
9, 10
 
Interestingly, the appearance of the [PSI+] prion appears to be regulated by the presence of another 
yeast prion, called [RNQ+] (or [PIN+]) which is the aggregated form of the Rnq1 protein.
11-15
 Though the 
soluble protein Rnq1 (in [rnq-] cells) has no known function, the prion state of Rnq1, [RNQ+], functions to 
promote the de novo induction of [PSI+], and is often required for the aggregation of other amyloidogenic 
proteins in yeast.
16
  
Although the prion conformation is self-templating, the maintenance of prions in yeast relies on 
the molecular chaperone network to produce aggregates that can be transmitted from mother to daughter 
cells.  The AAA+ ATPase chaperone Hsp104 is a disaggregase required for propagation of both [PSI+] 
and [RNQ+], as well as all other recognized yeast prions.
11, 17-19
  Hsp104, in concert with Hsp70 and 
Hsp40 chaperones, also functions to resolubilize proteins that aggregate as a consequence of various 
environmental stresses.
20, 21
  Hsp104 has five distinct domains and is functional as a hexamer that 
contains a central pore used for threading substrates.
22-24
  The N-terminal domain is proposed to play a 
role in substrate recognition and may also be a site for interaction of co-chaperones, though the N-
terminal domain is not required for either thermotolerance or prion propagation.
25
  The two ATP-binding 
domains (NBD1 and NBD2), connected by a coiled-coil linker domain, both bind and hydrolyze ATP to 
power the disaggregation mechanism.
26, 27
  Lastly, the function of the fifth modular domain, the C-terminal 
domain, is still mostly unclear, though some data have implicated this domain as having a role in 
substrate interaction and processing.
28, 29
 
The proposed role of Hsp104 in prion propagation is to fragment prion aggregates in order to 
generate the smaller heritable species, or propagons.
30-32
  Consequently, deletion of Hsp104 eliminates 
both [PSI+] and [RNQ+], and several mutants in each domain of Hsp104 have been characterized that 
affect [PSI+] and [RNQ+] propagation.
12, 17, 33-36
  Interestingly, [PSI+] is especially sensitive to changes in 
the Hsp104 system as the overexpression of Hsp104 eliminates [PSI+] to generate [psi-] cells, whereas 
Hsp104 overexpression does not eliminate [RNQ+].
12, 17, 37, 38
  Hsp104 has also been shown to catalyze 
amyloid formation of prion proteins in vitro.
37, 39, 40
  Furthermore, maintenance of prions by Hsp104 is 
aided by Hsp70 and Hsp40 co-chaperones, and overexpression or deletion of these chaperones can 
affect prion propagation.
41-47
 
113 
 
Yeast prions exist as an array of self-propagating structures, known as prion variants (analogous 
to “prion strains” in mammalian prion nomenclature).  Although formed from the same protein sequence, 
prion variants maintain distinct structures having varying stabilities and causing different cellular 
phenotypes, much like mammalian prion strains result in variation in disease pathology.
48-52
  Prion 
variants have been described for both [PSI+] and [RNQ+].  [PSI+] variants are characterized by the 
amount of nonsense suppression they confer, which is related to the ability of the aggregate to template 
monomeric Sup35.
53-55
  Weak variants of [PSI+] maintain an increased pool of monomeric Sup35 relative 
to strong [PSI+] variants.  As such, weak [PSI+] variants show less nonsense suppression (more folded, 
soluble Sup35 means more translation termination).  Additionally, distinct Sup35 amyloid structures have 
been generated using denatured, recombinant protein (usually using just the prion-forming domain, also 
called “NM”) by simply changing the temperature at which amyloid fibers are formed.
49, 50
  From structural 
studies of in vitro formed amyloid, Sup35 aggregates with a shorter protected amyloid core are less stable 
and give rise to a strong [PSI+] phenotype when [psi-] cells are infected with these aggregates, while 
fibers with longer, more stable cores tend to give rise to weak [PSI+] phenotypes upon infection.
49, 50, 56
  
Recent data suggest that the longer, more stable core associated with the weaker [PSI+] variants is more 
refractory to Hsp104 activity or interaction.
57, 58
  In contrast, the shorter core of strong variants is more 
labile to Hsp104 disaggregation, resulting in the generation of more propagons in strong [PSI+] cells, and 
thus increased conversion of monomeric Sup35.
57
  As such, strong [PSI+] variants present a stronger 
nonsense suppression phenotype as compared to weak [PSI+] variants, and are better able to propagate 
when challenged with fluctuations in Hsp104 activity. 
Variants of [RNQ+] were first identified in vivo and were characterized by their differential ability 
to facilitate formation of the [PSI+] prion.
15, 59
  These variants were named low, medium, high, and very 
high [PIN+] to indicate their rate of [PSI+] induction.
15
  These [PIN+]/[RNQ+] variants were further 
described by their patterns of fluorescence when Rnq1 was tagged with GFP.
60
  Two distinct phenotypes 
were observed: cells that contained multiple, small fluorescent foci termed multi-dot (m.d.), and cells that 
contained a single, large fluorescent focus termed single-dot (s.d.).  [RNQ+] variants that induced [PSI+] 
at low, medium, high, and very high rates were all found within the microscopic s.d. pattern, while only 
one m.d. [RNQ+] variant was characterized and it induced [PSI+] at a high rate.  Further investigation of 
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these established [RNQ+] variants showed that a distinct region of the Rnq1 protein was required for 
propagation of certain variants, suggesting that [RNQ+] variants, like [PSI+], may also differ in their core 
region.
61
  Similar to Sup35, Rnq1 fibers display distinct characteristics when generated under various 
conditions in vitro,
62
 though structural studies to elucidate the amyloid core of these [RNQ+] variants have 
not yet been done.  Additionally, much less is understood about the interaction between [RNQ+] and 
Hsp104 and how changes in Hsp104 activity affect propagation of specific [RNQ+] variants. 
Here, we characterize two novel mutations in Hsp104 that we identified as causing a defect in 
[PSI+] propagation.  We show that these mutations decrease select activities of Hsp104, resulting in 
diminished disaggregation activity of specific substrates.  Finally, we find that defects in [PSI+] and 
[RNQ+] propagation are specific for certain prion variants, thereby providing further evidence for the 
hypothesis that Hsp104 may interact more efficiently with less stable [PSI+] variants than more stable 
variants, and that this may also hold true for variants of [RNQ+]. 
 
Results 
Point mutations in HSP104 cause a defect in the maintenance of [PSI+].  We performed a 
mutagenesis screen in order to identify factors required for the propagation of a specific variant of the 
[PSI+] prion.  To identify such factors, we used a colony color based phenotypic assay commonly used to 
track [PSI+] prion propagation.  In this colorimetric assay, a premature stop codon in the ADE1 gene, 
ade1-14, blocks the completion of the adenine biosynthesis pathway and results in the accumulation of a 
red-pigmented intermediate.  Disruption of the pathway at this point also results in the inability of these 
cells to grow on media lacking adenine.  Cellular changes that afford an increase in nonsense 
suppression of the premature stop codon in ade1-14 can result in production of sufficient Ade1 protein to 
generate light pink or white colonies and allow for growth on media lacking adenine.  Such an increase in 
nonsense suppression can be generated by reduced function of the translation termination complex 
(eRF1 and eRF3, or Sup45 and Sup35, respectively).
8
  This can occur either by mutation of either 
termination factor or by conversion of wild type Sup35 into a prion state.  When Sup35 is monomeric and 
fully functional in [psi-] cells, the premature stop codon in ade1-14 is recognized, resulting in colonies that 
are red in color on rich media and cannot grow on media lacking adenine.  When Sup35 is aggregated in 
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[PSI+] cells, however, the nonsense codon is suppressed and the [PSI+] cells appear white on rich media 
and can grow on media lacking adenine.   
In addition, structural variants of the [PSI+] prion present a range of color phenotypes indicative 
of the amount of soluble Sup35 characteristic of those variants.  For example, because of the relative 
increase in soluble Sup35, weak [PSI+] strains harboring ade 1-14 are pink in color on rich media.  In our 
screen, we expected to find mutants that affected [PSI+] propagation by a change in color phenotype 
from the light pink indicative of strong [PSI+] in our parent 74-D964 strain.  Interestingly, in addition to 
mutations that completely inhibited [PSI+] propagation, we found a subset of mutations that partially 
inhibited [PSI+] inheritance.  These mutants displayed a sectoring color phenotype on rich media (Fig. 
4.1A).  Color sectoring within a [PSI+] colony results when a fraction of the budding daughter cells lose 
the prion, thereby producing sections of the colony that are [psi-] and phenotypically red.  We identified 
two point mutations in the chaperone Hsp104 that demonstrated an interesting effect on the inheritance of 
[PSI+] unlike the curing phenotype that is often characterized.  These mutants, which we sequenced to 
identify as hsp104-G730D and hsp104-G254D, presented varying levels of sectoring and [PSI+] loss (Fig. 
4.1A).  We recreated both mutants in an unmutagenized [PSI+] 74-D694 strain by double homologous 
recombination to verify the phenotypic effects and used these strains for all subsequent analyses. 
In order to determine how the mutants affected the biochemical properties of Sup35 in [PSI+] 
cells, we first performed SDD-AGE (semi-denaturing with detergent agarose gel-electrophoresis)
63
 and 
analyzed the SDS-resistant Sup35 species.  In hsp104-G254D and hsp104-G730D cell lysates, we found 
that the size of the Sup35 aggregate distribution was increased, as was the amount of Sup35 monomer 
(Fig. 4.1B).  From these data, one could hypothesize that these Hsp104 mutants are unable to efficiently 
fragment Sup35 aggregates, resulting in larger aggregates that cannot be as easily passed on to 
daughter cells. In addition, less propagons would also result in decreased monomer addition and a larger 
pool of monomeric Sup35.  Alternatively, the mutants could be propagating a weak variant of [PSI+] which 
would be predicted to show the same change in aggregate pattern. 
 
Strong [PSI+] propagons are maintained in both hsp104-G254D and hsp104-G730D.  The SDD-AGE 
analysis of the mutant strains (Fig. 4.1B) showed an increase in both high-molecular weight species and 
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Sup35 monomer, which is characteristic of weak [PSI+] variants.
30
  However, the original [PSI+] variant in 
the screen was strong [PSI+].  Thus, we used a genetic test and phenotypic test to analyze whether the 
mutants appeared to be propagating a different variant of [PSI+] or if the variant propagated in the 
sectoring colonies still appeared to be strong [PSI+].  As the mutants are recessive, we could readily 
analyze the properties of the variant by mating the sectoring hsp104-G254D and hsp104-G730D cells to 
wild type [psi-] cells, sporulating diploids, and analyzing resultant haploid progeny phenotypically and 
biochemically.  Mating [PSI+] hsp104-G254D and [PSI+] hsp104-G730D cells to wild type [psi-] cells 
resulted in diploids that were light pink, and more similar to the strong [PSI+] parent than the mutant 
haploids (Fig. 4.2A).  Sporulation of the diploids resulted in tetrads with two stable [PSI+] haploids and 
two sectoring/ weaker [PSI+] haploids.  For both heterozygous diploids, the two haploid progeny that 
expressed wild type HSP104 resembled strong [PSI+] phenotypically, by both color and growth on media 
lacking adenine (Fig. 4.2B).  Finally, we performed SDD-AGE analysis on cell lysates from full tetrads 
obtained from the heterozygous diploids and compared the aggregate distribution of the wild type 
HSP104 haploids to lysates from control cells containing the parental strong [PSI+] variant.  The 
biochemical analyses correlated with the colorimetric phenotypes: all the wild type haploids propagated 
Sup35 aggregates that resembled those from control strong [PSI+] cell lysates (Fig. 4.2C).  In sum, our 
phenotypic and biochemical analyses suggest that the underlying structure of Sup35 aggregates is 
retained in [PSI+] cells harboring the hsp104-G254D and hsp104-G730D mutations; however, when 
these mutations are present as the only copy of Hsp104 in the cell they are unable to efficiently propagate 
the prion to maintain the strong [PSI+] phenotype. 
 
Hsp104 missense mutant proteins are defective in ATP hydrolysis and efficient hexamer 
formation.  As the increased size of the Sup35 aggregates in hsp104-G254D and hsp104-G730D cells 
could suggest a fragmentation defect of Hsp104, we next investigated whether these mutations affected 
ATP hydrolysis.  We purified recombinant wild type Hsp104, Hsp104-G254D, and Hsp104-G730D 
proteins from E. coli cells.  We then tested the ability of Hsp104-G254D and Hsp104-G730D to hydrolyze 
ATP by monitoring release of inorganic phosphate using the Malachite Green assay.
64
  The G254D 
mutation is in NBD1 and G730D is in NBD2 and as such, may be involved in ATP binding or hydrolysis.  
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As compared to wild type Hsp104, both mutants had significantly reduced ATPase activity (Table 4.1).  
Surprisingly, these results contradict previous results in the literature, which demonstrate that mutants of 
Hsp104 that display similarly low levels of ATP hydrolysis often cure [PSI+].
17, 33
 
As ATP hydrolysis is dependent on the ability of Hsp104 to form hexamers,
64
 we next 
investigated whether these mutants were capable of oligomerizing in the presence of nucleotide.
65
  Using 
glycerol gradient fractionation in the presence of ATP, we found that Hsp104-G254D and Hsp104-G730D 
do form hexamers, though appear to do so less efficiently than wild type, as there was a slight shift in the 
peak of Hsp104-G254D and Hsp104-G730D toward the top of the gradient (Fig. 4.3).  In the absence of 
ATP, wild type Hsp104 and the mutant proteins remain monomeric (data not shown).  Thus, the reduced 
ATP hydrolysis of both Hsp104-G254D and Hsp104-G730D may correlate with their inefficient 
hexamerization ability. 
We reasoned that if the majority of the mutant were in the hexameric state, we might observe wild 
type levels of ATPase activity from the mutants.  Hsp104 has previously been shown to hexamerize even 
in the absence of ATP when incubated in a buffer containing low salt (<20mM).
64
  Therefore, we again 
measured hydrolysis of ATP by the Malachite green assay, this time in a low salt (15mM NaCl) buffer to 
promote hexamerization.  In low salt buffer, we found that the NBD2 mutant, Hsp104-G730D, displayed 
ATPase activity similar to wild type (Table 4.1).  Hsp104-G254D, however, did show an increase in ATP 
hydrolysis in low salt buffer, but not to the same extent as Hsp104 or Hsp104-G730D, suggesting the 
hexamer defect of Hsp104-G254D may not be the only cause of the reduced rate of ATP hydrolysis. 
 
Low activity mutations in HSP104 vary in their ability to disaggregate non-prion substrates.  In 
addition to its role in prion propagation, Hsp104 is also necessary for cell survival following acute heat 
shock.
21
  With the aid of Hsp70 and Hsp40 co-chaperones, Hsp104 resolubilizes proteins that aggregate 
as a result of heat or other stresses and is crucial for cellular recovery from such stresses.
20
  Therefore, 
we tested the ability of Hsp104-G254D and Hsp104-G730D to provide thermotolerance.  We first pre-
treated cells at 37°C to induce Hsp104 expression, and then heat-shocked HSP104, hsp104Δ, hsp104-
G254D, and hsp104-G730D cells at 50°C for various times as indicated, before plating on rich media to 
determine the relative viability.  We found that both wild type HSP104 and hsp104-G254D were 
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thermotolerant, but hsp104-G730D cells were not, and resembled the hsp104Δ strain (Fig. 4.4).  Thus, 
despite having lower ATPase activity, Hsp104-G254D was more active in thermotolerance assays than 
Hsp104-G730D, suggesting that the mechanism of disaggregation is de-coupled from the ATP hydrolysis 
activity for these two mutants. 
 
hsp104-G254D and hsp104-G730D do not propagate weak [PSI+].  Recently, it has been shown that 
some mutations in Hsp104 that reduce ATPase activity can impair the propagation of weak [PSI+] 
variants, but not strong [PSI+] variants.
66
  Accordingly, we next tested the ability of hsp104-G254D and 
hsp104-G730D to propagate weak [PSI+] variants.  We mated hsp104-G254D [psi-] and hsp104-G730D 
[psi-] cells to two previously characterized weak [PSI+] variants and examined the diploids and haploid 
progeny phenotypically and biochemically.
49, 53
  In both weak [PSI+] variants, the heterozygous diploids 
displayed decreased nonsense suppression as compared to the wild type weak [PSI+] parent (Fig. 4.5A).  
These data suggest that both hsp104-G254D and hsp104-G730D were inhibiting weak [PSI+] 
propagation, even in the presence of wild type HSP104.  After sporulation, we observed two distinct 
patterns of inheritance in the haploid progeny.  Resultant tetrads were either all red and [psi-], or 
segregated 2:2 weak [PSI+]:[psi-] (Fig. 4.5B) where the [PSI+] progeny segregated with the wild type 
HSP104.  Loss of the [PSI+] phenotype, even in the wild type haploids, is consistent with the increased 
mitotic loss of weak [PSI+] we observed in the diploids.  Presumably, the reduced activity of Hsp104-
G254D and Hsp104-G730D prevent weak [PSI+] propagation and also partially inhibit wild type Hsp104 
from stably propagating weak variants.  Next, we chose tetrads that maintained weak [PSI+] in the wild 
type haploids for SDD-AGE analysis and found that the variant propagated resembled the weak [PSI+] 
parent (Fig. 4.5C).  Thus, hsp104-G254D and hsp104-G730D do not irreversibly decrease the ability of 
wild type HSP104 to propagate weak [PSI+] variants and do not appear to alter the prion variant structure 
by phenotypic assays. 
 
hsp104-G730D propagates a known variant of [RNQ+].  Like [PSI+], the [RNQ+] prion is also 
dependent on Hsp104 for its maintenance.
12
  To determine if the prion propagation defect observed in 
hsp104-G254D and hsp104-G730D cells was specific to [PSI+], we tested the ability of both mutants to 
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propagate several established [RNQ+] variants.  After mating [psi-] hsp104-G254D and [psi-] hsp104-
G730D cells to the s.d. low, medium, high, very high, and m.d. high variants of [RNQ+]
59
 and sporulating 
the diploids, we performed SDD-AGE on the hsp104-G254D and hsp104-G730D haploids to determine 
the [RNQ+] state of the cells.  Interestingly, we found one variant of [RNQ+], the m.d. high variant, that 
was propagated, at least to some extent, in hsp104-G730D cells (Fig. 4.6).  None of the s.d. variants 
could be propagated by hsp104-G730D, and hsp104-G254D did not propagate any of the [RNQ+] 
variants tested (data not shown).  Thus, similar to recent reports for [PSI+], these data may suggest that 
the m.d. [RNQ+] variant is less stable than the s.d. [RNQ+] variants and thus more refractory to changes 
in the activity or interaction with Hsp104. 
 
Discussion 
Here, we identify two novel mutations in Hsp104, Hsp104-G254D and Hsp104-G730D, which 
affect Hsp104 activity in a substrate- and prion variant-specific manner.  Cells carrying the NBD1 mutant, 
hsp104-G254D, or the NBD2 mutant, hsp104-G730D, display high mitotic loss of the strong variant of 
[PSI+].  Phenotypically, hsp104-G730D displays a high degree of sectoring while hsp104-G254D exhibits 
fewer sectoring colonies but more completely [psi-] (red) colonies.  Despite both showing marked 
reductions in ATP hydrolysis activity under physiological conditions, the mutants differ in their ability to 
disaggregate a broad range of substrates, though both are unable to propagate weak variants of [PSI+].  
The hsp104-G254D mutant is active in thermotolerance, but is defective in the propagation of all tested 
variants of [RNQ+].  On the other hand, Hsp104-G730D expressing strains are unable to resolve 
disordered aggregates but, curiously, can propagate at least one variant of the [RNQ+] prion to some 
extent. 
Manipulation of the chaperone network has long been known to regulate prion propagation and 
formation.
17, 20, 27, 67
  Hsp104 is a general prion regulator
26, 68, 69
; deletion of Hsp104 eliminates all of the 
known yeast prions and dependence on Hsp104 is often one of the criteria used when identifying new 
yeast prions.
18, 70-72
  Therefore, we were not surprised when several candidates from our mutagenesis 
screen for factors involved in [PSI+] propagation were identified as mutations in Hsp104.  Several 
interdependent features of Hsp104 contribute to its overall function in substrate disaggregation, and 
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understanding the effect these features have on each other is not simple.  For example, as an AAA+ 
ATPase, hydrolysis of ATP provides the primary energy for the disaggregase ability of Hsp104 and yet we 
identified two mutations, Hsp104-G254D in NBD1 and Hsp104-G730D in NBD2, that still disaggregate 
substrates despite having significantly lower rates of ATP hydrolysis.  Interestingly, reducing the ATPase 
activity of Hsp104 was previously shown to enhance substrate disaggregation.
73, 74
  However, the 
increased disaggregation ability extended only to disordered substrates; decreased ATPase activity 
instead impaired prion remodeling.
66, 73
  On the other hand, a highly characterized mutation in the Walker 
B motif in NBD1, E285A/Q, hydrolyzes ATP at a rate much higher than wild type (300-500%), but fails to 
support either thermotolerance or prion propagation.
33
  Therefore, ATP hydrolysis is not always a reliable 
indicator for substrate disaggregation ability. 
One hypothesis proposed suggested that disordered substrates are less stable and thus require 
less overall force by Hsp104 to be disaggregated.
66
  High temperature and other stresses result in the 
increased exposure of hydrophobic regions in proteins, leading to the formation of unstable, 
heterogeneous protein aggregates.  Unlike these stress-induced aggregates, prions are highly ordered, 
stable protein aggregates that are typically resistant to denaturation by detergents and high temperatures.  
Mutations in Hsp104 that promote thermotolerance but are not sufficient for prion propagation have been 
previously described.
33
  Interestingly, hsp104-G730D cells can propagate strong [PSI+] and m.d. high 
[RNQ+], but are unable to function in thermotolerance.  Additionally, mutations in the C-terminal domain 
including K774E, L814S, L840Q, and 22 or 38 residue deletions of the C-terminus cause a loss of 
thermotolerance but these mutants are able to propagate [PSI+] to some extent.
26, 29, 33
  These previously 
characterized mutants are similar to Hsp104-G730D in that they exhibit reduced ATP hydrolysis and 
show defects in hexamerization.
29
  As yet, no function has been ascribed to the Hsp104 C-terminal 
domain, though some data suggest it is a site of substrate interaction.
28
 
 The hypothesis that Hsp104 is better able to remodel less stable aggregates can also be applied 
to the broad range of prion variants.
57
  Despite having the same sequence, prion variants compose 
distinct structures that vary in stability and hence, may vary in their interaction with Hsp104.  Hsp104 has 
previously been shown to play a role in prion variant selection.
75
  Continued expression of high levels of 
Hsp104 resulted in propagation of a [PSI+] variant dependent on overexpression of Hsp104.
76
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Additionally, recent data show that, like with disordered aggregates, less stable variants of [PSI+] are 
more efficiently remodeled by Hsp104 despite equal binding affinities for Hsp104.
57
  At low 
concentrations, Hsp104 catalyzed the generation of prion-competent seeds of strong variants but was 
unable to remodel weak variants.  Therefore, the decreased activity of our Hsp104 mutants may 
specifically inhibit weak variants of [PSI+] in vivo due to the inability to interact with or remodel this 
specific amyloid structure or any structure that is more stable.  Moreover, expressing the mutant 
concurrently with wild type, as seen in the diploids, caused mitotic loss of weak [PSI+] variants, thereby 
supporting previous results indicating that weak variants require a high level of cooperativity between 
hexameric subunits to propagate.
66
   
In addition to causing unstable strong [PSI+] propagation, hsp104-G730D is also able to 
propagate m.d. high [RNQ+] to some extent.  The m.d. high [RNQ+] variant has been shown to be less 
thermal-stable than the s.d. [RNQ+] variants.
61, 76
  We have previously published another mutation in 
Hsp104, E190K, which also had a differential effect on the propagation of the [RNQ+] variants.  Like 
hsp104-G730D, hsp104-E190K was unable to maintain the s.d. variants, but was able to propagate m.d. 
high [RNQ+].
34
  Additionally, both hsp104-G730D and hsp104-E190K showed defects in both [PSI+] 
propagation and thermotolerance.  Our data from these two mutants suggest that variants of the [RNQ+] 
prion may be regulated by Hsp104 in a manner similar to the mechanisms elucidated for [PSI+].  
Interestingly, the m.d. [RNQ+] variant that is the most resistant to alterations in Hsp104 activity also 
facilitates a high rate of [PSI+] induction.  It’s interesting to theorize that changing environmental 
conditions may cause fluctuations in Hsp104 activity that in turn control the appearance and 
disappearance of prions, and as such, the environment may influence prion-dependent phenotypic 
variation, adaptability and survival in different conditions.  Therefore, discerning Hsp104’s mechanism of 
disaggregation, as it applies to distinct prion variants, is critical to understanding how prions appear, 
disappear, and evolve. 
As our understanding of self-propagating prions continues to develop, so too does the knowledge 
that the biological phenomenon of protein-only heritability is highly complex.  In addition to mutations in 
the primary sequence affecting aggregation and propagation, we now understand that the same primary 
sequence can adopt multiple conformations, and these conformations differ in stability, heritability, and 
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function.  How a single protein sequence can adopt multiple conformations is a biological phenomenon 
that is still relatively unclear.  Just as gene expression is regulated by an intricate network of transcription 
factors and promoter elements, prion variant propagation is regulated by a network of chaperones and in 
some cases, other prions.  Understanding how changes in the chaperone network regulate prion variant 
formation and propagation will broaden our understanding of the mechanisms of prion variant generation, 
selection, and evolution. 
 
Materials and Methods 
Strain and Plasmid Construction 
S. cerevisiae strains used in this study were derivatives of 74-D694 and were grown and 
manipulated using standard techniques.  Yeast strains were either grown in rich media (1% yeast extract, 
2% peptone, 2% glucose) or synthetic media lacking amino acids corresponding to plasmid selection 
(0.67% yeast nitrogen base, 2% glucose) or nonsense suppression analyses.  Diploids were generated 
by mating haploids containing selectable plasmids and were verified by growth on minimal media and 
plating on haploid tester strains.  Haploid progeny from diploids were isolated by micromanipulation and 
verified by phenotypic assays and mating type testing. 
Hsp104 mutants from the original mutagenized strains were PCR amplified and cloned into the 
pRS306 integrating vector.  The mutants were integrated into a clean 74-D694 background by the pop-
in/pop-out method and verified by DNA sequencing.  The pProEx-Htb-Hsp104 purification plasmid has 
previously been described.
29
  Hsp104 mutations were cloned into pProEx-Htb-Hsp104 by restriction 
digest with BamHI and Bsu36I followed by ligation and sequencing to verify the mutation. 
The “strong” and “weak” [PSI+] variants were characterized and kindly provided by the Chernoff 
and Liebman labs.
17
  The Sc37 [PSI+] variant was made by transforming Sup35NM fibers generated at 
37°C into [psi-] cells.  These strains were made and kindly provided by the Weissman lab.
49
  The [RNQ+] 
variant strains were characterized as specific [PIN+] strains initially, but later confirmed to be [RNQ+], and 
were kindly provided by the Liebman lab.
59, 60
  To analyze the Hsp104 mutants in both [RNQ+] and [PSI+] 
variants, each variant was mated to both hsp104-G254D [psi-][rnq-] and hsp104-G730D [psi-][rnq-] cells 
and diploids were selected.  The diploids were sporulated and dissected by micromanipulation. 
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EMS Mutagenesis Screen 
A strong [PSI+] yeast strain was subjected to EMS mutagenesis as previously described.
34
  Two 
cultures with viabilities of about 17% were plated to determine changes in color.  Candidates were 
selected based on color phenotype and were initially identified as mutations in HSP104 by back-crossing 
to an hsp104Δ strain and analyzing the progeny for segregation of the phenotype.  Genomic DNA was 
PCR amplified and sequenced to identify the point mutations in HSP104. 
SDD-AGE 
SDD-AGE analysis was performed as previously described.  Cells were lysed by beadbeating in 
PEB buffer (25mM Tris-HCl pH 7.5, 50mM KCl, 10mM MgCl2, 1mM EDTA, 10% Glycerol plus mini EDTA-
free protease inhibitors (Roche), Aprotinen (Sigma) and PMSF (Sigma)).  Samples were incubated in 
sample buffer at room temperature for seven minutes then separated on a 1.5% agarose gel.  The protein 
distribution was analyzed by western blot with anti-Sup35 antibodies or anti-Rnq1 antibodies. 
Hsp104 Purification 
Recombinant Hsp104 was expressed in E. coli cells and purified as previously described with one 
further separation step added.
23
  Briefly, Hsp104, tagged with a 6xHis tag on the N-terminus, was first 
isolated on a Nickel-sepharose column, the 6xHis tag was cleaved off using the TEV protease, and 
Hsp104 was re-applied to the Nickel-sepharose column to separate the untagged Hsp104.  Untagged 
Hsp104 was then applied to an anion exchange Q-sepharose column followed by an S-300 size exclusion 
column to isolate monomeric Hsp104 from any aggregated Hsp104 species.  Untagged, monomeric 
Hsp104 was stored at -80°C. 
ATP Hydrolysis Assays 
ATP hydrolysis was measured by the Malachite green assay as previously described.
64
  Briefly, 
2µg of purified protein was incubated in buffer (40mM TrisHCl pH7.5, 175mM NaCl, 5mM MgCl2, 0.02% 
Triton X-100) with 5mM ATP at 37°C.  At various times, Malachite green dye was added to the sample for 
one minute and the reaction was stopped by the addition of 34% citric acid.  The dye absorbance was 
determined at 650nm and the amount of free phosphate calculated based on a standard of KH2PO4. 
Glycerol Gradients 
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Purified Hsp104 was applied to a 4mL linear (10-35%) glycerol gradient and centrifuged at 34k 
rpm for 18 hours in a SLA-600 rotor.  Gradients were fractionated and equal volumes of each fraction 
were analyzed by SDS-PAGE and western blot using an anti-Hsp104 antibody.  Individual bands from 
each fraction were quantified using Image J and reported as a percent of total Hsp104.  
Thermotolerance 
An equal number of cells from cultures of HSP104, hsp104-G254D, hsp104-G730D, and 
hsp104Δ grown to mid-log phase were pre-treated at 37°C to induce HSP104 expression then heat-
shocked at 50°C.  At the indicated time intervals, samples were taken and spotted on rich media in a five-
fold serial dilution. 
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Figure 4.1. hsp104-G254D and hsp104-G730D strains show inefficient [PSI+] propagation. 
 
 (A) hsp104-G254D and hsp104-G730D cells display a sectoring [PSI+] phenotype as a result of 
inefficient [PSI+] inheritance. (B) Lysates of sectoring hsp104-G254D and hsp104-G730D cells with 
strong [PSI+] cells ([PSI+]) and [psi-] cells ([psi-]) as controls were analyzed by SDD-AGE analysis 
followed by western blot and blotting for Sup35.  These results were reproduced at least three times. An 
example of the shift is shown.  The general loss of the lower aggregate species and the decrease in 
aggregated Sup35 is reproducible.  The appearance of monomeric Sup35 on SDD-AGE western blots is 
more variable, even with controls, for unknown reasons. 
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Figure 4.2 hsp104-G254D and hsp104-G730D cells propagate the original strong [PSI+] variant.  
 
(A) hsp104-G254D and hsp104-G730D cells (G254D and G730D, respectively) and diploids from the 
mating of hsp104-G254D and hsp104-G730D to wild type [psi-] cells (WT/G254D and WT/G730D) were 
spotted on rich media (YPD) and media lacking adenine (SD-Ade). Strong [PSI+] and [psi-] cells are 
spotted for comparison. The second spot in each row is a five-fold dilution of the first spot. (B) Full tetrads 
from the sporulation of the diploids in (A) were spotted for each mutant as indicated.  Each haploid 
progeny in the tetrad is labeled, A-D.  Strong [PSI+] and [psi-] are spotted for color comparison. The 
second spot in each row is a five-fold dilution of the first spot. (C) A representative tetrad from (B) was 
analyzed by SDD-AGE analysis and western blot. The letters A-D correspond to the haploids with the 
same label in (B) and weak [PSI+] (Weak), strong [PSI+] (Strong) and [psi-] were analyzed for 
comparison.  SDD-AGE analysis was performed four times with haploids from both hsp104-G254D and 
hsp104-G730D cells. 
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Table 4.1 Hsp104 mutants display defects in ATP hydrolysis under physiological salt conditions 
 Physiological* Low
†
 
WT 0.225 ± 0.0397 0.732 ± 0.0543 
G254D 0.0325 ± 0.00177 0.211 ± 0.00177 
G730D 0.00583 ± 0.00439 0.677 ± 0.0321 
Numbers represent the average initial rate (nmol·µg
-1
·min
-1
) of ATP hydrolysis for WT Hsp104, Hsp104-G254D, 
and Hsp104-G730D.  ATPase assays were measured by the Malachite Green assay.  Rates were calculated from 
three separate experiments from two different preparations of purified protein. 
*Buffer contains 150mM NaCl 
†
Buffer contains only 15mM NaCl 
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Figure 4.3 Hsp104-G254D and Hsp104-G730D mutant proteins form hexamers in vitro. 
 
 Hsp104 (blue), Hsp104-G254D (green), and Hsp104-G730D (red) were incubated with 5mM ATP for 10 
minutes then subjected to ultracentrifugation through a linear (10-35%) glycerol gradient.  Equal volume 
fractions were collected and the amount of Hsp104 protein in each fraction was analyzed by SDS-PAGE 
and western blot.  Individual bands were quantified and the amount of Hsp104 in each fraction was 
plotted as a percent of the total Hsp104 protein.  The graph shows the data from one assay.  This assay 
was performed three times and all gave similar results. 
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Figure 4.4 hsp104-G254D and hsp104-G730D display different levels of non-prion disaggregation.   
 
The thermotolerance of HSP104, hsp104Δ, hsp104-G254D, and hsp104-G730D cells was tested.  Cells 
were first grown at 37°C in liquid culture to induce HSP104 expression, heat-shocked at 50°C for 10 to 30 
minutes as indicated, and then spotted on rich media.  Control cells (No Heat) were plated without heat 
shock.   Thermotolerance assays were repeated four times and all showed similar results. 
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Figure4.5 Neither hsp104-G254D nor hsp104-G730D can propagate weak [PSI+].  
 
(A) Cured hsp104-G254D [psi-] and hsp104-G730D [psi-] cells, weak [PSI+], the weak [PSI+] variant 
Sc37(from transformation of [psi-] cells with Sup35NM fibers formed at 37°C), and the diploids from the 
matings of the weak [PSI+] cells to the mutants were spotted on YPD.  The second spot in each row is a 
five-fold dilution of the first spot. (B) Diploids of the mutants crossed to weak [PSI+] (Weak/Mut in (A)) 
were sporulated and 16 tetrads dissected.  Two representative tetrads on YPD are shown.  Each haploid 
is labeled A-D. (C) Diploids of weak [PSI+] crossed to the mutants (Weak/Mut in (A)) and a representative 
tetrad from these heterozygous diploids were subjected to SDD-AGE and western blot analysis to 
determine Sup35 aggregate distribution.  SDD-AGE analysis was performed twice using four distinct 
tetrads. 
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Figure 4.6 hsp104-G730D can propagate multi-dot high [RNQ+].  
 
hsp104-G730D cells weremated to s.d. low (low), medium (med), high (high), very high (v.high) and m.d. 
high (m.d. high) [RNQ+] and then sporulated. The hsp104-G730D haploid progeny from four separate 
tetrads of each variant mating, along with the unmated [RNQ+] variants as controls (WT), were analyzed 
by SDD-AGE and western blot. 
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Chapter 5: Conclusions and Future Directions 
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5.1 Hsp104-R830S and soluble Sup35 oligomers future directions 
Summary 
Yeast prions are self-replicating, protein-only epigenetic elements that are non-toxic.
1
  To be 
efficiently propagated, prions must be fragmented to generate smaller, prion-competent propagons that 
are easily transmissible to the budding cells.
2, 3
  Propagons must also maintain the structural information 
of the prion in order to faithfully propagate the prion to the soluble prion protein in the newly budded cell.  
The generation of these propagons requires the AAA+ ATPase chaperone Hsp104.
2-4
  In Chapter 2, I 
investigate a point mutant of Hsp104 that propagates soluble, more SDS-sensitive oligomers of Sup35 
that are sufficient for transmission of the prion state but are incapable of conferring the nonsense 
suppression phenotype associated with [PSI+].  The novel properties of the soluble, prion-competent 
Sup35 oligomers can provide insight into the mechanisms of prion formation and propagation.  The 
following section will describe some experiments designed to utilize them. 
 
Structural analysis of soluble Sup35 oligomeric propagons 
 Our findings in chapter 2 represent the first identification of soluble oligomers of a prion protein in 
vivo.  From protein transformation experiments where we transformed [psi-] cells with these soluble 
oligomers, we discovered that these oligomers could transmit the prion state to a soluble pool of 
monomer.  Several studies have hypothesized that propagons in yeast are a soluble oligomeric species, 
but until now, these structures have always been transient and have yet to be characterized structurally.  
One future experiment is to characterize these amyloid oligomers by several structural methods to 
investigate how these structures differ from the large aggregates that confer the [PSI+] phenotype.  For 
example, structural data of the amyloid aggregate is difficult to achieve due to its large bulky structure.  
However, we have shown from matings of hsp104-R830S cells containing soluble Sup35 oligomers to 
[psi-] cells that these oligomers retain the same amyloid core as the parental [PSI+] strain.  Perhaps, now, 
given their soluble nature and small size these structures are more amenable to various structural 
techniques such as NMR.  Furthermore, these oligomers be analyzed by EM and AFM to determine if 
they share ultrastructural features with the intermediate protofilaments identified of Aβ aggregation.  
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These oligomers could also be used in single-molecule studies to investigate the templating or joining 
mechanism. 
 In addition to the correct structure, propagons also need to interact with molecular chaperones for 
efficient propagation.  One area of chaperone involvement that is the least characterized is in prion 
formation.  When prion monomers template into the β-sheet rich conformation, they first have to unfold 
and many prion proteins have natively unfolded or destabilized domains already present.  One very 
important job of molecular chaperones is to bind unfolded or exposed domains to prevent aggregation.  
Interestingly, overexpression of the Hsp70 chaperone Ssa1 leads to increased [PSI+] production, while 
the overproduction of another Hsp70, Ssb1, results in increased [PSI+] loss from excess Sup35. What 
these mechanisms are and why they are opposing is still unclear.  We should use the oligomers to probe 
the role of chaperones in the formation of prions by looking at chaperone binding, oligomeric stimulation 
of chaperone activity, and specific chaperone domains or activities that may be required for an 
interaction. 
  
Analyze the role of oligomeric intermediates for the [RNQ+] prion 
In order to determine if oligomeric intermediates are a general property of yeast prions, future 
experiments should examine the role of oligomers in the propagation of the [RNQ+] prion.
5
  In our 
experiments, we only closely looked at the Sup35 species in hsp104-R830S cells.  By solubility assays, 
hsp104-R830S cells were able to maintain [RNQ+].  Similar to wild type [PSI+] cells, wild type [RNQ+] 
cells may also contain oligomeric species sufficient for transmission of the [RNQ+] state.  Wild type 
[RNQ+] cells should be separated by sedimentation and the soluble and insoluble fractions transformed 
into [rnq-] cells to determine if any infectious species exist in the soluble fraction.  Subsequently, wild type 
[RNQ+] lysates should be separated by sucrose gradient fractionation and analyzed by western blot and 
protein transformation into [rnq-] cells.  Since [RNQ+] does not have an easily observable phenotype like 
[PSI+] does, a Rnq1 reporter developed in our lab should be used to quantify the infectivity of specific 
soluble or oligomeric species.  The RRP construct is a chimera of the Rnq1 prion-forming domain and the 
middle and C-terminal domains of Sup35 and can be used as a phenotypic readout of the [RNQ+] state. 
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Analyze the role of oligomeric intermediates in the propagation of conformational variants 
Recombinant Sup35 can form distinct amyloid structures in vitro when assembled under different 
temperatures.
6, 7
  Structural variation is also the basis for prion variants observed in cells, such as weak 
and strong [PSI+] and the low, medium, high, and very high variants of [RNQ+].
8-10
  One hypothesis is 
that the formation of amyloid oligomers is also conformation-dependent and may only occur under certain 
conditions, as seen for Sup35 and PrP.
11-13
  Therefore, the presence of amyloid oligomers in variants of 
the [PSI+] and [RNQ+] prions should be assessed.  Again, this could be done by separating soluble 
oligomers from SDS-resistant aggregates by sucrose gradients and sedimentation assays and using the 
species isolated to infect [psi-] or [rrp-] cells and quantify the amount of infectivity.  By SDD-AGE and 
solubility assays, weak [PSI+] maintains an increased soluble pool of Sup35 compared to strong [PSI+].
14, 
15
  Perhaps this soluble pool is not simply functional monomer, but a mix of oligomeric species, of which 
some may be highly infectious. 
 
Determine the domains of Sup35 involved 
 Although we were able to separate the soluble oligomeric species from large aggregates in wild 
type HSP104 cells, we originally identified these propagons in a point mutant of Hsp104.  We could use 
this mutant again to help identify domains and regions of Sup35 important for oligomer formation.  For 
example, we have seen that full-length Sup35 is capable of forming soluble propagons but what about the 
PFD of Sup35 alone?  Investigating the mechanism of Hsp104-R830S on distinct Sup35 domain deletion 
or truncations mutants not only provides information about Sup35 regions involved in amyloid formation, 
but also gives insight into the interaction between Hsp104 and Sup35.  I would propose using a plasmid 
shuffle technique to replace full-length Sup35 with various Sup35 deletions and truncations and 
measuring the amount of soluble oligomers.  Additionally, measuring the amount of infectious soluble 
oligomers by protein transformation may provide insight into which regions of Sup35 are important in 
forming infectious structures. 
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Investigation of a “dead-end” substrate 
 In Figure 2.4, the sucrose gradient of lysates from hsp104-R830S cells showed that Sup35 
species migrated just as far as Sup35 from the wild type cells.  The difference between these species 
was in their levels of infectivity.  High molecular weight species from hsp104-R830S cells were not 
infectious suggesting they might be examples of “dead-end” substrates or non-heritable amyloids.  I 
propose that these structures should be isolated as well and compared by structural techniques like EM 
or sensitivity to denaturants or proteases to their counterparts in the wild type cells to determine 
differences between infectious aggregates and non-infectious aggregates. 
 
Conclusions 
 We found that soluble, prion-competent oligomers exist in wild type [PSI+] cells and are highly 
infectious.  These oligomers have mostly remained elusive because of their transient and unstable 
nature.  Here, we have identified a mutation in Hsp104 which propagates these oligomers allowing a 
more stable system within which to investigate the structure and mechanism of these structures. 
 
5.2 Hsp104 M-domain Future Directions 
Summary 
Hsp104 is composed of five functionally distinct domains that each contribute to the overall 
function of the disaggregase chaperone.  The middle domain (M-domain) is a coiled-coil whose position 
in the hexamer has been a matter of much debate.
16-18
  Recent studies have suggested that this domain 
plays a role in regulating the function of the whole chaperone.  The M-domain of ClpB  was proposed to 
alternate between two conformational states, repressed and de-repressed.
19
  The repressed M-domain is 
stabilized against the body of the hexamer through an interaction with the NBD1 of the neighboring 
subunit.  The de-repressed state, however, is unattached from the body of the hexamer and accessible to 
co-chaperones.  We found that mutations that were predicted to promote the repressed state inhibited 
Hsp104 function.  These mutations inhibited ATPase activity, disaggregation activity, and were not able to 
form efficient hexamers.  Conversely, mutations proposed to induce the de-repressed state stimulated 
ATPase activity but exhibited reduced disaggregation activity.  Interestingly, the mutants exhibited 
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variation in their ability to propagate prions, suggesting that de-regulation of the function of the M-domain 
can cause defects in yeast prion propagation.  
 
The Interaction of the M-domain with Co-chaperones 
 One of the proposed roles for the M-domain of Hsp104 and ClpB is as a site for co-chaperone 
interaction.  Hsp104 and the co-chaperones, Hsp40 and Hsp70, often have opposing effects on [PSI+] 
propagation.  Perhaps, then, reducing or increasing the levels of co-chaperones may complement the 
defects in [PSI+] propagation observed from these M-domain mutants.  A comprehensive genetic 
experiment to delete (or reduce in the case of the essential chaperones) or overexpress each co-
chaperone with each mutant would enhance our knowledge of the interactions between the M-domain 
and the co-chaperones as well as the role of Hsp70 chaperones in prion propagation. 
 
Structural Studies of M-domain mutants 
 As yet, no evidence has been reported on the movement of the M-domain of Hsp104 and 
whether it can actually alternate between the repressed and de-repressed states similar to what has been 
reported for ClpB.
19
  One way to investigate this question would be to create cysteine mutants of the 
predicted pairs and perform both cross-linking and FRET studies.  Both methods would provide 
information on the interactions between the predicted residues and would provide evidence for the model 
of alternating repressed and de-repressed conformations. 
 
Hsp1040Y507D and [PSI+] 
 Despite repeated efforts, I was unable to isolate more than one cell that contained both Hsp104-
Y507D and [PSI+].  Clearly, antagonistic interactions of Hsp104-Y507D and [PSI+] led to toxicity but how 
this occurs is unknown.  One way to investigate this mechanism is by using a shutoff system, much like 
the one we employed in Chapter 2.  Expression of hsp104-Y507D in [PSI+] cells containing wild type 
HSP104 is not toxic.  Therefore, a plasmid with wild type HSP104 driven by a repressile promoter could 
be used to maintain viability before adding the repressing agent, such as glucose for the galactose 
promoter or doxycycline for the tetracycline-repressible promoter.  As wild type Hsp104 is repressed, the 
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activity of Hsp104-Y507D and [PSI+] in the cell could be investigated by numerous methods to look at the 
Sup35 aggregates themselves or protein aggregation or defects in translation.  Thus, this system could 
be used to understand how co-expression of Hsp104-Y507D and [PSI+] are toxic. 
 
Conclusions 
 From our data, we find that the function of the M-domain is very important for proper Hsp104 
function.  De-regulation of this domain can either cause a loss-of-function or a toxic gain-of-function.  
Investigating the function of the M-domain will elucidate the mechanisms of disaggregation and ATPase 
substrate stimulation in addition to co-chaperone interactions.  
 
5.3 Low Hsp104 Activity Mutants Future Directions 
Summary 
The optimal activity of the molecular chaperone Hsp104 is dependent on several variables 
including ATPase activity, hexamer formation, and ability to bind and translocate substrates.  Mutations in 
Hsp104 that inhibit these features often inhibit chaperone activity.  As Hsp104 is essential for yeast prion 
propagation, changes in Hsp104 expression or activity can have severe consequences for prion 
maintenance.  However, several conformational variants exist which are not as sensitive to changes in 
Hsp104 activity.  For example, the [PSI+] prion is cured by overexpression of Hsp104, but the [RNQ+] 
prion is not.  Clearly conformational features of the prion substrates play a role in their interaction with 
Hsp104. 
 Here we show two novel mutants of Hsp104 which inhibit Hsp104 activity but are still capable of 
propagating certain variants of both [PSI+] and [RNQ+].  These mutants have very low ATPase activity 
and do not form stable hexamers and appear not to be functional.  However, enough activity is 
maintained for unstable prion propagation.  What are the differences in requirements for prion and non-
prion substrates in their interaction with Hsp104?  Furthermore, how are specific conformations 
maintained but not others?  The ability of Hsp104 to efficiently propagate some prion variants and not 
others is a mechanism not well understood. 
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Changes in Hsp104 activity alter propagation of specific variants 
 Classically, much of the mutational analysis done with Hsp104 has been focused on the [PSI+] 
prion.  And yet, the [PSI+] prion cannot form without the presence of [RNQ+] suggesting that the 
interaction of Hsp104 with the [RNQ+] prion is as equally important.  Many of the mutations that affect 
Hsp104 ATPase activity or disaggregation activity should be re-evaluated in the context of [RNQ+] and 
variants of [RNQ+] which show differences in their ability to induce [PSI+].  Furthermore, variants of 
[PSI+] exist that are more susceptible to changes in Hsp104 activity and the interaction of Hsp104 with 
these weak variants should be further investigated. 
 
Conclusions 
 Investigating how different aggregated structures respond to changes in Hsp104 activity will 
elucidate mechanisms of protein disaggregation.  Furthermore, structural studies of the substrates of 
Hsp104 will provide insight into why some structures appear dominant or more likely to aggregate.  All in 
all, investigating the interaction between Hsp104 and various substrates will provide insight into the 
physical characteristics of protein folding. 
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Introduction
Prions are proteins that can form a self-propagating aggregated 
state. In mammals, prions are a causative agent of neurodegener-
ative disease.1 In yeast, however, prions act as an epigenetic mode 
of inheritance. The prion-forming proteins in yeast are involved 
in a variety of cellular processes, including nitrogen catabolism, 
translation termination and chromatin modification.2-4 One 
of the yeast prions, [PSI+], provides a potential mechanism to 
respond to environmental stresses.5-8 Interestingly, [PSI+] is regu-
lated by another prion, [RNQ+], whose presence increases the 
rate of [PSI+] appearance.9-12 However, [RNQ+] is not required 
for the maintenance of [PSI+]. Thus, the maintenance of [RNQ+] 
is critical for the formation of [PSI+] and its adaptive effect on 
the cells.
The maintenance of yeast prions is regulated by the cellular 
chaperone machinery.13,14 A crucial player in this regulation is the 
AAA+ ATPase Hsp104p that is essential for the survival of acute 
heat shock.15,16 Hsp104p is a disaggregase and has been shown 
to dissociate aggregated proteins both in vivo and in vitro.15,17,18 
Like its bacterial homolog ClpB, the active form of Hsp104p is 
a ring-shaped hexamer with a pore in the center.19 Interestingly, 
Hsp104p can be divided up into five functionally distinct 
domains. Although the N terminus is generally dispensable for 
function, the amino and carboxy termini are likely involved 
in substrate binding.20,21 The two nucleotide binding domains 
(NBDs) coordinate to hydrolyze ATP to ADP and this enzy-
matic activity is required for Hsp104p function in prion mainte-
nance.22-25 Finally, the M domain lies between the two NBDs and 
is thought to coordinate the activities of the NBDs by propagat-
ing a conformational change in response to binding or hydrolysis 
of ATP.23,26,27 Due to the discrete nature of the domains, a variety 
of mutations have been described in each domain of Hsp104p 
that affect prion propagation.20,25,28-31
One model of Hsp104p function in prion biology posits 
that Hsp104p has two roles in prion maintenance: generation 
of transmissible material (seeds) from prion aggregates and 
conversion of monomer into a prion-competent form.17,32-34 A 
complete loss of Hsp104p activity eliminates (cures) all known 
yeast prions.3,4,11,25,35 However, increasing Hsp104p activity by 
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The formation and maintenance of prions in the yeast Saccharomyces cerevisiae is highly regulated by the cellular chaperone 
machinery. The most important player in this regulation is hsp104p, which is required for the maintenance of all known 
prions. The requirements for other chaperones, such as members of the hsp40 or hsp70 families, vary with each individual 
prion. [RNQ+] cells do not have a phenotype that is amenable to genetic screens to identify cellular factors important in prion 
propagation. Therefore, we used a chimeric construct that reports the [RNQ+] status of cells to perform a screen for mutants 
that are unable to maintain [RNQ+]. We found eight separate mutations in hsp104p that caused [RNQ+] cells to become [rnq-]. 
These mutations also caused the loss of the [PSI+] prion. The expression of one of these mutants, hsp104p-e190K, showed 
differential loss of the [RNQ+] and [PSI+] prions in the presence of wild type Hsp104p. Hsp104p-E190K inefficiently propagated 
[RNQ+] and was unable to maintain [PSI+]. The mutant was unable to act on other in vivo substrates, as strains carrying it 
were not thermotolerant. Purified recombinant Hsp104p-E190K showed a reduced level of ATP hydrolysis as compared to 
wild type protein. This is likely the cause of both prion loss and lack of in vivo function. Furthermore, it suggests that [RNQ+] 
requires less hsp104p activity to maintain transmissible protein aggregates than Sup35p.  Additionally, we show that the L94A 
mutation in Rnq1p, which reduces its interaction with Sis1p, prevents Rnq1p from maintaining a prion and inducing [PSI+].
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Here, we describe a screen for cellular factors that affect the 
propagation of the [RNQ+] prion. Using a chimeric reporter for 
the [RNQ+] status of the cell, we found several novel alleles of 
HSP104 that are unable to propagate both [RNQ+] and [PSI+]. 
Interestingly, one of the alleles shows differential rates of cur-
ing of [RNQ+] and [PSI+] in the presence of wild type Hsp104. 
Additionally, we show that Rnq1p-L94A, which has a decreased 
interaction with Sis1p, aggregates non-specifically and cannot 
support [PSI+] induction.
Results
EMS mutagenesis reveals genes necessary for the maintenance 
of [RNQ+]. We developed a system to identify cellular factors 
important in the propagation of [RNQ+]. The phenotypes asso-
ciated with [RNQ+], insolubility of the Rnq1 protein and an 
increase in the induction rate of [PSI+], are not amenable for use 
in a high-throughput screen. Therefore, we used the RRP reporter 
to assay the [RNQ+] status of the cells. As described previously,50 
RRP consists of a fusion of the Rnq1p prion forming domain 
(PrD) and the C-terminal translation termination domain of 
Sup35p. In [rnq-] cells, RRP is soluble and able to promote faith-
ful termination of translation. In [RNQ+] cells, RRP aggregates 
and is unable to promote faithful translation termination. We 
used a strain that has the ade1-14 allele for a sensitive readout of 
nonsense suppression. This allele harbors a premature stop codon 
that is read through when RRP is aggregated. Therefore, [rnq-] 
cells expressing RRP are adenine auxotrophs and appear red on 
rich medium (YPD) due to the accumulation of an intermedi-
ate in the adenine biosynthesis pathway. [RNQ+] cells expressing 
RRP are adenine prototrophs and appear light pink on YPD.
We used EMS to create an unbiased set of mutants that are 
unable to maintain [RNQ+]. A strain that was light pink due to 
expression of RRP in a [RNQ+] background was mutagenized 
with EMS to approximately 14% viability and plated on YPD. 
Following plating on YPD, some of the colonies turned red, indi-
cating a deficiency in adenine biosynthesis, possibly as a conse-
quence of the loss of RRP-associated nonsense suppression (Fig. 
1A). Of the approximately 150,000 colonies screened, 312 colo-
nies turned red on YPD. These 312 colonies were re-plated onto 
YPD to determine if the red phenotype was stable. 40 of these 
colonies remained red following two passages on YPD, indicat-
ing a stable phenotype.
The red phenotype created by the EMS mutagenesis could 
result not only from the loss of the [RNQ+] prion but also from 
a variety of different mutations affecting adenine biosynthe-
sis or translation termination. Therefore, we wanted to select 
those red mutants that had, in fact, converted from [RNQ+] to 
[rnq-]. The solubility of the Rnq1 protein was analyzed by western 
blot following high speed centrifugation of cell lysates. In [rnq-] 
cells, Rnq1p remains in the soluble fraction while in [RNQ+] cells 
Rnq1p is found in the insoluble fraction. The solubility of Rnq1p 
in the 40 stable red colonies was assayed. Of these 40 mutants, 14 
showed soluble Rnq1p, indicating that [RNQ+] had been cured 
(Fig. 1B and data not shown).
overexpressing the disaggregase cures only the [PSI+] prion and 
does not affect [RNQ+] or any other yeast prion.3,4,9,11,25,35 This 
indicates that Hsp104p has both general effects on all known 
yeast prions and specific effects on the [PSI+] prion, at least when 
overexpressed.
Other members of the cellular chaperone machinery also 
show differential effects on prion propagation. For example, 
overexpression of the Hsp70 family member Ssa1p cures [URE3] 
but not [PSI+].36 Excess Ssa1p does, however, reduce the curing 
of [PSI+] by Hsp104p overexpression and promote [PSI+] forma-
tion.37,38 Overexpression of the Hsp40 member Ydj1p cures the 
[URE3] prion but affects only certain variants of [PSI+] and 
[RNQ+].35,39,40 Deletion of either of two different Ssa1p nucleotide 
exchange factors, SSE1 or FES1, cures [URE3] but not [PSI+], 
though the deletion of SSE1 weakens [PSI+]-mediated nonsense 
suppression.41,42 Moreover, Hsf1p, which regulates the expres-
sion of heat shock proteins, influences [PSI+] formation. Hsf1p 
contains two activation domains and deletion of the N-terminal 
activation domain inhibits [PSI+] formation while deletion of the 
C-terminal activation domain promotes [PSI+] formation.43 This 
suggests two classes of interaction with [PSI+] by proteins regu-
lated by Hsf1p.
Rnq1p has been shown to interact with both Ssa1p and the 
Hsp40 family member Sis1p.44,45 The propagation of [RNQ+] can 
be abolished by mutations within Sis1p.33,44,46,47 Sis1p depletion 
cures [RNQ+], [PSI+] and [URE3], albeit with varying efficiency, 
which may indicate different requirements for its activity in prion 
maintenance.48
Figure 1. RRP reporter reveals [rnq-] cells after eMS mutagenesis. (A) 
[RNQ+] cells carrying the RRP reporter were mutagenized with eMS to 
approximately 14% viability and plated on YPD to assess color nonsense 
suppression of ade1-14. Left panel shows colonies prior to eMS treatment 
while right panel shows colonies after eMS treatment. (B) Solubility of 
Rnq1p in mutagenized cells. Following eMS mutagenesis, the red colonies 
were lysed and the lysate was fractionated into soluble and insoluble 
components by ultracentrifugation. The total (T), soluble (S) and insoluble 
pellet (P) were subjected to SDS-PAGe, transferred to PVDF and probed 
with an anti-Rnq1p antibody. The strain is indicated above the blot with 
[RNQ+] and [rnq-] controls shown on the left.  An example of a mutagen-
ized strain that remained [RNQ+], Red4, and one that converted to [rnq-], 
Red8, are shown.
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multi-locus trait. We chose to focus on the mutants whose phe-
notypes were caused by alteration of a single locus.
Missense mutations in HSP104 cure [RNQ+]. We set out 
to identify the specific mutations that cured the [RNQ+] prion. 
Since inactivation of the cellular disaggregase Hsp104p is known 
to cure all yeast prions it was an obvious candidate for our 
Genetic linkage indicates the [rnq-] phenotype is caused 
by single mutations. Next, we assessed the genetic properties of 
the red mutants. We mated the 14 [rnq-] mutants to a wild type 
[RNQ+] strain. We then assayed the solubility of Rnq1p in the 
resulting diploids as described above. Three of the diploids showed 
soluble Rnq1p, indicating that the diploids were [rnq-] and that 
the mutant phenotype was dominant over wild type (data not 
shown). The remaining eleven mutants had insoluble Rnq1p in 
the diploids, indicating that [RNQ+] was propagating in the cells 
and that the mutations were recessive (data not shown).
To determine if the loss of [RNQ+] was caused by a single genetic 
lesion we employed a genetic test. The [RNQ+] diploids generated 
above were sporulated to obtain haploid progeny. Single mutations 
should segregate in a 2:2 ratio and produce two [rnq-] cells and two 
[RNQ+] cells. Multiple mutations would create a variety of ratios 
due to random segregation. The haploid progeny acquired from 
the sporulation of the recessive mutants were analyzed for their 
[RNQ+] status using the solubility assay described above. Eight of 
the recessive mutants generated the 2:2 ratio of [rnq-] to [RNQ+] 
cells, indicating a single mutation (Fig. 2A and data not shown). 
The remaining three mutants showed other ratios of [RNQ+] to 
[rnq-] haploid progeny, suggesting that multiple mutations had pos-
sibly been acquired.
Due to the ability of the three dominant mutations to cure 
[RNQ+] in the diploid, all four haploid progeny will be [rnq-], 
regardless of whether the phenotype is caused by one or more 
loci. However, the haploids can then be backcrossed to a wild 
type, [RNQ+], haploid strain and the [RNQ+] status of the result-
ing diploids analyzed. Single gene traits should produce a 2:2 
ratio of [RNQ+] diploids to [rnq-] diploids. The haploid progeny 
from the dominant mutants were analyzed in this manner. Only 
one of the dominant mutations produced the 2:2 ratio indicative 
of a single gene trait (Fig. 2B). One of the dominant mutants 
failed to sporulate and, therefore, could not be analyzed in this 
manner, while the third produced variable ratios indicative of a 
Figure 2. curing of the [RNQ+] prion is caused by mutation at a single 
genetic locus. (A) Biochemical analysis of recessive mutations that cure 
[RNQ+]. The red [rnq-] cells carrying recessive mutations created by eMS 
were mated to a strain carrying wild type Rnq1p in the [RNQ+] state. The 
resulting diploids were sporulated and the solubility of the Rnq1 protein 
from individual haploids was analyzed as described in the legend of Figure 
1.  A single representative tetrad is shown.  A minimum of eight tetrads 
were tested for each mutant. (B) Analysis of dominant mutation that cure 
[RNQ+]. The red [rnq-] cells carrying dominant mutations created by eMS 
were mated to a strain carrying wild type Rnq1p in the [RNQ+] state. The 
resulting diploid was sporulated and haploid progeny of this cross were 
then backcrossed to strains carrying wild type Rnq1p in the [RNQ+] state. 
The resulting diploids from these matings were lysed and fractionated 
as above. Three tetrads were tested and a single representative tetrad is 
shown.
Figure 3. The eMS-induced mutations that cure [RNQ+] are in HSP104. (A) HSP104 was deleted in the mutant strains as indicated in the methods. The 
resulting Dhsp104 strains were mated to a strain carrying wild type Rnq1p in the [RNQ+] state. The resulting diploids were sporulated and the solubility of 
Rnq1p from individual haploids determined by well trap assay as described in Materials and Methods, transferred to PVDF and probed with an anti-Rnq1p 
antibody. Two representative tetrads are shown.  A minimum of four tetrads were tested for each mutant. (B) Diagram of mutations in hsp104p that cure 
[RNQ+]. The general domain structure of hsp104p is indicated above the diagram. NTD, N-terminal domain; NBD1, nucleotide binding domain one; M 
domain, middle domain; NBD2, nucleotide binding domain two; cTD, c-terminal domain. Mutations found in strains cured of [RNQ+] are indicated below the 
diagram.
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to a [PSI+] [RNQ+] strain. We dissected the resulting diploids 
and analyzed the degree of nonsense suppression of their hap-
loid progeny in order to determine their [PSI+] status (Fig. 4 and 
data not shown). Each of the mutants that cured [RNQ+] was 
also able to cure [PSI+], indicating that the mechanism of curing 
by the mutants is not specific to [RNQ+] but likely affects prion 
propagation in general. Surprisingly, Hsp104p-E190K, which 
was recessive for the curing of [RNQ+], appeared to be domi-
nant for the curing of [PSI+] (Fig. 4). All of the other mutations 
showed the same dominant or recessive effects on the curing of 
both [RNQ+] and [PSI+].
Hsp104p-E190K cures [RNQ+] slowly in the presence of 
wild-type Hsp104p. To further investigate the E190K mutation, 
the mutant strain was recreated by the pop-in/pop-out method 
in an unmutagenized version of 74-D694. Interestingly, initial 
results indicated that HSP104-E190K was dominant for curing 
[PSI+] but recessive for curing [RNQ+]. Further analysis, how-
ever, suggested that [RNQ+] was cured in a dominant fashion as 
well. We hypothesized that Hsp104p-E190K was less efficient at 
 curing [RNQ+] than [PSI+] in the presence of wild type Hsp104p. 
Two other mutations of Hsp104, P557L and L462R, are known 
to cure [PSI+] but not [RNQ+].29 Of these two, Hsp104p-L462R 
looked cured by the lack of Rnq1p-GFP fluorescent foci but was 
confirmed [RNQ+] by SDD-AGE and mating to [rnq-]. Therefore, 
Hsp104p-L462R was suggested to weaken or destabilize [RNQ+] 
but not cure it.29 To determine if Hsp104p-E190K was similar 
to either of these two mutants, we transformed haploid [RNQ+] 
cells expressing wild type Rnq1p with a plasmid that expresses 
Hsp104p Hsp104p-E190K. We then tested the transformants for 
the [RNQ+] prion by well-trap assay. Of the 24 transformants 
tested, all but two had become [rnq-] (Fig. 5A). The two remain-
ing [RNQ+] transformants were grown in selective medium for 
22 generations and then retested for soluble Rnq1p (Fig. 5B). 
Both had become [rnq-]. This is consistent with our hypothesis 
that Hsp104-E190K shows inefficient curing of [RNQ+] in the 
presence of wild type Hsp104p.
In order to gain more insight into the slow curing of [RNQ+] 
by Hsp104p-E190K, we looked at the effect of Hsp104p-E190K 
on prion strain variants of [RNQ+]. Three strain variants of 
[RNQ+] have been identified that induce [PSI+] with differing 
frequencies.40 The three [RNQ+] variants we used were previously 
characterized as low, medium and high [PIN+] ([PSI+] inducibil-
ity) and are so named for their increasing ability to induce [PSI+] 
in the presence of moderate overexpression of Sup35p. We trans-
formed haploid cells of low, medium and high [PIN+] with a plas-
mid expressing Hsp104p, Hsp104p-E190K, or a vector control. 
We then immediately analyzed the transformants that grew for 
the state of [RNQ+] by a solubility assay (Fig. 5C). Contrary to a 
previous report that showed differences in the amount of soluble 
Rnq1p in these variants, our vector control revealed that all three 
variants had only insoluble Rnq1p.40 This discrepancy could be 
due to the difference in the solubility assays with which Rnq1p 
was measured but our assay consistently shows no soluble Rnq1 
protein in the lysates from these strain variants. As expected, 
overexpression of Hsp104p did not cure [RNQ+] in any of the 
variants. Interestingly, the expression of Hsp104p-E190K in the 
mutants.3,4,11,25,35 To determine if our mutants were in Hsp104p, 
we deleted the HSP104 gene in each of our mutants. The result-
ing Dhsp104 mutants were then mated to a [RNQ+] strain. These 
diploids were sporulated and the [RNQ+] status of the haploid 
progeny was assessed by a Rnq1p well-trap assay (Fig. 3A and 
data not shown). For this assay, lysates from the haploid cells were 
resuspended in sample buffer containing 1% SDS and incubated 
at room-temperature. Insoluble Rnq1p in [RNQ+] strains resists 
solubilization by SDS and does not enter the separating gel when 
subjected to electrophoresis, but soluble Rnq1p enters the gel and 
can be detected by western blot. All of the HSP104 deletions pro-
duced a 2:2 ratio of [RNQ+] to [rnq-] haploids, indicating that 
the mutations caused by EMS were in HSP104.
We sequenced HSP104 from each of the mutant strains and 
found that eight of the single gene mutants carried a single mis-
sense mutation in the gene while one carried a nonsense mutation 
(Fig. 3B). The missense mutations found were as follows: A178T, 
E190K, A297T, A502T, G619D, A660T, E689K and T726I. The 
G619D mutant was dominant for the curing of [RNQ+]. Of these 
mutations, T726I, has been previously described.26 Additionally, 
a different mutation in G619, G619V, has also been described 
and both T726I and G619V have been shown to affect prion 
maintenance.26,28,54 The other mutations found in this screen are 
novel.
HSP104 missense mutations cure [PSI+]. Because Hsp104p 
is also required for the propagation of [PSI+], we tested whether 
the mutations also affected the [PSI+] prion. In order to isolate 
haploids containing both the HSP104 mutation and SUP35, we 
mated the original mutant strain which contained the mutant 
HSP104 and RRP to a [RNQ+] strain that contained wild type 
HSP104 and SUP35. We used western blot analysis to identify 
spores containing wild type Sup35p that had become [rnq-] due 
to the presence of the mutant HSP104 (data not shown). RRP 
is recognized by polyclonal antibodies raised against Sup35p 
and can easily be distinguished from wild type Sup35p by its 
larger size. The [rnq-] strains carrying wild type Sup35p will also 
carry the HSP104 mutation. We then backcrossed these strains 
Figure 4. The identified mutations in Hsp104p cure [PSI+]. haploid [rnq-] 
progeny from a cross between the mutant strains and a wild type strain 
(SUP35) were mated to a wild type [PSI+] strain. The resulting diploids 
were sporulated and the haploid progeny plated on YPD. Representa-
tive tetrads from four mutants are shown. hsp104-e689K shows a 2:2 
inheritance of [RNQ+] to [rnq-] colonies which is indicative of a recessive 
trait. hsp104p-A297T and hsp104p-A502T also show a 2:2 inheritance. 
hsp104p-e190K shows a 0:4 inheritance of [RNQ+] to [rnq-] colonies 
which indicates a dominant trait.  A minimum of eight tetrads were  
analyzed for each mutant.
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[RNQ+] prion. Had our screen been to saturation, we would have 
predicted it to reveal point mutations in SIS1, which is required 
for [RNQ+] propagation, as well as mutations in RNQ1 itself that 
abolish prion propagation. The domains of Sis1p required for 
the propagation of [RNQ+] have been described.44 We recently 
performed a screen for mutations in Rnq1p that disrupt prion 
propagation with the same RRP reporter and [RNQ+] dependent 
phenotype used here.50 Interestingly, we identified mutations 
that allow [RNQ+] to propagate but affect the ability of [RNQ+] 
to induce [PSI+]. None of those mutations affected the interac-
tion with Sis1p, however, as detected by co-immunoprecipitation 
(Bardill JP and True HL, unpublished data). Recently, one bind-
ing site for Sis1p on Rnq1p was identified and a mutation in 
Rnq1p that severely reduces the interaction with Sis1p has been 
presence of wild type Hsp104p resulted in significant Rnq1 pro-
tein in the soluble pools of the three variants. In the low [PIN+] 
strain, the majority of the protein had shifted to the soluble pool 
while in the high [PIN+] strain, the majority of Rnq1p stayed in 
the insoluble fraction. In the medium [PIN+] strain, the distri-
bution between soluble and insoluble was approximately equal. 
Thus, the efficiency of [RNQ+] curing by Hsp104p-E190K is 
dependent on the strain variant of [RNQ+].
Hsp104p-E190K does not support thermotolerance. Since 
our data suggest that there is a difference in handling vari-
ous substrates by Hsp104p-E190K, we next asked whether the 
mutant was defective in recognition and processing of other sub-
strates in vivo. As Hsp104p is required for resistance to lethal 
heat shock, we tested whether the strain carrying the Hsp104p-
E190K mutant was thermotolerant. Strains expressing either 
wild type Hsp104p, Hsp104p-E190K, or no Hsp104p at all were 
first exposed to a sublethal heat stress (37°C) to induce HSP104 
expression and then exposed to a lethal heat stress (50°C). Strains 
expressing wild type Hsp104p were able to recover from a 20 
minute heat shock while the Dhsp104 strains showed significant 
cell death (Fig. 6). The strain expressing Hsp104p-E190K was 
also unable to survive lethal heat stress and appeared similar to 
the deletion (Fig. 6). This indicates that the in vivo function of 
Hsp104p in resolubilizing essential proteins aggregated by heat 
stress is compromised by the E190K mutation.
E190K forms hexamers but has a defect in ATP hydroly-
sis. As the maintenance of prions is closely tied to the levels of 
Hsp104p, we wanted to determine if the steady state expression 
of the Hsp104p-E190K mutant is similar to that of wild type. 
Lysates from logarithmically growing cells were analyzed by west-
ern blot using an antibody against Hsp104p. Hsp104p-E190K 
was expressed to a similar level as wild type Hsp104p (Fig. 7A).
To determine the reason why Hsp104p-E190K is unable to 
support prion propagation and is defective in protecting the cells 
from heat stress, we examined two biochemical properties of 
Hsp104p, hexamer formation and ATPase activity. To test the 
ability of Hsp104p-E190K to form hexamers, we expressed and 
purified recombinant wild type Hsp104p and Hsp104p-E190K 
from E. coli. Purified protein was analyzed by size exclusion 
chromatography under conditions that promote hexamer forma-
tion.54 The mutant protein eluted in a similar volume as both the 
wild type Hsp104 protein and a 670 kDa standard, indicating 
that under these conditions, the mutant is able to form hexamers 
(Fig. 7B and data not shown).
Given that Hsp104p-E190K forms hexamers, we wanted to 
see whether it is able to hydrolyze ATP as efficiently as the wild 
type protein. To test this, the purified protein was incubated with 
a fixed concentration of ATP. At various time points, the amount 
of free P
i
 produced by the hydrolysis of ATP to ADP was mea-
sured. While Hsp104p-E190K did show hydrolysis of ATP, it did 
not hydrolyze ATP as well as wild type Hsp104p (Fig. 7C). This 
provides a likely explanation for its defect in both thermotoler-
ance and prion propagation.
Rnq1p-L94A is unable to propagate the [RNQ+] prion. 
Our screen uncovered novel mutations in Hsp104p but failed to 
uncover other novel factors required for the maintenance of the 
Figure 5. e190K cures [RNQ+] slowly in the presence of wild type 
hsp104p. (A) Well-trap assays of cells containing both wild type hsp104p 
and the e190K mutant.  A strain carrying wild type hsp104p was 
transformed with a plasmid expressing the e190K mutant. Lysate from 
individual transformants was subjected to a well trap assay as detailed in 
Materials and Methods, transferred to PVDF membrane, and blotted with 
an anti-Rnq1p antibody. (B) Strains carrying both wild type hsp104p and 
the hsp104p-e190K mutant lose [RNQ+] over time. The strains from (A) 
that remained [RNQ+] were grown in selective media for the number of 
generations indicated (# gen), lysed, and the [RNQ+] status was determined 
by [RNQ+] solubility assay as described in Materials and Methods. (c) 
The rate of [RNQ+] curing differs among [PIN+] prion strain variants. The 
strain variants of [RNQ+] (high, med, low [PIN+]) which have endogenous 
wild type hsp104p were transformed with an empty plasmid (Vector) or 
a plasmid containing either wild type hsp104p (WT) or hsp104p-e190K 
(e190K). Transformants were scraped off plates, lysed and subjected to a 
full solubility assay as described in Materials and Methods, transferred to 
PVDF membrane and blotted with an anti-Rnq1p antibody. Three separate 
transformations were analyzed and all showed similar results. Total, T; 
soluble, S; insoluble pellet, P.
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described.58 We created this mutation in Rnq1p, L94A, to ask 
whether the alteration in the interaction with Sis1p at this site 
would affect the propagation of the [RNQ+] prion.
We created the L94A mutation in a Rnq1p-expressing plas-
mid and analyzed its ability to maintain the [RNQ+] prion. 
Expression from the native RNQ1 promoter was undetectable 
by western blot, so we used a GPD promoter which produced 
Rnq1p-L94A at steady state levels approximately equal to wild 
type Rnq1p (data not shown). This plasmid was used to replace 
wild type Rnq1p by plasmid shuffle in either a [RNQ+] or [rnq-] 
cell. The solubility of the Rnq1p-L94A mutant was then assayed. 
Wild type Rnq1p fractionates into either the insoluble or soluble 
fraction when shuffled through a [RNQ+] or [rnq-] strain, respec-
tively (Fig. 8A). Rnq1p-L94A also fractionated into the insoluble 
fraction when shuffled through a [RNQ+] strain. However, the 
mutant was also insoluble when shuffled through a [rnq-] strain, 
indicating that the aggregation of Rnq1p-L94A is non-specific 
(Fig. 8A). Furthermore, we crossed the strain carrying Rnq1p-
L94A to a [rnq-] strain and found that the haploid progeny carry-
ing the wild type RNQ1 remained [rnq-] (data not shown). This 
suggests that the aggregates from the mutant L94A strain were 
unable to transmit the aggregate structure and are thus not prion-
like. We also tested the ability of Rnq1p-L94A to induce [PSI+]. 
Following overexpression of Sup35p, cells containing Rnq1p-
L94A showed a severe reduction in the ability to induce [PSI+] 
(Fig. 8B). These data indicate that the interaction of Rnq1p with 
Sis1p is important for the maintenance of the [RNQ+] prion as 
well as [PSI+] induction.
Discussion
Here we describe six novel mutations within HSP104 that cure 
both the [RNQ+] and [PSI+] prions. Five of these mutations are 
located in one of the nucleotide binding domains and one was 
found in the M domain. One of the Hsp104p mutants, E190K, 
displays differential kinetics for curing [PSI+] and [RNQ+] in the 
presence of wild type Hsp104p. Furthermore, Hsp104p-E190K 
shows varying kinetics within [RNQ+] variants that suggests 
Hsp104 may function differently in different prion strain vari-
ants. Hsp104p-E190K is unable to support thermotolerance on its 
own and shows reduced ATPase activity, suggesting that [RNQ+] 
requires less Hsp104p activity to propagate the prion state than 
[PSI+].
To our knowledge this represents the first screen for cellular 
factors that affect [RNQ+] propagation. The phenotypes typically 
Figure 6. hsp104p-e190K does not allow for the yeast to recover from acute heat shock. Following 30 minutes of pre-treatment at 37°c, liquid cultures 
containing identical numbers of cells of the indicated genotypes were heat-shocked at 50°c for the time indicated. Following heat shock, the cells were seri-
ally diluted and spotted onto YPD.
Figure 7. Hsp104-E190K is deficient in hydrolyzing ATP but not in form-
ing hexamers. (A) expression analysis of hsp104p-e190K. Lysate from 
strains grown to an OD600 of 1.0 were normalized by Bradford analysis, 
subjected to SDS-PAGe, transferred to PVDF and blotted with an anti-
Hsp104p antibody. Equal loading was confirmed by probing the same blot 
with anti-Pgk1p antibody. (B) hsp104p-e190K forms hexamers. Recombi-
nant purified Hsp104-E190K was run through a Sephacryl S-300 column in 
the presence of ATP. Fractions were collected and analyzed by SDS-PAGe 
followed by western blot with anti-Hsp104p and the bands quantified by 
densitometry. The percent of total protein in each fraction was calculated. 
The positions of eluted standards are indicated above the graph. The 
molecular weight of the standards is thyroglobulin-670 kDa (T), cata-
lase-250 kDa (c), bovine serum albumin-66 kDa (B). (c) ATP hydrolysis by 
hsp104p-e190K. The assays were performed in buffer A at 37°c.  At vari-
ous time points the amount of free Pi in the reaction of either hsp104p 
(circles) or hsp104p-e190K (squares) was calculated as compared to a 
standard of Kh2PO4 concentrations.
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of Rnq1p may require less Hsp104p activity to propagate than 
aggregates of Sup35p. Interestingly, too much Hsp104p activ-
ity cures [PSI+] but not [RNQ+].11,25 Thus, [RNQ+] appears 
to persist through a broader range of Hsp104 activities. This 
may be one reason why [RNQ+] cells are found in nature while 
[PSI+] cells are not.61 Allowing [RNQ+] to persist over a broader 
range of conditions may also benefit the yeast as the presence 
of the [RNQ+] prion dramatically increases the appearance of 
[PSI+].10-12,62 Further investigations into the different regulation 
of yeast prions will lead to a better understanding of their bio-
logical function.
In further characterizing the effect of E190K on [RNQ+] by 
looking at the high, medium and low [PIN+] variants, we found 
that the mixed hexamers of wild type and Hsp104p-E190K dif-
fer in their ability to recognize and/or propagate the [RNQ+] 
variants. Previous data suggests that medium and low [PIN+] 
have different aggregate structures than high [PIN+].63 While 
Hsp104p-E190K is not the first Hsp104p mutant to show dif-
ferential curing of [PSI+] and [RNQ+],29 it is the first Hsp104 
mutant that demonstrates a difference in recognition between 
the variants of [RNQ+]. Interestingly, the overexpression of the 
Hsp40 co-chaperone Ydj1p showed differential curing of the 
associated with the [RNQ+] prion, aggregation of Rnq1p and 
[PSI+] inductions, are not readily amenable to large scale screens. 
However, as the nonsense suppression of RRP is dependent on 
the cells being [RNQ+],50 it constitutes an excellent system to 
screen for factors that affect [RNQ+] propagation.
Our screen for mutants that are unable to propagate [RNQ+] 
only uncovered mutations within HSP104. Hsp104p is the only 
known protein required for the propagation of all known yeast 
prions.3,4,11,25,35 Furthermore, over thirty different mutations have 
been discovered in Hsp104p that affect prion propagation.20,25,28-31 
These mutations are found throughout the protein and may inter-
fere with Hsp104p activity at a variety of different steps including 
substrate recognition, hexamer formation and nucleotide hydro-
lysis. Thus, there are many targets within Hsp104p that can be 
altered and cause the loss of prion propagation. Generally, the 
mutations that cure [PSI+] cause the cells to lose the thermotoler-
ance phenotype. However, this is not always a complete loss of 
thermotolerance.28 This indicates that thermotolerance and prion 
propagation are genetically separable.
The majority of the mutants found in this screen were in either 
NBD1 (A178T, E190K, A297T) or NBD2 (G619D, A660T, 
E689K, T726I). A loss of ATPase activity from either of these 
domains or the inability to form hexamers generally results in 
defects in the propagation of [PSI+]. Of the two domains, NBD1 
appears to provide the majority of the ATPase activity required 
for disaggregation activity.23,59 While NBD2 has a low rate of 
hydrolysis, nucleotide binding to NBD2 regulates the formation 
of hexamers as well as the rate of hydrolysis of NBD1.22-24 As an 
example of the importance of these two domains, the K218T and 
K620T mutations which lie within the Walker A motifs of NBD1 
and NBD2, respectively, have been shown previously to impair 
ATPase activity.54 Thus, in our screen the mutants in NBD1 and 
NBD2 likely alter the ATPase activity or oligomerization ability 
of the protein to produce the loss of prion phenotypes. This con-
clusion is supported by the decreased rate of ATP hydrolysis of 
Hsp104p-E190K as compared to wild type Hsp104p.
The final mutation we identified was in the M domain (A502T). 
Deletions within this middle domain abrogate the function of 
Hsp104p27 as this domain likely plays a role in transducing the 
allosteric signal from NBD2 to NBD1. Thus, the A502T muta-
tion we identified likely disrupts the coordination between the 
domains, reducing the ATPase activity and inhibiting the overall 
disaggregation ability of the protein. Interestingly, the mutation 
A503V has differential effects on [PSI+] and [RNQ+].60 It causes 
toxicity in [PSI+] strains and affects aggregate size but does not 
affect [RNQ+] propagation.60
Due to its differential effects on curing [RNQ+] and [PSI+] in 
the presence of wild type Hsp104, we extended our analysis of the 
E190K mutant. While it is competent to form hexamers, it shows 
significantly decreased ATPase activity in vitro as compared to 
wild type Hsp104. The in vivo function of the mutant is also 
compromised as it cannot support thermotolerance. Given that 
it appeared to have no defect in hexamer formation, the mutant 
likely forms mixed hexamers with wild type Hsp104p. This 
mixed hexamer may have enough activity to temporarily propa-
gate [RNQ+] but not [PSI+]. Our data indicate that aggregates 
Figure 8. Rnq1p-L94A aggregates but does not maintain [RNQ+] or 
facilitate [PSI+] induction. (A) Rnq1p-L94A was expressed as the only copy 
of Rnq1p in either a [RNQ+] or [rnq-] strain by plasmid shuffle. Lysate from 
these strains were fractionated into total (T), soluble (S) and insoluble 
pellet (P) by high speed centrifugation and subjected to SDS-PAGe. A 
western blot was performed with anti-Rnq1p antibody. [RNQ+] status of 
original plasmid shuffle strain is indicated to the left of the blot. (B) Wild 
type Rnq1p was replaced with Rnq1p-L94A by plasmid shuffle in a [RNQ+] 
strain. The plasmid-shuffled strain was transformed with a plasmid that 
overexpresses Sup35p and plated on YPD. [PSI+] was scored by the appear-
ance of light pink sectoring on the colonies. Three independent trans-
formants were scored for [PSI+] induction.  Approximately 200 colonies 
were analyzed for each and a total of four [PSI+] colonies were obtained. 
The graph indicates the percentage of sectoring cells with wild type set 
to 100%. error bars indicate standard error of at least three separate 
replicates.
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methyl sulfonate (EMS) at a final concentration of 3% (v/v). 
Mutagenesis was halted at various time points by the addition of 
an equal volume of 10% Na
2
S
2
O
3
. The treated cells were exten-
sively washed with H
2
O and their viability was determined by 
plating assay. A culture with approximately 14% viable cells was 
plated on YPD to assess color.
Analysis of [RNQ+] status. The [RNQ+] status of the cells 
was biochemically assessed in one of two ways.52 For a full 
solubility assay, yeast cells were lysed with glass beads in buf-
fer containing 100 mM Tris-HCl pH 7, 200 mM NaCl, 1 mM 
ethylendiaminetetraacetic acid (EDTA), 5% glycerol, 0.5 mM 
dithiothreitol (DTT), 50 mM N-ethylmaleimide (NEM), 3 mM 
phenylmethanesulphonylfluoride (PMSF) and complete Mini 
protease inhibitor cocktail (Roche). Following lysis, an equal vol-
ume of RIPA buffer (50 mM Tris-HCl pH 7, 200 mM NaCl, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate (SDS)) was added to the lysate and cell debris was cleared 
by a brief centrifugation. This cleared lysate is the total protein. 
Insoluble protein was pelleted by centrifugation at 80,000 RPM 
(27,000 xg) in a Beckman TLA-100 rotor for 30 minutes. The 
supernatant containing the soluble protein was removed and 
the pellet was resuspended in a 1:1 mix of lysis buffer and RIPA 
buffer. Total, supernatant and pellet fractions were subjected to 
SDS-PAGE, transferred to PVDF membranes and probed with 
an anti-Rnq1p antibody.
Well trap assays were performed as previously described.52 
Cells were lysed with glass beads in buffer containing 50 mM 
Tris-HCL pH 7.5, 50 mM KCl, 10 mM MgCl
2
 and 5% glycerol 
supplemented with an anti-protease solution (Sigma), 10 mM 
PMSF, 50 mM NEM. Lysate was incubated in sample buffer 
(100 mM Tris-Cl pH 6.8, 1% SDS, 10% glycerol, 0.1% bro-
mophenol blue) for seven minutes at room temperature. Treated 
lysates were subjected to SDS-PAGE, transferred to PVDF and 
blotted with an anti-Rnq1p antibody.
Thermotolerance assays. Thermotolerance assays were 
 performed as previously described.53 Equal numbers of yeast cells 
in logarithmic growth were resuspended in liquid medium. The 
resuspended cells were pretreated at 37°C for 30 minutes and 
then shifted to 50°C for various periods of time. Following heat 
shock, the cells were incubated on ice for 2 minutes. The cells 
were then serially diluted and spotted onto YPD.
Hsp104p purification. His
6
-Hsp104p and His
6
-Hsp104p-
E190K were expressed and purified from E. coli BL21(DE3) 
as previously described.21 Polyhistidine-tagged Hsp104p and 
Hsp104-E190K were isolated by affinity chromatography on 
Ni-NTA sepharose. The histidine tag was cleaved with TEV 
protease and the untagged protein further purified by anion 
exchange chromatography. The fractions were analyzed by SDS-
PAGE, pooled and frozen at -80°C.
ATPase activity assay. Characterization of Hsp104 ATPase 
activity was performed in Buffer A (40 mM Tris, pH 7.5, 175 
mM NaCl, 5 mM MgCl
2
, 0.02% Triton X-100) as reported.54 
The reactions were performed at 37°C with either 1 μg Hsp104p 
or 5 μg Hsp104-E190K and 5 mM ATP (Sigma). At various time 
points during the reaction, Malachite Green Reagent was added 
to the reaction tube to quantify the amount of free P
i
 and the 
[RNQ+] strain variants, suggesting that the whole chaperone net-
work is involved in recognizing distinct structures.40
Another Hsp40, Sis1p, is essential for the propagation of 
[RNQ+] and interactions between Sis1p and Rnq1p have been 
proposed to generate the infectious seeds required for [RNQ+] 
propagation.33,44 The Rnq1p-L94A mutation dramatically 
reduces the ability of Rnq1p to bind Sis1p but does not com-
pletely abolish binding.58 Our data indicate that the reduction in 
Sis1p binding prevents the protein from effectively maintaining 
a prion. It appears that Rnq1p-L94A aggregates non-specifically, 
indicating that the interaction with Sis1p promotes the formation 
of ordered aggregates. These non-specific aggregates are unable to 
induce [PSI+], suggesting the aggregation of Rnq1p alone is not 
sufficient to promote [PSI+] induction.
Materials and Methods
Strain and plasmid construction. All S. cerevisiae strains were 
derived from 74-D694. Standard culturing and manipulation 
techniques were used for both yeast and Escherichia coli.49 Yeast 
strains were grown in either a rich medium, YPD (1% yeast 
extract, 2% peptone, 2% glucose), or a synthetic medium (0.67% 
yeast nitrogen base, 2% glucose) lacking the appropriate amino 
acids to select for plasmids. Haploid spores were generated from 
diploid parents and isolated by micromanipulation.
RRP has been described previously.50 pPROEx Htb Hsp104 
has previously been described.21 A fragment containing the E190K 
mutation was amplified using the oligonucleotides 5'-TTC TTT 
CAA AGG CAC CAT CC and 5'-CGG GAT CCA CCC TTG 
AAT CGA ATC AGC A. This product was digested with BglII 
and EcoRI and ligated into a BglII/EcoRI fragment of pPROEx 
Htb Hsp104 to generate pPROEx Htb Hsp104-E190K. HSP104 
was cloned into pRS316,51 by digesting pPROEx Htb Hsp104 
with BamHI and XhoI and ligated into a BamHI/XhoI fragment 
of pRS316. Sequence carrying the E190K mutation was excised 
from pPROEx Htb Hsp104-E190K on a BglII and EcoRI frag-
ment and ligated into a cognate fragment of pRS316-Hsp104 or 
pRS306-Hsp104 to create pRS316-Hsp104-E190K and pRS306-
Hsp104-E190K, respectively. Single mutants were also cloned 
with bridge PCR. The N-terminus of RNQ1 was amplified with 
the oligonucleotide 5'-GGG GAT ATC ATG GAT ACG GAT 
AAG TTA ATC TCA GAG G-3' and an oligonucleotide specific 
to the mutant. The reverse complement of the mutant specific 
oligonucleotide was then used along with the oligonucleotide 
5'-CCC GTC GAC TCA GTA GCG GTT CTG GTT GCC 
G-3' to amplify the C-terminus of RNQ1. This produced full 
length RNQ1 carrying the desired mutation which was digested 
with EcoRV and SalI and ligated into pRS313 that contained the 
RNQ1 promoter on an EcoRV/EcoRI fragment and the RNQ1 
terminator on a SalI/XhoI fragment. For GPD-Rnq1-L94A, an 
EcoRV/SalI fragment was removed from the pRS313-Rnq1-L94A 
mutant and cloned into a EcoRV/SalI fragment of p413-GPD.
EMS mutagenesis. Overnight cultures of [RNQ+] cells 
expressing RRP were washed twice in 50 mM potassium phos-
phate buffer pH 7.0 and then resuspended in buffer. The cells 
were normalized to 5 x 107 cells/ml and incubated with ethyl 
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growth, [PSI+] colonies were counted as any colony with a light 
pink sector. Representative colonies were checked for curing on 
plates containing 3 mM GdnHCl. The vast majority (>95%) of 
colonies with light pink sectors were curable on 3 mM GdnHCl 
(data not shown). Overexpression of Sup35p in a [RNQ+] strain 
has also been shown to create non-heritable amyloids of Sup35p 
that cause nonsense suppression similar to [PSI+].57 Since this 
nonsense suppression is dependent on the overexpression of 
Sup35p, we selected cells with light pink sectors and spotted 
them onto medium containing 5-FOA. Cells that converted to 
[PSI+] remained light pink on 5-FOA medium, while cells with 
 non-heritable amyloids reverted back to red. Experiments with 
both wild type Rnq1p and the mutants revealed that, on average, 
about 12% of colonies with light pink sectors were the result of 
non-heritable amyloids while the rest were bona fide [PSI+] (data 
not shown). This proportion is in line with the frequency of non-
heritable amyloid induction previously reported.57
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color development was stopped by the addition of citric acid. The 
A
650
 of the sample was determined and the absorbance units cali-
brated against a standard of known concentrations of KH
2
PO
4
. 
Each time point was done three independent times and the mean 
± standard deviation was calculated.
Gel filtration chromatography. Gel filtration was performed 
as previously described.55 Two milligrams of purified Hsp104p 
or Hsp104p-E190K were incubated for 5 minutes on ice with 
Buffer B (40 mM Tris-HCL, pH 8.0, 15 mM NaCl, 5 mM 
MgCl
2
, 10 mM ATP) before loading onto Sephacryl S-300 High 
Resolution resin (Amersham Biosciences). The column was 
equilibrated in Buffer B and was run at 4°C at a flow rate of 
0.05 mL/min. Fractions (5 mL) were collected and analyzed for 
the presence of Hsp104 by western blot using an antibody probe 
against Hsp104p. Resolved bands were quantified using Image J. 
Molecular weights of Hsp104p and Hsp104p-E190K were esti-
mated by comparison of their elution profiles with the follow-
ing standards: thyroglobulin M
r
 670,000; catalase M
r
 250,000; 
bovine serum albumin M
r
 66,000.
[PSI+] induction assays. [PSI+] induction assays were per-
formed as described previously.50 Plasmid shuffled strains con-
taining the Rnq1p mutants were transformed with a Ura-marked 
plasmid carrying SUP35 (pSUP2,56) and plated on selective media 
for both plasmids. Individual transformants were grown in selec-
tive media to OD
600
 ~1.6 and plated on YPD. After five days of 
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